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Abstract	  The	  Tumour	  necrosis	  factor-­‐related	  apoptosis-­‐inducing	  ligand	  (TRAIL)	  is	  one	  of	  the	  most	  recently	  identified	  death	  inducing	  ligands	  of	  the	  TNF	  cytokine	  family.	  TRAIL	  induces	  apoptosis	  in	  most	  cancer	  cells,	  whereas	  the	  majority	  of	  normal	  cells	   are	   resistant.	   TRAIL	   receptor	   agonists	   are	   therefore	   considered	   to	   be	   a	  promising	   anti-­‐cancer	   therapeutic.	   However,	   because	   many	   cancer	   cells	  develop	   resistance	   to	   TRAIL,	   understanding	   the	   mechanisms	   by	   which	  resistance	  is	  acquired	  will	  be	  critical	  for	  the	  therapeutic	  use	  of	  TRAIL	  in	  cancer	  therapy.	  	  	  We	   have	   discovered	   that	   Activated	   Cdc42-­‐associated	   kinase	   1	   (Ack1)	   is	  required	  for	  TRAIL	  induced	  apoptosis	  in	  human	  epithelial	  cells.	  Ack1	  is	  a	  non-­‐receptor	   tyrosine	  kinase	  with	  numerous	  protein-­‐protein	   interaction	  domains,	  suggested	   to	   have	   a	   role	   in	   several	   cellular	   processes	   such	   as	   trafficking,	  endocytosis	  and	  cell	  motility.	  	  Knockdown	   of	   Ack1	   in	   various	   epithelial	   cell	   lines	   leads	   to	   significantly	  impaired	  TRAIL	  induced	  apoptosis	  as	  evident	  by	  reduced	  cleavage	  of	  Caspase-­‐8	  and	   -­‐3	   and	   surface	   exposure	   of	   phosphatidylserine.	   Exploring	   the	   underlying	  mechanism	  we	   found	   that	  Ack1	  knockdown	   leads	   to	   impaired	  TRAIL	   induced	  clustering	  of	  TRAIL-­‐R1	  and	  a	  reduction	  in	  the	  recruitment	  of	  Caspase-­‐8	  to	  the	  DISC	  complex,	  essential	  for	  death	  inducing	  signal	  transduction.	  	  	  Translocation	   of	   the	   TRAIL	   receptors	   to	   lipid	   rafts	   in	   the	   plasma	  membrane	  have	   been	   suggested	   to	   be	   crucial	   for	   TRAIL	   receptor	   dynamics	   and	  downstream	  signalling	   following	  TRAIL	   ligand	  binding.	   In	   this	  work	  we	  show	  that	  Ack1	   is	  required	   for	   the	  translocation	  of	   the	  TRAIL	  receptors	   to	   the	   lipid	  rafts.	  	  	  	  In	   this	   thesis,	   a	   novel	   regulatory	   role	   of	   Ack1	   in	   apoptosis,	   death	   receptor	  signalling	   and	   lipid	   raft	   trafficking	   is	   presented,	   contributing	   further	   to	   the	  understanding	  of	  the	  molecular	  regulation	  of	  TRAIL	  receptor	  signalling.	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   receptor	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  TRAIL-­‐R1	   	   TRAIL	  receptor	  1	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Chapter	  1	  -­	  Introduction	  
1.1 Overview	  of	  apoptosis	  Apoptosis	   is	   an	   important	   process	   regulating	   cellular	   homeostasis,	  development	   and	   immune	   surveillance.	   Deficiency	   in	   apoptosis	   is	   one	   of	   the	  key	   contributing	   factors	   in	   cancer	   and	   also	   occurs	   in	   some	   autoimmune	  disorders.	  In	  contrast,	  excessive	  apoptosis	  leading	  to	  loss	  of	  essential	  cells	  takes	  place	   in	   neurodegenerative	   diseases,	   such	   as	   Alzheimer's	   [1].	   Some	   of	   the	  hallmarks	   of	   apoptosis	   are	   cell	   shrinkage,	   chromatin	   condensation,	   DNA	  fragmentation	   [2],	   membrane	   blebbing,	   and	   exposure	   of	   the	   phospholipid,	  phosphatidylserine	   (PS)	   in	   the	   outer	   leaflet	   of	   the	   plasma	  membrane	   [3].	   In	  contrast	  to	  necrosis,	  apoptosis	  does	  not	  induce	  an	  inflammatory	  response,	  and	  only	  individual	  cells	  are	  affected	  by	  apoptosis	  in	  vivo.	  	  	  The	   main	   executors	   of	   apoptosis	   are	   a	   group	   of	   cysteine	   proteases	   called	  initiator	  and	  effector	  caspases	  [4,	  5].	  Caspases	  are	  constitutively	  expressed	  as	  inactive	  proenzymes	  (zymogens)	  and	  require	  proteolytic	  processing	  at	  specific	  aspartic	  acid	  residues	  in	  order	  to	  gain	  full	  activity.	  The	  caspases	  are	  activated	  in	  a	   hierarchical	   fashion;	   apoptotic	   signals	   first	   activate	   initiator	   caspases	  (caspase-­‐2,	   -­‐8,	   -­‐9	   and	   -­‐10).	   Once	   activated	   the	   initiator	   caspases	   cleave	   and	  activate	  the	  effector	  caspases	  (caspase-­‐3,	   -­‐6	  and	  -­‐7),	  which	  in	  turn	  are	  able	  to	  cleave	   a	  wide	   range	  of	   vitally	   important	   cellular	   substrates	   in	   the	   cell,	   finally	  leading	   to	   cell	   death.	   Apoptotic	   signalling	   can	   be	   divided	   into	   two	   main	  pathways;	  the	  mitochondrial	  pathway	  and	  the	  death	  receptor	  pathway	  [6].	  	  	  
1.2 The	  mitochondrial	  pathway	  The	  mitochondrial	  pathway,	  also	  known	  as	   the	   intrinsic	  pathway,	   is	   triggered	  by	  cellular	  stresses	  such	  as	  DNA-­‐damage,	  starvation	  and	  hypoxia.	  The	  pathway	  is	  primarily	   regulated	  by	   the	  pro-­‐	  and	  anti-­‐apoptotic	  Bcl-­‐2	   family	  of	  proteins.	  The	   BH3-­‐only	   subfamily	   of	   the	   Bcl-­‐2	   family,	   such	   as	   Bad,	   NOVA	   and	   PUMA,	  function	  as	   cellular	   sensors	  of	  damage	  or	   stress	   (p53	  activation	  etc.)	   and	   can	  activate	   BAX	   and	   BAK,	   leading	   to	   mitochondrial	   outer	   membrane	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permeabilisation	  (MOMP).	  In	  contrast,	  the	  anti-­‐apoptotic	  Bcl-­‐2	  proteins,	  BCL-­‐XL	  and	   Bcl-­‐2	   inhibit	   the	   activity	   of	   BAX	   and	   BAK	   thereby	   preventing	   MOMP.	  Permeabilisation	  of	  the	  mitochondria	  leads	  to	  the	  release	  of	  cytochrome	  c	  (cyt	  c)	   [7-­‐9]	   and	   the	   protein	   second	   mitochondria-­‐derived	   activator	   of	   caspases	  (SMAC)	   [10]	   into	   the	   cytosol.	   SMAC	   promotes	   apoptosis	   by	   binding	   and	  inactivating	  a	  family	  of	  endogenous	  inhibitors	  of	  apoptosis,	  called	  Inhibitors	  of	  Apoptosis	   (IAP).	   Released	   cyt	   c	   interacts	  with	   the	   adaptor	   protein,	   Apoptotic	  protease	   activating	   factor-­‐1	   (Apaf-­‐1),	   and	   inactive	   pro-­‐caspase-­‐9	   molecules,	  forming	  a	  complex	  called	   the	  apoptosome.	  Assembly	  of	   the	  apoptosome	   leads	  to	   cleavage	   and	   activation	   of	   caspase-­‐9	   which	   in	   turn	   activates	   effector	  caspases,	  such	  as	  caspase-­‐3	  and	  -­‐7,	  subsequently	  leading	  to	  apoptosis.	  	  	  
	  
	  
Figure	  1.	  The	  mitochondrial	  pathway	  	  The	   mitochondrial	   pathway	   is	   induced	   by	   various	   cellular	   stresses.	   The	   pro-­‐apoptotic	   Bcl-­‐2	  proteins	  Bad,	  PUMA	  and	  NOXA	  senses	  cellular	   stresses	  and	  activate	  BAX	  and	  BAK,	   leading	   to	  the	   permeabilisation	   of	   the	   outer	   mitochondrial	   membrane.	   Permeabilisation	   leads	   to	   the	  release	  of	  cyt	  c	  and	  SMAC	  to	  the	  cytosol.	  Bcl-­‐2	  and	  BCL-­‐XL	  negatively	  regulate	  the	  mitochondrial	  permeabilisation.	  SMAC	  promotes	  apoptosis	  by	  inhibiting	  IAPs.	  Cyt	  c	  together	  with	  Apaf-­‐1	  and	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pro-­‐caspase-­‐9	   form	  an	  apoptosome,	   facilitating	   the	  activation	  of	  caspase-­‐9.	   In	   turn,	  caspase-­‐9	  cleaves	  and	  activates	   effector	   caspases	   such	  as	   caspase-­‐3	  and	   -­‐7,	   finally	   leading	   to	  apoptosis.	  
Abbreviations:	  Apaf-­1:	  Apoptotic	  protease	  activating	  factor-­1,	  Cyt	  c:	  Cytochrome	  c,	  IAP:	  Inhibitors	  
of	  Apoptosis,	  SMAC:	  second	  mitochondria-­derived	  activator	  of	  caspases	  
1.3 The	  death	  receptor	  pathway	  The	  death	  receptor	  pathway,	  also	  known	  as	  the	  extrinsic	  pathway,	   is	   initiated	  by	   the	  binding	  of	  an	  extracellular	  death	   ligand	  to	  a	  death	  receptor	  on	  the	  cell	  surface.	   To	   date,	   six	   death	   receptors	   have	   been	   identified;	   Tumour	   necrosis	  factor	   receptor	   1	   (TNF-­‐R1)[11],	   Fas	   receptor	   (Fas)[12,	   13],	   two	   TNF	   related	  apoptosis	  inducing	  ligand	  (TRAIL)	  receptors	  (TRAIL-­‐R1	  and	  TRAIL-­‐R2)	  [14-­‐18]	  and	   the	   less	   potent	   death	   inducers,	   Death	   receptor-­‐3	   and	   -­‐6	   (DR3,	  DR6)	   [19,	  20].	   A	   defining	   characteristic	   of	   the	   receptors	   are	   extracellular	   domains	  containing	   several	   cysteine	   rich	   domains	   (CRD)	   that	   determine	   ligand	  specificity.	   Additionally,	   the	   receptors	   all	   share	   a	   homologous	   interaction	  domain	   of	   approximately	   80-­‐amino	   acids	   in	   the	   C-­‐terminal	   cytoplasmic	   tail,	  called	  a	  death	  domain	  (DD).	  The	  death	  receptors	  bind	  death-­‐promoting	  ligands	  belonging	   to	   the	   TNF	   superfamily	   of	   ligands,	   such	   as	   TNFα,	   FasL	   and	   TRAIL	  (Figure	   2).	   The	   ligands	   are	   mainly	   expressed	   as	   type-­‐II	   transmembrane	  proteins,	  with	  a	  C-­‐terminal	   extracellular	   tail,	   a	   transmembrane	   region	  and	  an	  intracellular	  N-­‐terminal	  domain.	  Proteolytic	  cleavage	  by	  metalloproteases	  can	  in	  some	  cases	  lead	  to	  the	  release	  of	  a	  soluble	  ligand.	  No	  ligand	  belonging	  to	  the	  TNF	   superfamily	   has	   been	   found	   to	   bind	   DR6	   so	   far.	   Recently	   the	   β-­‐amyloid	  precursor	  protein	  was	  identified	  as	  a	  DR6	  ligand;	  however	  this	  interaction	  does	  not	  lead	  to	  classical	  apoptotic	  downstream	  signalling	  [21].	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Figure	  2.	  The	  death	  receptors	  and	  their	  ligands	  	  Six	  death	  receptors	  have	  been	   identified	  to	  date;	  TNF-­‐R1,	  Fas,	  DR3,	  TRAIL-­‐R1,	  TRAIL-­‐R2,	  and	  DR6.	  They	  all	  share	  a	  homologous	  death	  domain	  in	  the	  cytoplasmic	  tail	  and	  extracellular	  ligand	  binding	  CRDs.	  The	   receptors	  bind	   ligands	  belonging	   to	   the	  TNF	  superfamily,	   except	  DR6	   that	  binds	   APP.	   Abbreviations:	   APP:	   β-­amyloid	   precursor	   protein,	   CRD:	   Cysteine-­rich	   domain,	   DD:	  
Death	   domain,	   DR:	   Death	   receptor,	   FasL:	   Fas	   ligand,	   TL1A:	   TNF-­like	   ligand	   1A,	   TNFα:	   Tumour	  
necrosis	   factor	   α,	   TNF-­R1:	   Tumour	   necrosis	   factor	   receptor	   1,	   TRAIL-­R:	   TNF	   related	   apoptosis	  
inducing	  ligand	  receptor	  	  	  Upon	  ligation,	  the	  death	  receptors	  and	  the	  ligand	  bind	  each	  other	  in	  a	  trimeric	  conformation.	  Ligand	  binding	  leads	  to	  a	  conformational	  change	  in	  the	  DD	  of	  the	  receptor	  enabling	  the	  recruitment	  of	  the	  adaptor	  protein,	  Fas	  associated	  death	  domain	   (FADD),	   to	   the	   intracellular	   death	   domain	   of	   the	   receptors	   [22,	   23].	  FADD	   interacts	   with	   pro-­‐caspases-­‐8	   molecules	   via	   a	   death	   effector	   domain	  (DED)	  in	  both	  proteins,	  leading	  to	  the	  formation	  of	  a	  complex	  called	  the	  death	  inducing	   signalling	   complex	   (DISC)	   (Figure	   3).	   TNFR1	   and	   DR3	   require	   the	  binding	   of	   an	   additional	   adaptor	   molecule,	   Tumour	   necrosis	   factor	   receptor	  type	   1-­‐associated	   death	   domain	   protein	   (TRADD),	   prior	   to	   the	   FADD	   and	  caspase-­‐8	   recruitment.	   Assembly	   of	   the	   DISC	   leads	   to	   the	   cleavage	   and	  activation	  of	  caspase-­‐8	  and	  further	  downstream	  death	  signalling.	  Pro-­‐caspase-­‐
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10	   also	   binds	   FADD	  and	   is	   activated	   at	   the	  DISC,	   however	   the	   significance	   of	  caspase-­‐10	  binding	  is	  not	  fully	  understood.	  Caspase-­‐10	  has	  been	  reported	  to	  be	  unable	  to	  functionally	  substitute	  caspase-­‐8	  [24].	  	  	  The	  mechanisms	   by	  which	   the	   initiator	   caspases	   are	   activated	   are	   still	   being	  debated	   and	   several	   mechanisms	   have	   been	   proposed.	   According	   to	   the	  “induced	  proximity	  model”,	  initiator	  caspases	  have	  a	  low	  intrinsic	  activity	  and	  are	  therefore	  capable	  of	  trans-­‐activate	  each	  other	  when	  the	  caspase	  molecules	  are	   in	   close	   proximity	   at	   a	   high	   local	   concentration	   [25].	   A	   second	  modified	  model	   called	   the	   “proximity-­‐induced	   dimerisation	   model”	   has	   also	   been	  suggested.	   According	   to	   this	  model,	   the	   accumulation	   of	   initiator	   caspases	   in	  the	   DISC	   promotes	   dimerisation	   of	   the	   caspases	   leading	   to	   activation,	  suggesting	  that	  while	  cleavage	  is	  not	  required	  for	  the	  activation,	  it	  may	  stabilise	  the	   active	   form	   [26].	   In	   the	   most	   recent	   model,	   the	   “induced	   conformation	  model”,	  initiator	  caspases	  are	  suggested	  to	  be	  activated	  due	  to	  a	  conformational	  change	  in	  the	  active	  site	   following	  binding	  to	  adaptor	  protein	  complexes	  [27].	  Others	   however	   claim	   that	   both	   dimerisation	   and	   cleavage	   is	   required	   for	  caspase-­‐8	  activation	  [28].	  Ultimately,	  activation	  of	  caspases-­‐8	  leads	  to	  cleavage	  and	   activation	   of	   caspase-­‐3	   and	   other	   effector	   caspases,	   causing	   the	   cell	   to	  undergo	  apoptosis.	  	  	  Cells	  can	  be	  classified	  as	  type	  I	  or	  type	  II	  by	  the	  mechanisms	  in	  which	  apoptosis	  is	   induced.	   In	   type	   II	   cells	   the	   formation	   of	   the	   DISC	   is	   slow	   and	   less	   active	  caspase-­‐8	  appears	   to	  be	  generated.	  The	  death	   signal	   in	   type	   II	   cells	   therefore	  requires	   amplification	   by	   the	   activation	   of	   the	   mitochondrial	   pathway.	   The	  bridge	   between	   the	   two	   pathways	   is	   achieved	   through	   caspase-­‐8	   dependent	  cleavage	   of	   the	   pro-­‐apoptotic	   Bcl-­‐2	   protein	   Bid	   to	   a	   truncated	   form	   (tBid),	  which	   triggers	   the	   mitochondrial	   pathway	   by	   promoting	   MOMP	   and	   cyt	   c	  release.	   In	   type	   I	   cells,	   the	   apoptotic	   signalling	   amplitude	   via	   the	   death	  receptors	   is	   sufficient	   to	   induce	  apoptosis	   independently	  of	   the	  mitochondria	  [29,	  30]	  (Figure	  3).	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Figure	  3.	  The	  death	  receptor	  pathway	  The	  death	  receptor	  pathway	  is	  initiated	  by	  death	  promoting	  ligands	  binding	  to	  transmembrane	  death	   receptors.	  Following	   ligation,	   the	  adaptor	  protein	  FADD	  binds	   the	  death	  domain	  of	   the	  death	  receptor,	  directly	  or	   indirectly	  via	  TRADD,	   followed	  by	   the	  recruitment	  of	   inactive	  pro-­‐caspase-­‐8	   molecules.	   Together	   they	   form	   a	   complex	   called	   a	   DISC,	   facilitating	   the	   auto-­‐activation	  of	  caspase-­‐8	  which	  in	  turn	  activates	  caspase-­‐3	  and	  subsequent	  cell	  death.	  Type	  I	  cells	  can	   induce	   apoptosis	   independent	   of	   the	   mitochondria,	   whereas	   type	   II	   cells	   require	  amplification	  of	  the	  death	  signal	  via	  the	  mitochondrial	  pathway.	  Caspase-­‐8	  dependent	  cleavage	  of	  the	  Bcl-­‐2	  protein,	  Bid,	  functions	  as	  the	  link	  between	  the	  two	  pathways.	  Abbreviations:	  Apaf-­1:	  
Apoptotic	  protease	  activating	   factor	  1,	   c-­FLIP:	  Cellular	  FLICE-­like	   inhibitory	  protein,	  DD:	  Death	  
domain,	  DISC:	  Death	   inducing	  signalling	  complex,	  FADD:	  Fas	  associated	  death	  domain,	  Fas-­R/L:	  
Fas	  receptor/ligand,	  tBid,	  truncated	  Bid,	  TNF:	  Tumour	  necrosis	   factor,	  TRADD:	  Tumour	  necrosis	  





1.4 TRAIL	  receptor	  signalling	  The	  tumour	  necrosis	  factor-­‐related	  apoptosis-­‐inducing	  ligand	  (TRAIL)	  is	  one	  of	  the	  more	  recently	  identified	  death-­‐inducing	  ligands	  of	  the	  TNF	  cytokine	  family	  [36,	  37].	  Interestingly,	  TRAIL	  promotes	  apoptosis	  in	  many	  cancer	  cells,	  whereas	  most	  normal	  cells	  are	  resistant.	  The	  TRAIL	  receptors	  are	  therefore	  considered	  as	  a	  promising	  target	  for	  cancer	  therapy	  [38].	  	  	  TRAIL	   is	   a	   281	   amino	   acid,	   type	   2	   transmembrane	   bound	   glycoprotein,	  expressed	   in	  various	   tissues;	   in	  particular	  spleen,	  prostate,	   lung	  and varies	  of	  immune	   cells,	   such	   as	   macrophages,	   natural	   killer	   cells	   and	   dendritic	   cells,	  depending	  on	  cell	  stimulation	  [36,	  37,	  39].	  The	  extracellular	  C-­‐terminal	  part	  of	  TRAIL	  can	  be	  cleaved	  off;	  however	  the	  activity	  of	  the	  soluble	  form	  is	  generally	  lower.	   TRAIL	   forms	   homotrimers,	   with	   a	   zinc-­‐binding	   site	   required	   for	   the	  structure	   and	   function	   of	   the	   trimeric	   complex.	   Trimerisation	   of	   TRAIL	  increases	   the	   biological	   activity	   compared	   to	   its	   monomeric	   form	   [37,	   40].	  TRAIL	   ligand	   binds	   three	   TRAIL	   receptors,	   leading	   to	   the	   formation	   of	   a	  trimeric	  receptor	  complex	  [41,	  42].	  	  	  The	  biological	  role	  of	  TRAIL	  is	  still	  not	  fully	  understood.	  TRAIL	  has	  been	  shown	  to	  be	  essential	  for	  the	  regulation	  of	  apoptosis	  in	  the	  immune	  system	   in	  vivo.	  It	  has	   also	   been	   suggested	   to	   have	   both	   immunosuppressive	   and	  immunoregulatory	   functions	   by	   eliminating	   auto-­‐reactive	   immune	   cells	  (reviewed	  by	  [43]).	  Several	  studies	  also	  suggest	  that	  TRAIL	  is	  important	  for	  the	  immune	   surveillance	   of	   developing	   tumours	   and	   metastasis,	   thereby	  functioning	   as	   a	   tumour	   suppressor	   [44].	   Gene-­‐expression	   studies	   of	   368	  human	  breast	  tumour	  samples	  found	  that	  down	  regulation	  of	  TRAIL	  correlates	  with	   brain	   metastasis	   [45].	   In	   addition,	   studies	   on	   TRAIL	   receptor	   (mDR5)	  knockout	   mice	   demonstrated	   that	   while	   the	   mice	   develop	   normally,	   tumour	  formation	   and	   metastasis	   are	   increased	   in	   several	   tissues	   such	   as	   skin	   and	  mammary	   gland	   [46].	   It	   has	   also	  been	   shown	   that	  TRAIL-­‐deficient	  mice	  have	  defective	   thymocyte	   apoptosis,	   which	   is	   responsible	   for	   negative	   selection,	  leading	   to	   an	   increased	   susceptibility	   to	   autoimmune	  diseases	   [47].	   	   There	   is	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however	   much	   yet	   to	   be	   understood	   with	   regard	   to	   TRAIL	   function,	   as	   a	  contrasting,	  study	  reported	  that	  loss	  of	  mDR5	  in	  the	  intestine	  or	  thymus	  did	  not	  increase	  tumour	  formation	  [48]	  .	  
1.5 The	  TRAIL	  receptors	  To	  date,	   five	  TRAIL	  binding	   receptors	  have	  been	   identified	   in	  human.	  Two	  of	  them	   are	   death	   receptors,	   TRAIL-­‐R1	   (DR4)	   and	   TRAIL-­‐R2	   (DR5),	   capable	   of	  inducing	   apoptosis	   [14-­‐18].	   They	   are	   both	   transmembrane	   receptors	  with	   an	  extracellular	  cysteine-­‐rich	  ligand	  binding	  domain	  and	  a	  functional	  intracellular	  death	   domain.	   The	   death	   domain	   of	   TRAIL-­‐R1	   shares	   30%	   homology	   to	   the	  corresponding	  domains	  in	  TNFR-­‐1	  and	  DR3,	  but	  only	  19%	  homology	  is	  shared	  with	  the	  death	  domain	  of	  Fas	  [14].	  	  Two	   other	   receptors	   binding	   TRAIL,	   Decoy	   receptor	   1	   (DcR1)	   and	   Decoy	  receptor	   2	   (DcR2),	   both	   have	   a	   highly	   similar	   extracellular	   ligand-­‐binding	  domain	   to	   that	   of	   TRAIL-­‐R1	   and	   -­‐R2	   [15,	   18].	   However,	   the	   receptors	   are	  unable	   to	   induce	   apoptosis	   due	   to	   the	   absence	   of	   a	   functional	   death	   domain.	  DcR1	   is	   anchored	   to	   the	  membrane	   via	   glycophospatidylinositol	   (GPI)	   and	   is	  completely	   lacking	  a	  death	  domain,	  whereas	  DcR2	  contains	  a	   truncated	  death	  domain	   (Figure	   4).	   The	   decoy	   receptors	   can	   inhibit	   TRAIL	   induced	   apoptosis	  either	   by	   sequestering	   TRAIL	   or	   by	   forming	   heteromeric	   receptor	   complexes	  with	   TRAIL-­‐R1	   or	   -­‐R2,	   preventing	   DISC	   formation	   [49-­‐51].	   The	   fifth	   TRAIL	  binding	   receptor	   is	   the	   secreted	   Osteoprotegerin	   (OPG),	   which	   binds	   TRAIL	  with	  low	  affinity.	  The	  significance	  of	  this	  interaction	  in	  vivo	  is	  however	  not	  yet	  fully	   understood,	   although	   it	   has	   been	   suggested	   that	   OPG	   might	   sequester	  TRAIL	  and	  thereby	  block	  apoptosis	  [52,	  53].	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Figure	  4.	  TRAIL	  binding	  receptors	  TRAIL	   binds	   five	   receptors:	   two	   death	   receptors	   (TRAIL-­‐R1	   and	   -­‐2),	   with	   functional	   death	  domains	  capable	  of	   inducing	  apoptosis,	   two	  decoy	  receptors	  (DcR1	  and	  -­‐2)	  with	  a	  missing	  or	  non-­‐functional	   death	   domain	   respectively	   and	   the	   soluble	   receptor	   OPG	   at	   a	   lower	   affinity.	  
Abbreviations:	   DcR:	   Decoy	   receptor,	   DD:	   Death	   domain,	   OPG:	   Osteoprotegerin,	   TRAIL-­R:	   TNF	  
related	  apoptosis	  inducing	  ligand	  receptor	  	  	  The	  TRAIL	  receptors	  are	  widely	  expressed,	  with	  particularly	  high	  expression	  in	  liver,	  spleen	  and	  thyroid	  [39].	  	  As	  previously	  mentioned,	  in	  contrast	  to	  humans,	  mice	   only	   exhibit	   one	   TRAIL	   receptor	   called	  mDR5,	   which	   is	   homologous	   to	  both	  human	  TRAIL-­‐R1	  and	  R2	  [54].	  It	  has	  yet	  to	  be	  explained	  why	  humans	  have	  evolved	   to	   express	   two	   TRAIL	   receptors	   and	   whether	   there	   is	   a	   significant	  difference	  in	  their	  signalling	  cascades.	  TRAIL-­‐R2	  shares	  58%	  overall	  homology	  to	   TRAIL-­‐R1	   with	   the	   greatest	   homology	   found	   in	   the	   intracellular	   death	  domain.	  Distinct	  roles	  of	  the	  two	  receptors	  have	  not	  yet	  been	  shown,	  although	  by	  using	   receptor	   selective	   agonists	   it	   has	  been	   shown	   that	   certain	   cell	   types	  depend	  more	  or	  less	  on	  one	  of	  the	  receptors	  [55].	  For	  example,	  TRAIL	  induced	  apoptosis	  of	   chronic	   lymphocytic	   leukemic	   (CLL)	  and	  pancreatic	   tumour	  cells	  been	   shown	   to	   be	  mediated	   primarily	   via	   TRAIL-­‐R1,	   even	   in	   the	   presence	   of	  functional	  TRAIL-­‐R2	  [55,	  56],	  whereas	  others	  report	   that	  TRAIL-­‐R2	   is	  a	  more	  potent	  inducer	  of	  apoptosis	  in	  hepatocytes	  and	  lung	  cancer	  cell	  lines	  [57].	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Similar	   to	   other	   death	   receptors,	   the	   extracellular	   domain	   of	   the	   TRAIL	  receptors	  consists	  of	  three	  cysteine	  rich	  domains	  (CRD).	  The	  ligand-­‐binding	  site	  is	  within	  CRD2	  and	  3	  of	  TRAIL-­‐R2	  [41]	  (Figure	  5).	  It	  was	  first	  believed	  that	  the	  death	  receptors	  existed	  as	  monomers	  in	  the	  absence	  of	  ligand.	  However	  several	  studies	   have	   shown	   that	   TNFR1	   and	   Fas	   can	   self-­‐associate	   before	   ligand	  binding	   in	   the	   membrane	   independently	   of	   ligand	   binding.	   The	   receptors	  interact	   via	   pre-­‐ligand-­‐binding	   assembly	  domains	   (PLAD)	   in	   CRD1	   (Figure	  5)	  [58,	  59].	  A	  PLAD	   interaction	  has	  also	  been	  suggested	   for	   the	  TRAIL	  receptors	  and	   Dcr2	   has	   been	   proposed	   to	   form	   heteromeric	   pre-­‐ligand	   complexes	  together	   with	   TRAIL-­‐R1	   and	   -­‐R2,	   thereby	   preventing	   proper	   DISC	   formation	  [59,	  60].	  The	  significance	  of	  the	  pre-­‐ligand	  trimerisation	  of	  the	  TRAIL	  receptors	  needs	  to	  be	  further	  investigated	  and	  the	  interaction	  has	  not	  yet	  been	  confirmed	  with	  endogenously	  expressed	  protein.	  	  	  	  	  	  
	  	  
Figure	  5.	  TRAIL	  ligand	  binding	  and	  pre-­ligand	  trimerisation	  model	  	  A	   PLAD	   interaction,	   independent	   of	   ligand	   binding,	   via	   the	   CRD1	   of	   the	   receptor	   has	   been	  suggested	  for	  the	  TRAIL	  receptors.	  TRAIL	  interacts	  with	  CRD2	  and	  CRD3.	  	  	  
Abbreviations:	  CRD:	  Cysteine	  rich	  domain,	  DD:	  Death	  domain,	  PLAD:	  Pre-­ligand-­binding	  assembly	  
domain,	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1.5.1 Alternative	  signalling	  mediated	  through	  TRAIL	  receptors	  The	  death	  receptors	  were	  initially	  thought	  to	  only	  induce	  apoptotic	  signalling.	  However	   it	   is	   now	  known	   that	  TRAIL	  binding	   can	   also	  mediate	   signalling	   via	  alternative	   signalling	   pathways.	   The	   death	   receptors	   have	   been	   shown	   to	  regulate	  processes	  such	  as	  proliferation,	   inflammation	  and	  migration	   [61-­‐63].	  TRAIL	  can	  for	  example	  stimulate	  the	  inhibitor	  of	  κB	  kinase	  (IKK)	  [64],	  c-­‐Jun	  N-­‐terminal	   kinase	   (JNK),	   and	   p38	   MAPK	   signalling	   cascades.	   Activation	   of	   IKK	  leads	  to	  the	  degradation	  of	  inhibitor	  of	  κB	  (I-­‐κB)	  resulting	  in	  Nuclear	  factor	  κB	  (NfκB)	   activation	   and	   transcription	   of	   genes	   involved	   in	   immune	   function,	  apoptosis	  and	  inflammation.	  The	  biological	  significance	  of	  TRAIL	  induced	  NfκB	  activation	   is	   however	   not	   fully	   understood.	   Some	   report	   that	  NfκB	   activation	  can	  promote	   invasiveness,	   survival	   and	  proliferation	   in	   some	  TRAIL	   resistant	  cell	   lines	   [62],	  whereas	   others	   claim	   that	  NfκB	   signalling	   can	   increase	   TRAIL	  sensitivity	  in	  human	  β-­‐cells	  [65].	  	  	  The	   alternative	   signalling	   pathways	   are	   activated	   by	   the	   formation	   of	   a	  secondary	   signalling	   complex	   (Complex	   II)	   subsequent	   to	   the	  DISC	   assembly.	  Complex	  II	  consists	  of	  FADD,	  caspase-­‐8,	  receptor-­‐interacting	  protein	  1	  (RIP1),	  TNF	  receptor-­‐associated	  factor	  2	  (TRAF2)	  and	  IKKγ	  [66].	  	  	  	  Further	   understanding	   of	   mechanisms	   directing	   death	   receptor	   signalling	  towards	   death	   or	   non-­‐death	   actions	   is	   needed	   in	   order	   to	   better	   understand	  resistance	  mechanisms	  and	  how	  to	  overcome	  them.	  	  	  
1.5.2 TRAIL	  resistance	  mechanisms	  and	  cancer	  therapeutic	  potential	  TNFα and	  FasL	  efficiently	  induce	  apoptosis	  in	  cancer	  cells.	  However,	  the	  use	  of	  the	   ligands	   in	   cancer	   treatment	   is	   not	   feasible	   due	   to	   severe	   toxicity	   after	  systemic	   administration.	   Treatment	   with	   Fas	   or	   TNFα caused extensive	  apoptosis	  of	  hepatocytes	  leading	  to	  liver	  failure	  in	  mice	  [67].	  On	  the	  other	  hand,	  recombinant	  TRAIL	  has	  been	   shown	   to	  be	   generally	   safe	   in	   in	   vivo	   studies	   in	  mice	   [68]	   as	   well	   as	   in	   cancer	   patients	   assessed	   during	   clinical	   trials	   [69].	  Antagonistic	  antibodies	  targeting	  the	  TRAIL	  receptors,	  such	  as	  mapatumumab	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and	  lexatumumab,	  have	  also	  been	  tolerated	  well	  in	  patients.	  However,	  concerns	  were	   raised	  with	   certain	   tagged	   recombinant	  TRAIL	   and	   anti-­‐TRAIL	   receptor	  mAbs	  developed,	  where	  the	  drug	  had	  toxic	  effect	  on	  hepatocytes	  [70,	  71].	  	  	  	  	  Due	   to	   the	   low	   toxicity	   of	   TRAIL	   in	   normal	   cells,	   TRAIL	   signalling	   is	   still	  considered	  as	  a	  promising	  target	  for	  cancer	  therapy.	  Even	  though	  cancer	  cells	  are	  significantly	  more	  sensitive	  to	  TRAIL-­‐induced	  apoptosis,	  many	  cancer	  cells	  develop	  resistance.	  Innate	  and	  required	  resistance	  is	  thus	  an	  evolving	  problem	  and	   it	   is	   becoming	   more	   evident	   that	   TRAIL	   receptor	   targeting	   alone	   as	  monotherapy	  might	   not	   be	   sufficient.	   TRAIL	   treatment	   together	   with	   a	   wide	  range	   of	   pharmaceutical	   agents,	   such	   as	   cisplatin	   (DNA	   crosslinker),	   or	  Gefitinib	  (EGFR	  inhibitor),	  have	  been	  shown	  to	  effectively	  increase	  the	  success	  rate	  of	  the	  treatment	  [72,	  73].	  The	  development	  of	  resistance	  against	  TRAIL	  has	  been	   intensively	   studied	   and	   several	   mechanisms	   have	   been	   proposed.	  However	   the	  significance	  of	   the	  different	  mechanisms	  varies	   to	  a	   large	  extent	  between	   cell	   types.	   Further	   understanding	   of	   the	   resistance	  mechanisms	   and	  how	   to	   overcome	   them	   is	   required	   in	   order	   to	   develop	   effective	   cancer	  therapeutics.	  	  	  Loss	   of	   cell	   surface	   expression	   of	   the	   TRAIL-­‐receptors,	   due	   to	   constitutive	  endocytosis,	  has	  been	  correlated	  to	  TRAIL	  resistance	  and	  could	  be	  a	  potential	  biomarker	   for	   TRAIL	   sensitivity	   [74].	   Additionally,	   TRAIL	   induced	   c-­‐Cbl	  mediated	  ubiquitinylation	  of	  the	  TRAIL	  receptors	  leading	  to	  degradation	  of	  the	  receptors	   via	   proteasomal	   and	   lysosomal	   pathways	   has	   been	   suggested	   to	  correlate	  with	  early	  phase	  TRAIL	  resistance	  [75].	  	  	  Loss	  of	  function	  mutations	  in	  TRAIL-­‐R1	  and	  TRAIL-­‐R2	  have	  been	  identified	  in	  human	  tumours	  such	  as	  breast	  carcinoma	  and	  non-­‐Hodgkin's	  lymphoma.	  Most	  of	   the	  mutations	   identified	  were	   in	   the	   intracellular	   death	   domain	   important	  for	  FADD	  binding	  and	   thereby	  potentially	  disturbing	  DISC	   formation	   [76,	  77].	  Epigenetic	  silencing,	  particularly	  of	  TRAIL-­‐R1,	  has	  been	  found	  in	  up	  to	  70%	  of	  glioblastomas	  [78]	  and	  30%	  of	  ovarian	  carcinomas	  [79].	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Furthermore,	  downregulation	  of	  caspase-­‐8	  or	  overexpression	  of	  c-­‐FLIP,	  which	  both	  result	  in	  lowering	  the	  caspase-­‐8/c-­‐FLIP	  ratio	  can	  also	  contribute	  to	  lower	  sensitivity	  to	  TRAIL	  [80].	  Alteration	  in	  the	  levels	  or	  balance	  between	  pro-­‐	  and	  anti-­‐apoptotic	  Bcl-­‐2	  protein	   can	  cause	  TRAIL	   resistance	   in	   type	   II	   cells	  which	  require	  activation	  of	  the	  mitochondrial	  pathway	  [81].	  	  	  Post-­‐translational	  modifications	  of	  the	  TRAIL	  receptors	  have	  also	  shown	  to	  be	  important	  for	  the	  sensitivity	  to	  TRAIL.	  O-­‐glycosylation	  of	  TRAIL-­‐R1	  and	  TRAIL-­‐R2	  promotes	  ligand	  induced	  receptor	  clustering	  and	  the	  formation	  of	  the	  DISC	  and	   further	   downstream	   signalling.	   High	   mRNA	   expression	   of	   O-­‐glycosyltransferases,	  such	  as	  N-­‐acetyl	  galactosamine	  transferase	  14	  (GALNT14)	  and	   O-­‐glycan	   processing	   enzymes	   such	   as	   fucosyltransferase	   3	   (FUT3)	   have	  been	   correlated	  with	   an	   increased	   sensitivity	   for	   TRAIL-­‐induced	   apoptosis	   in	  several	   tumours	   [82].	   Additionally	   a	   putative	   N-­‐glycosylation	   site	   has	   been	  detected	   in	  TRAIL-­‐R1	  and	   inhibition	  of	  N-­‐glycosylation	   impairs	   the	  clustering	  of	  TRAIL-­‐R1	  but	  not	  TRAIL-­‐R2	  [83].	  
1.5.3 TRAIL	  receptor	  dynamics	  and	  trafficking	  Little	   is	   known	   about	   the	   trafficking	   and	   spatiotemporal	   regulation	   of	   the	  TRAIL	  receptors.	  The	  dynamics	  of	  Fas	  and	  TNFR1	  have	  however	  been	  studied	  more	   in	   detail.	   Fas	   and	   TNFR1	   require	   ligand	   dependent	   internalisation	   to	  endosomal	   compartments	   for	   the	   formation	   of	   the	  DISC,	   caspase-­‐8	   activation	  and	  a	   full	  apoptotic	  response	  [84,	  85].	   Inhibition	  of	  endocytosis	   in	  type	  I	  cells	  leads	   to	   the	   inhibition	   of	   Fas	   induced	   apoptosis,	   instead	   leading	   to	   survival	  signalling	  via	  MAPK	  and	  NF-­‐κB	  signalling	  pathways	  [85].	  Fas	  is	  internalised	  via	  clathrin	   mediated	   apoptosis.	   Knockdown	   of	   adaptor	   protein	   2	   (AP2),	   an	  important	   adaptor	  protein,	   or	   the	  heavy	   chain	  of	   clathrin	   resulted	   in	   a	   lower	  cell	  surface	  expression	  of	  Fas	  and	  decreased	  apoptosis	  [85].	  	  In	   contrast	   to	   Fas	   and	   TNFR1,	   the	   TRAIL	   receptors	   do	   not	   require	  internalisation	   for	   the	   formation	   of	   the	   DISC	   and	   induction	   of	   apoptosis.	  Inhibition	   of	   endocytosis	   rather	   promotes	   apoptotic	   signalling	   via	   the	   TRAIL	  receptors	  [86].	  TRAIL-­‐DISC	  complexes	  can	  be	  formed	  without	  internalisation	  as	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the	   DISC	   is	   formed	   at	   4°C	   and	   after	   inhibition	   of	   endocytosis	   by	   hypertonic	  medium	  or	  overexpression	  of	  dominant	  negative	   forms	  of	  AP180	  or	  dynamin	  [86].	   TRAIL	   and	   its	   receptors	   are	   however	   rapidly	   internalised	   in	   a	  concentration-­‐	  and	  time-­‐dependent	  manner	  after	   ligand	  binding,	  although	  the	  biological	   significance	   of	   this	   is	   not	   yet	   understood	   [86].	   Both	   clathrin	  dependent	   and	   clathrin-­‐independent	   pathways	   have	   been	   suggested	   for	   the	  internalisation	  of	  the	  TRAIL	  receptors	  [86].	  	  	  Inhibition	   of	   clathrin	   mediated	   apoptosis	   using	   the	   drug	   Chlorpromazine	   or	  knockdown	   of	   AP2	   or	   Clathrin	   resulted	   in	   a	   restoration	   of	   cell	   surface	  expression	  of	  the	  TRAIL	  receptors	  and	  increased	  sensitivity	  to	  TRAIL	  induced	  apoptosis.	  In	  contrast,	  inhibition	  of	  raft/caveola	  mediated	  apoptosis,	  using	  the	  drug	   filipin	   III	   did	   not	   restore	   surface	   expression	   or	   affect	   the	   apoptotic	  response	  [74].	  Others	  have	  shown	  that	  dynamin	  inactivation	  inhibits	  TRAIL-­‐R2	  endocytosis	  in	  HELA	  cells	  and	  thereby	  claim	  that	  clathrin	  mediated	  endocytosis	  is	   required	   [87].	   However,	   dynamin	   is	   involved	   in	   both	   clathrin	   mediated	  endocytosis	  and	  other	  routes	  of	  endocytosis,	   so	   these	  results	  do	  not	  conclude	  that	  other	  endocytosis	  pathways	  might	  be	  involved.	  Endocytosis	  of	  TRAIL-­‐R1	  is	  mediated	  via	  a	  sorting	  signal	   (EAQC337LL)	   in	   the	   intracellular	  domain.	  Similar	  signals	   are	   present	   in	   many	   other	   receptors	   and	   have	   been	   implicated	   in	  mediating	  the	  rapid	  internalization	  of	  proteins	  and	  targeting	  to	  the	  endosomal-­‐lysosomal	  compartments.	  TRAIL-­‐R1	  with	  a	  mutated	  sorting	  signal	  (EAQC337AA)	  was	   almost	   exclusively	   expressed	   on	   the	   cell	   surface	   and	   the	   sensitivity	   to	  TRAIL	  was	  increased	  [74].	  	  	  In	   addition	   to	   internalisation,	   TRAIL	   signalling	   is	   also	   regulated	   by	   the	  localisation	   of	   the	   receptors	   in	   lipid	   raft	   micro-­‐domains	   in	   the	   plasma	  membrane.	   The	   role	   of	   lipid	   raft	   in	   death	   receptor	   signalling	   is	   discussed	   in	  detail	  in	  the	  next	  paragraph.	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1.6 The	  role	  of	  lipid	  rafts	  in	  death	  receptor	  signalling	  	  
1.6.1 Definition	  of	  lipid	  raft	  	  Lipid	   rafts	   are	   defined	   as	   dynamic	  microdomains	  within	   cellular	  membranes	  enriched	   with	   sphingolipids	   and	   cholesterol	   and	   resistant	   to	   detergent	  extraction.	   The	   rafts	   function	   as	   a	   signalling	   platform	   for	   targeted	   protein	  traffic	   and	   are	   involved	   in	   endocytosis	   via	   flotillin	   and	   caveolar-­‐dependent	  pathways	  [88].	  There	  are	  two	  different	  types	  of	  lipid	  rafts,	  the	  non-­‐invaginated	  rafts	  called	  planar	  rafts	  and	  tube-­‐like	   invaginations	  called	  caveola.	   In	  contrast	  to	   planar	   lipid	   rafts,	   the	  morphology	   of	   the	   caveola	   can	   be	   clearly	   visualised	  using	   electron	  microscopy.	   	   The	   reported	   size	   of	   lipid	   rafts	   varies	   to	   a	   large	  extent,	   although	   a	   recent	   consensus	   was	   made,	   considering	   lipid	   rafts	   to	   be	  between	  10–200	  nm	  in	  diameter	  [89].	  	  	  Although	   lipid	   rafts	   have	   been	   extensively	   studied,	   their	   biological	   relevance	  and	  even	  their	  very	  existence	  is	  still	  a	  matter	  of	  debate.	  The	  doubts	  are	  mainly	  due	  to	  limitations	  and	  lack	  of	  assays	  to	  isolate	  and	  study	  lipid	  rafts.	  Lipid	  rafts	  are	   considered	   to	   be	   highly	   dynamic	   structures	   and	   depending	   on	   the	   assay	  used,	  variations	  of	  protein	  composition	  in	  the	  raft	  fraction	  are	  observed	  which	  further	   contributes	   to	   the	   controversy	   [89].	   	   However,	   a	   variety	   of	   proteins	  such	   as	   receptor	   tyrosine	   kinases,	   adaptor	   proteins	   and	   G-­‐protein	   coupled	  receptors	  are	  preferentially	  compartmentalised	  in	  lipid	  rafts	  and	  caveola	  and	  it	  is	  suggested	   that	  protein	   localisation	   in	  rafts	  regulates	  or	  promotes	  signalling	  events	  and	  act	  as	  an	  important	  signalling	  platform	  [90].	  	  Caveolin	  proteins	  are	  key	  scaffolding	  proteins	  important	  for	  the	  formation	  and	  function	   of	   the	   caveola.	   Three	   isoforms	   of	   caveolin	   have	   been	   identified	  (caveolin	   1,	   2	   and	   3).	   Caveolin-­‐1	   and	   2	   are	   co-­‐expressed	   in	  many	   cell	   types,	  whereas	  caveolin	  3	  is	  mainly	  expressed	  in	  muscle	  cells	  [91].	  Caveolin-­‐1	  forms	  homo	   and	   hetero-­‐oligomers	   (~15	   molecules)	   with	   caveolin-­‐2	   in	   the	  endoplasmic	  reticulum	  and	  in	  the	  Golgi	  and	  are	  thereafter	  trafficked	  to	  the	  cell	  surface	   where	   they	   form	   the	   higher	   molecular	   mass	   complexes	   involved	   in	  caveola	  formation.	  Caveolin-­‐1	  expression	  alone	  has	  been	  shown	  to	  be	  sufficient	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for	   caveola	   formation	   and	   the	   role	   of	   caveolin-­‐2	   in	   this	   process	   is	   less	  understood.	   Caveolin-­‐1	   consists	   of	   a	   central	   hydrophobic	   region	   inserted	   in	  inner	   membrane	   of	   the	   plasma	   membrane	   with	   both	   C-­‐	   and	   N-­‐terminus	  exposed	  to	  the	  cytoplasm.	  The	  C-­‐terminal	  is	  important	  for	  the	  oligomerisation,	  whereas	  the	  N-­‐terminal	  contains	  a	  caveolin	  scaffolding	  domain	  (CSD)	  required	  for	  caveolin	  dimerisation	  and	  functions	  as	  an	   interaction	  domain	  with	  several	  signalling	  proteins	  that	  containing	  caveolin-­‐binding	  domains	  (CBD)	  (reviewed	  in	  [92]).	  	  	  The	  family	  of	  flotillins	  are	  also	  crucial	  for	  the	  formation	  of	  lipid	  rafts	  and	  they	  interact	  with	  actin,	  thereby	  linking	  the	  rafts	  to	  the	  cytoskeleton	  of	  the	  cell.	  The	  cytoskeleton	   is	   important	   for	   the	   mobility	   and	   distribution	   of	   the	   lipid	   rafts	  (reviewed	   in	   [93]).	   Endocytosis	   can	   occur	   via	   four	   different	   raft	   dependent	  routes.	  There	  are	  dynamin	  dependent	  and	  independent	  pathways.	  Furthermore	  the	   dynamin	   dependent	   pathway	   can	   be	   divided	   into	   Cav1	   dependent	   or	  independent	   routes	   (reviewed	   by	   [94]).	   The	   Cav1	   and	   dynamin	   independent	  endocytosis	  pathway	  requires	  Flotillin-­‐1	  and	  Cdc42	  [95].	  
1.6.2 Lipid	  rafts	  and	  death	  receptor	  signalling	  Studies	   have	   shown	   that	   death	   receptor	   signalling	   is	   dependent	   on	   the	  localisation	  of	  death	  receptors	  in	  the	  plasma	  membrane.	  Compartmentalisation	  of	   Fas	   and	   the	   TRAIL	   receptors	   in	   lipid	   rafts	   have	   been	   shown	   to	   promote	  receptor	   clustering	   and	   DISC	   formation,	   subsequently	   promoting	   apoptotic	  signalling	   [96,	   97].	   It	   has	   also	   been	   suggested	   that	  whereas	   TRAIL	   receptors	  located	   in	   lipid	   rafts	   mediate	   apoptotic	   signalling,	   receptors	   in	   non-­‐rafts	  promote	   alternative	   signalling	   pathways,	   such	   as	   NfκB	   signalling	   [98].	  Treatment	   with	   several	   drugs,	   such	   as	   epirubicin,	   oxaliplatin	   and	   quercetin results	   in	   a	   translocation	   of	   the	   TRAIL	   receptors	   to	   lipid	   rafts	   and	   increased	  receptor	  clustering	  leading	  to	  increased	  sensitivity	  to	  TRAIL	  [99-­‐101].	  Little	  is	  known	   regarding	   the	   mechanisms	   promoting	   compartmentalisation	   of	   lipid	  rafts,	  although	  the	  translocation	  of	  the	  death	  receptors	  to	  the	  rafts	  appears	  to	  be	  ligand	  dependent	  at	  least	  in	  some	  cell	  types.	  In	  human	  T-­‐cells,	  low	  levels	  of	  Fas	  were	   detected	   in	   lipid	   rafts	   in	   non-­‐treated	   cells	   followed	   by	   a	   significant	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translocation	   of	   the	   receptor	   following	   FasL	   treatment.	   Moreover,	   treatment	  with	   a	   lipid	   raft	   disrupting	   drug,	   methyl-­‐beta-­‐cyclodextrin,	   inhibited	   the	  apoptotic	   response,	   further	   supporting	   the	   importance	   of	   the	   lipid	   rafts	   for	  efficient	   downstream	   cell	   death	   signalling	   [102].	   	   Similarly,	   experiments	  performed	  using	  the	  human	  lung	  carcinoma	  cell	  line,	  NCI-­‐H460,	  showed	  TRAIL-­‐R1	  and	  -­‐R2	  to	  be	  primarily	   localized	   to	   lipid	  rafts	  after	   treatment	  with	  TRAIL	  [103].	   In	   contrast,	  TRAIL-­‐R2	   is	   reported	   to	  be	   constitutively	   localised	   in	   lipid	  rafts	  in	  the	  Jurkat	  cell	  lines	  TIB152	  and	  TIB153,	  [104].	  	  S-­‐Palmitoylation	  functions	  as	  a	  key	  signal	  for	  the	  FasL	  dependent	  redistribution	  of	   Fas	   to	   lipid	   raft	   domains	   [105].	   S-­‐palmitoylation	   is	   a	   reversible	   post-­‐translational	   lipid	   modification,	   attaching	   a	   16-­‐carbon	   fatty	   acid	   to	   cysteine	  residues	  known	   to	   target	   several	   signalling	  proteins,	   such	   as	  Ras	  GTPases,	   to	  lipid	  rafts	  (reviewed	  in	  [106]).	  TRAIL-­‐R1	  is	  also	  palmitoylated,	  promoting	  lipid	  raft	  localisation	  and	  receptor	  oligomerisation.	  Palmitoylation	  of	  TRAIL-­‐R2	  and	  TNFR1	  has	  not	  been	  observed	  [107].	  	  	  	  	  	  	  In	  addition	  to	  the	  palmitoylation	  of	  the	  Fas	  receptor,	  a	  lysine	  rich	  region	  (LRR)	  in	   the	   cytoplasmic	   region	   adjacent	   to	   the	   transmembrane	   domain	   has	   been	  identified	  as	  a	  lipid	  raft	  targeting	  signal	  necessary	  for	  Fas-­‐mediated	  cell	  death.	  The	  LRR	  region	  consists	  of	  four	  or	  five	  lysines	  surrounding	  the	  palmitoylation	  site.	   TRAIL-­‐R2	   and	   TNFR1	   also	   have	   a	   region	   similar	   to	   the	   LRR	   of	   the	   Fas	  receptor,	  which	  may	  contribute	  to	  the	  lipid	  raft	  localisation	  [108].	  	  	  Further	   studies	   investigating	   the	   dynamics	   of	   lipid	   rafts	   and	   TRAIL	   receptor	  signalling	   is	   however	   required.	   Since	   the	   location	   of	   the	   TRAIL	   receptors	   in	  lipid	   rafts	   have	   been	   shown	   to	   be	   able	   to	   sensitise	   cells	   to	   TRAIL,	   further	  understanding	  of	  the	  lipid	  raft	  dynamics	  may	  contribute	  to	  development	  of	  new	  cancer	  therapy.	  In	  this	  thesis,	  the	  Activated	  Cdc42-­‐associated	  kinase	  1	  (Ack1)	  is	  identified	   as	   a	   protein	   promoting	   TRAIL	   induced	   apoptosis	   by	   inducing	   lipid	  raft	  localisation	  of	  the	  TRAIL	  receptors.	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1.7 Activated	  Cdc42-­associated	  kinase	  1	  Activated	   Cdc42-­‐associated	   kinase	   1	   (Ack1)	   also	   known	   as	   tyrosine	   kinase,	  non-­‐receptor	   2	   (Tnk2)	   has	   been	   described	   to	   regulate	   a	   variety	   of	   cellular	  events.	  Some	  of	  which	  are	  summarised	  below	  and	  might	  be	  linked	  to	  the	  novel	  role	  of	  Ack1	  in	  TRAIL	  signalling	  reported	  in	  this	  thesis.	  	  	  Ack1	  was	   first	  cloned	   in	  1993	   from	  a	  human	  hippocampal	  expression	   library,	  identified	  as	  an	  interacting	  partner	  with	  the	  activated	  form	  of	  the	  Rho-­‐GTPase	  Cdc42	   [109].	   	  The	  human	  Ack1	  gene	   is	   located	  at	   chromosome	  3q29	   [110],	   a	  region	  which	   have	   been	   associated	  with	   hematologic	  malignancies	   and	   [111]	  adrenocortical	  carcinomas	  [112].	  	  	  Ack1	   can	   be	   activated	   by	   several	   external	   stimuli	   such	   as	   platelet-­‐derived	  growth	   factor	   (PDGF),	   epidermal	   growth	   factor	   (EGF),	   insulin	   and	   integrin	  mediated	   adhesion.	   A	   pool	   of	   Ack1	   protein	   is	   constitutively	   phosphorylated,	  even	  after	  prolonged	  starvation	  [110].	  	  
1.7.1 Structure	  of	  Ack1	  	  Ack1	  is	  a	  120	  kDa	  tyrosine	  kinase	  containing	  a	  series	  of	  domains	  and	  binding	  regions	  (Figure	  6).	  The	  protein	  consists	  of	  a	  N-­‐terminal	  sterile	  α-­‐motif	  (SAM)	  -­‐like	   domain	   [110],	   followed	   by	   a	   tyrosine	   kinase	   domain,	   a	   Src-­‐homology	   3	  (SH3)	  domain,	  a	  Cdc42/Rac	  interactive	  binding	  (CRIB)	  domain	  and	  a	  conserved	  C-­‐terminal	   proline-­‐rich	   region	   homologous	   to	   the	   ErbB	   receptor	   inhibitor	  Mitogen	  inducible	  gene	  6	  (Mig6),	  functioning	  as	  a	  generic	  RTK-­‐binding	  domain	  [113].	   The	   SAM-­‐like	   domain	   has	   been	   suggested	   to	   function	   as	   a	  membrane-­‐targeting	  signal,	  thereby	  regulating	  the	  sub-­‐cellular	  localisation	  of	  Ack1	  [110].	  The	  tyrosine	  residue,	  Y284,	  found	  in	  the	  activation	  loop	  of	  the	  kinase	  has	  been	  identified	  as	   the	  primary	  autophosphorylation	  site	   in	  Ack1.	  A	  mutation	  of	   the	  Y284	  residue	  leads	  to	  a	  significant	  decrease	  in	  protein	  phosphorylation	  [114].	  Ack1	   also	   interacts	   with	   the	   adaptor	   Grb2	   mediating	   the	   recruitment	   of	  receptor	  tyrosine	  kinases	  such	  as	  Axl,	  leukocyte	  tyrosine	  kinase	  (LTK)	  and	  the	  anaplastic	  lymphoma	  kinase	  (ALK)	  [113].	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Ack1	   contains	   several	   protein-­‐protein	   interaction	   domains	   and	   a	   series	   of	  interaction	   partners	   and	   phosphorylation	   targets	   have	   been	   identified,	  however	  the	  significance	  of	  many	  of	  the	  interactions	  is	  not	  known.	  	  	  
	  
	  
Figure	  6.	  Domain	  structure	  of	  Ack1	  Ack1	   is	  a	  non-­‐receptor	  tyrosine	  kinase	  consisting	  of	  an	  N-­‐terminal	  SAM-­‐like	  domain	   followed	  by	   a	   tyrosine	   kinase	   domain,	   a	   SH3	   domain,	   CRIB	   domain,	   a	   C-­‐terminal	   proline-­‐rich	   region	  homologous	   to	   the	   ErbB	   receptor	   inhibitor	   Mig6	   and	   a	   UBA	   domain	   in	   the	   C-­‐terminus.	  
Abbreviations:	  CRIB:	  Cdc42/Rac	   interactive	  binding,	  EBD:	  EGFR	  binding	  domain,	  Mig6:	  Mitogen	  
inducible	  gene	  6,	  SAM:	  sterile	  α-­motif,	  SH3:	  Src-­homology	  3,	  UBA:	  Ubiquitin	  associated	  
1.7.2 Role	  of	  Ack1	  in	  vivo	  	  Ack1	   is	   ubiquitously	   expressed,	   with	   the	   highest	   expression	   in	   brain,	   spleen	  and	   thymus	   [110].	   Amplification	   of	   the	   ACK1	   gene	   and/or	   overexpression	   of	  Ack1	  mRNA	  have	  been	   identified	   in	  a	  variety	  of	  human	  primary	   tumours	  and	  been	  correlated	  with	  a	  poor	  prognosis	   [115].	  The	  overexpression	  and	  gain	  of	  copy	  number	  were	  most	  evident	  in	  late	  stage	  primary	  tumours	  and	  metastatic	  tumours	   but	  were	   uncommon	   in	   early	   stage	   tumours,	   suggesting	   that	   cancer	  cells	   acquiring	   overexpression	   of	   Ack1	   are	   more	   prone	   to	   metastasise.	   The	  highest	  frequency	  of	  ACK1	  amplification/overexpression	  was	  detected	  in	  lung,	  ovarian	  and	  prostate	  primary	  tumours	  [115].	  in	  vivo	  experiments	  in	  mice,	  with	  implantation	   of	   cancer	   cells	   overexpressing	   Ack1,	   showed	   that	   Ack1	  contributes	   to	   a	   significantly	   increased	   tumour	   burden	   in	   the	   lungs	   [115].	   A	  transgenic	   mouse	   model	   overexpressing	   an	   activated	   form	   of	   Ack1	   (L487F)	  exclusively	   in	   the	   prostate,	   develop	   prostatic	   epithelial	   neoplasia	   [116].	   Ack1	  has	   been	   suggested	   to	   promote	   prostate	   tumour	   progression	   via	   an	  ErbB2/ErbB3	  dependent	  mechanism,	  by	  phosphorylation	  and	  activation	  of	  the	  Androgen	   receptor	   (AR)	   [117]	  Ack1	  has	  also	  been	   reported	   to	  phosphorylate	  the	   putative	   tumour	   suppressor,	   WW	   domain	   containing	   oxidoreductase	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(Wwox),	   and	   thereby	   targeting	   it	   for	   poly-­‐ubiquitinylation	   and	   degradation	  [118].	  1.7.2.1 The	  role	  of	  Ack1	  in	  ErbB	  receptor	  signalling	  Ack1	   is	   implicated	   in	   the	   regulation	   of	   Epidermal	   growth	   factor	   receptor	  (EGFR)	   signalling	   however	   conflicting	   results	   have	   been	   published	   and	   the	  details	  regarding	  the	  role	  of	  Ack1	  have	  yet	  to	  be	  resolved.	  	  Ack1	  interacts	  with	  the	   EGFR	   receptor	   through	   a	   conserved	   EGFR-­‐binding	   domain	   (EBD)	   in	   the	  proline	   rich	   region	  of	   the	  protein.	  The	   interaction	  between	  Ack1	  and	  EGFR	   is	  dependent	   on	   the	   tyrosine	   kinase	   activity	   of	   EGFR,	   but	   independent	   of	  activation	   status	   of	   Ack1	   [119].	   One	   study	   proposes	   that	   Ack1	   induces	   EGFR	  degradation	   via	   the	   putative	   ubiquitin	   association	   (Uba)	   domain	   in	   the	   C-­‐	  terminus.	   Knockdown	  of	   Ack1	   or	   overexpression	   of	   an	  Uba-­‐domain	   defective	  mutant	   in	  HEK293	  cells,	   inhibited	  EGF-­‐induced	   internalisation	  of	  EGFR	  [119].	  Others	   report	   that	   both	   overexpression	   and	   siRNA	   mediated	   knockdown	   of	  Ack1	   leads	   to	  decreased	   internalisation	   rate	  of	  EGF.	   In	  addition,	   an	   increased	  recycling	  of	  EGFR	  in	  Ack1	  knockdown	  cells	  has	  been	  reported,	  suggesting	  that	  Ack1	   promotes	   endosomal	   sorting	   of	   the	   receptor	   to	   the	   endosomes	   for	  degradation	  [120].	  In	  contrast	  to	  this	  finding,	  an	  additional	  study	  suggests	  that	  Ack1	  promotes	  cell	  surface	  expression	  of	  EGFR	  in	  breast	  epithelial	  cells	  [121].	  In	   C.	   elegans,	   the	   related	   protein	   A	   Ras-­‐regulating	   Kinase	   1	   (Ark-­‐1)	   is	  functioning	  as	  negative	  regulator	  of	  Let-­‐23	  signalling,	  the	  C.	  elegans	  homologue	  of	  EGFR	  [122].	  However	  the	  role	  of	  Ack1	  in	  mammalian	  ErbB	  signalling	  is	  not	  conclusive.	  	  1.7.2.2 Ack1	  and	  endocytosis	  Additionally,	  Ack1	  also	  interacts	  with	  several	  proteins	  involved	  in	  endocytosis	  and	   trafficking.	   Two	   clathrin	   heavy	   chain	   (CHC)	   binding	   domains	   have	   been	  identified	   [123,	   124]	   and	   Ack1	   also	   interacts	   with	   adaptor	   protein	   2	   (AP2),	  Amphiphysins-­‐1	  and	  2	  and	   sorting	  nexin	  9	   (SNX	  9)	   all	   components	  of	   vesicle	  dynamics.	   The	   role	   of	   Ack1	   in	   clathrin	  mediated	   endocytosis	   is	   however	   not	  fully	   understood.	   Overexpression	   of	   ACK1	   leads	   to	   disturbed	   clathrin	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of	   the	   transferrin	   receptor,	   known	   to	   be	   internalised	   via	   clathrin	   mediated	  endocytosis	   [124].	   In	   addition	   it	   has	   also	   been	   suggested	   that	   the	  phosphorylation	  of	  Ack1	  is	  dependent	  on	  localisation	  of	  the	  protein	  at	  clathrin	  coated	  pits	  and	  Cdc42	  activation	  [123].	  	  	  1.7.2.3 Ack1	  is	  activated	  by	  Cdc42	  Ack1	  is	  a	  downstream	  effector	  of	  the	  Rho	  GTPase,	  Cell	  division	  control	  protein	  42	   (Cdc42)	   [109]	  Cdc42	   is	   involved	   in	   a	   variety	   of	   cellular	   functions,	   such	   as	  cell	   morphogenesis,	   migration	   and	   cell	   cycle	   progression	   (see	   1.8).	   Ack1	  mediates	  cell	  migration	  via	  a	  Cdc42	  dependent	  mechanism,	  by	  phosphorylating	  the	  adaptor	  protein	  p130cas,	   crucial	   for	   integrin-­‐mediated	  signalling	  pathways	  promoting	   cell	   migration	   [125].	   Moreover,	   Ack1	   can	   phosphorylate	   Wiskott-­‐Aldrich	   syndrome	  protein	   (WASP)	  and	   thereby	  promote	   its	  actin	   remodelling	  activity.	  In	  this	  thesis,	  a	  novel	  role	  of	  Ack1	  in	  death	  receptor	  signalling	  has	  been	  discovered,	  possibly	  via	  a	  Cdc42	  dependent	  mechanism.	  	  
1.7.3 Activation	  and	  regulation	  of	  Ack1	  It	  has	  been	  suggested	  that	  Ack1	  is	  an	  auto-­‐inhibited	  kinase,	  regulated	  by	  intra-­‐molecular	  interactions.	  Two	  models	  have	  been	  proposed,	  one	  where	  the	  EGFR	  binding	  domain	  in	  the	  proline-­‐rich	  region	  binds	  to	  the	  kinase	  domain	  [126]	  and	  secondly	  an	   interaction	  between	   the	  SH3	  domain	  and	   the	  proline-­‐rich	  region,	  potentially	   forming	  an	  auto-­‐inhibited	  state	   [110].	  However,	   these	   two	  models	  have	   recently	   been	   questioned	   by	   Manser	   et	   al.,	   2011.	   In	   their	   work,	   point	  mutations	   in	   the	   SH3	   and	   ErbB	   binding	   region	   did	   not	   activate	   Ack1,	   as	   has	  previously	  been	  reported.	  In	  contrast,	  they	  suggest	  that	  the	  oncogenic	  tyrosine	  kinase	  Src	   is	   required	   for	  Ack1	  activation	  by	  phosphorylation	  of	  Tyr284	   in	   the	  activation	  loop,	  functioning	  as	  the	  key	  regulator	  [127].	  	  	  The	   regulation	   of	   the	   turnover	   of	   Ack1	   has	   yet	   to	   be	   fully	   understood;	   both	  proteasomal	  and	  lysosomal	  degradation	  have	  been	  proposed.	  Two	  E3	  ubiquitin	  ligases;	  neural	  precursor	   cell	   expressed	  and	  developmentally	  down	   regulated	  4-­‐1	  and	  -­‐2	  (Nedd4-­‐1	  and	  Nedd4-­‐2)	  have	  been	  shown	  to	  interact	  with	  Ack1,	  via	  a	   conserved	   PPXY-­‐containing	   region	   in	   the	   proline	   rich	   domain	   of	   Ack1,	   and	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target	   the	   protein	   for	   degradation	   [128,	   129].	   Nedd4-­‐2	   and	   Ack1	   have	   been	  shown	  to	  co-­‐localise	  in	  clathrin-­‐rich	  vesicles	  and	  Nedd4-­‐2	  is	  proposed	  to	  down-­‐regulate	  Ack1	  by	  ubiquitinylation	   leading	   to	   targeting	  and	  degradation	   in	   the	  proteasome.	   The	   proteasome	   inhibitor	   MG132	   can	   inhibit	   this	   degradation.	  Kinase	  activity	  of	  Ack1	   is	   required	   for	   the	   interaction	  with	  Nedd4-­‐2	   [128].	   In	  contrast,	  another	  study	  reported	  that	  Ack1	  levels	  are	  regulated	  by	  the	  Nedd4-­‐1	  ligase	  and	  not	  Nedd4-­‐2,	  even	  though	  both	  interact	  with	  Ack1.	  They	  also	  claim	  that	  Ack1	  is	  degraded	  in	  the	  lysosome	  and	  not	  the	  proteasome,	  since	  lysosomal	  inhibitors	  inhibited	  degradation	  whereas	  proteasomal	  inhibitors	  did	  not	  [129].	  	  
1.7.4 The	  role	  of	  Ack1	  in	  apoptosis	  A	   role	   for	   Ack1	   in	   cell	   death	   has	   only	   been	   described	   once	  where	   Ack1	  was	  classified	   as	   survival	   kinase	   in	   an	   RNAi	   screen	   targeting	   all	   known	   kinases.	  Apoptosis	  was	   induced	  by	  cytotoxic	  drugs	  (paclitaxel,	   cisplatin,	  or	  etoposide),	  activating	   the	   mitochondrial	   pathway.	   Cell	   death	   was	   assessed	   using	   an	  enzyme-­‐linked	   immunosorbent	   assay	   (ELISA)	   against	  histone-­‐associated	  DNA	  fragments.	  Knockdown	  of	  Ack1	  induced	  ≥	  2.5	  times	  more	  apoptosis	  compared	  to	   control	   cells,	   leading	   it	   to	   be	   classified	   as	   a	   survival	   kinase.	   However,	   the	  phenotype	   was	   not	   further	   characterised	   and	   no	   molecular	   mechanism	   was	  described	  [130].	  	  	  In	   this	   thesis,	   a	   novel	   role	   of	   Ack1	   in	   death	   receptor	   signalling	   is	   presented,	  showing	   that	  Ack1	   is	   crucial	   for	  TRAIL	   induced	  apoptosis.	  We	  also	   show	   that	  Cdc42	  is	  required	  for	  TRAIL	  apoptosis,	  possibly	  by	  activating	  Ack1.	  Below	  is	  a	  summary	  of	  Cdc42	  function	  and	  regulation.	  	  
1.8 Cdc42	  mediated	  cell	  signalling	  Cdc42	   belongs	   to	   the	   Rho	   family	   of	   small	   GTPases	   together	   with	   Rho	   and	  Rac.	  Cdc42	  functions	  as	  a	  molecular	  switch,	  reverting	  from	  a	  GDP	  inactive	  state	  to	   a	   GTP-­‐bound	   active	   state	   in	   response	   to	   multiple	   stimuli	   such	   as	   growth	  factors,	   cytokines	  and	  cell-­‐cell	   interactions.	   In	   its	  active	   form,	  Cdc42	   interacts	  with	   a	   series	   of	   effector	   proteins	   thereby	   activating	   signalling	   pathways	  involved	   in	   a	   variety	   of	   cellular	   processes	   such	   as	   migration,	   invasion,	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reorganisation	   of	   the	   cytoskeleton,	   endocytosis,	   vesicle	   trafficking,	  transcription,	  cell	  polarity	  and	  cell	  cycle	  progression	  (Figure	  7).	  The	  activity	  of	  Cdc42	   is	   strictly	   regulated	   by	   three	   groups	   of	   regulators;	  guanine	   nucleotide	  exchange	   factors	   (GEFs)	   facilitate	   the	   hydrolysis	   from	   GDP	   to	   GTP,	   GTPase	  activating	   proteins	   (GAPs)	   increase	   the	   GTPase	   activity	   of	   Cdc42	   leading	   to	  inactivation,	   and	   guanine	   nucleotide-­‐dissociation	   inhibitors	   (GDI)	   sequester	  Cdc42	   from	   the	   cellular	   membrane,	   preventing	   its	   activation	   (reviewed	   in	  [131]).	  	  	  Cdc42	   promotes	   actin	   polymerisation	   and	   remodelling	   via	   N-­‐WASP	   and	  Arp2/3,	   important	   for	   regulating	   the	   formation	   of	   microspikes	   and	   filopodia	  [132-­‐135].	   Cdc42	   also	  modulates	   the	   formation	   of	   cell	   polarity	   by	   regulating	  vesicle	   trafficking	   in	   the	   cystoplasm	   towards	   the	   apical	   or	   basolateral	   side	   of	  the	  cell	  [136].	  Cdc42	  interacts	  with	  proteins	  regulating	  endocytosis	  and	  Cdc42	  also	  mediate	   traffic	  between	  ER	  and	  Golgi.	   Inhibiting	  Cdc42	  alters	  membrane	  traffic	   in	   polarized	   epithelial	   cells,	   affecting	   traffic	   via	   both	   the	   trans-­‐Golgi	  network	   and	   the	   recycling	   between	   the	   plasma	   membrane	   and	   endosomes	  [136-­‐138].	  	  	  Furthermore,	  Cdc42	  regulates	  cell-­‐cell	   junctions	  by	  regulating	  the	  endocytosis	  and	   trafficking	   of	   junctional	   proteins,	   although	   by	   which	   mechanism	   is	   still	  controversial.	  Whereas	  some	  suggest	  that	  active	  Cdc42	  is	  required	  for	  stable	  E-­‐cadherin	   adhesion	   at	   adherens	   junctions	   by	   actin	   cytoskeleton	   remodelling	  [139,	  140],	  others	  report	  that	  Cdc42	  promotes	  ubiquitination	  and	  degradation	  of	   E-­‐cadherin,	   subsequently	   leading	   to	   the	   dissolution	   of	   adherens	   junctions	  [141].	  Lack	  of	  Cdc42	  also	  leads	  to	  mislocalisation	  of	  junctional	  proteins	  such	  as	  α-­‐	   and	   β-­‐catenin	   in	   drosophila	   [142]	   and	   degradation	   of	   β-­‐catenin	   in	   mice,	  causing	  impairment	  of	  cell-­‐cell	  contacts	  [143].	  Cell-­‐cell	  junctions	  are	  discussed	  further	  in	  1.9.	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Figure	  7.	  Cdc42	  regulation	  and	  signalling	  	  The	   small	   GTPase,	   Cdc42,	   switches	   from	   an	   inactive	   (GDP-­‐bound)	   to	   an	   active	   (GTP-­‐bound)	  state.	  Active	  Cdc42	  can	  interact	  with	  multiple	  effector	  proteins,	  such	  as	  Ack1	  and	  WASP,	  leading	  to	  the	  activation	  of	  downstream	  signalling	  pathways	  regulating	  a	  variety	  of	  cellular	  processes.	  Cdc42	   is	   tightly	   regulated	   by	   three	   groups	   of	   regulatory	   proteins;	   GEFs,	   that	   mediate	   the	  hydrolysis	   of	   GDP	   to	   GTP,	   GAPs,	   that	   increase	   the	   GTPase	   activity	   of	   Cdc42	   leading	   to	  inactivation	   and	   GDIs,	   that	   sequester	   Cdc42	   in	   the	   cytosol	   preventing	   its	   activation.	  
Abbreviations:	  Ack1:	  Activated	  Cdc42-­associated	  kinase	  1,	  Cdc42:	  Cell	  division	  control	  protein	  42	  
homolog,	  GAP:	  GTPase	  activating	  proteins,	   GDI,	   guanine	  nucleotide-­dissociation	   inhibitors,	  GEF:	  
Guanine	   nucleotide	   exchange	   factor,	   PAK:	   p21-­activated	   protein	   kinase,	  RTK,	   Receptor	   tyrosine	  
kinase,	  WASP:	  Wiskott–Aldrich	  syndrome	  protein	  
	  
1.9 Epithelial	  cell-­cell	  junctions	  	  While	   elucidating	   the	   role	   of	   Ack1	   in	   TRAIL	   induced	   apoptosis,	   we	   also	  discovered	  that	  Ack1	  is	  required	  for	  cell-­‐cell	  junction	  stability	  or	  formation.	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Epithelial	   cells	  are	   joined	   together	  by	  a	  series	  of	   intercellular	   junctions	  at	   the	  lateral	  side	  of	  polarized	  cells.	  There	  are	  four	  different	  types	  of	   junctions;	  tight	  junctions	  (TJs),	  adherens	  junctions	  (AJs),	  gap	  junctions	  (GJs)	  and	  desmosomes.	  The	  TJs	  are	  the	  most	  apical	  junctions	  in	  epithelial	  cells,	  functioning	  as	  a	  strong	  barrier	   preventing	   leakage	  of	  molecules	   between	   the	   apical	   and	  basal	   side	   of	  the	  cells.	  They	  are	  often	  considered	  as	   the	  border	  between	  the	  apical	  and	  the	  basolateral	  side	  of	  a	  cell	  and	  have	  been	  suggested	  to	  play	  a	  role	  in	  polarity.	  Gap-­‐junctions	  function	  as	  a	  passage	  of	  small	  water-­‐soluble	  molecules	  between	  cells	  and	  are	  important	  for	  intercellular	  communication	  (reviewed	  in	  [144]).	  ZO-­‐1	  is	  a	   commonly	   used	   TJ	   junction	  marker	   and	  was	   the	   first	   TJ-­‐associated	   protein	  discovered	  [145]	  (Figure	  8).	  	  AJs	  and	  desmosomes	  provide	  adherent	  strength	  between	  cells	  and	  are	  linked	  to	  the	   actin	   cytoskeleton	   and	   intermediate	   filaments	   respectively.	   The	  desmosomes	  provide	  extra	  adherent	  strength	  and	  are	  more	  abundant	   in	  cells	  undergoing	  mechanical	  stress	  such	  as	  epidermis	  and	  cardiac	  muscle.	  Both	  AJs	  and	  desmosomes	  are	  highly	  calcium	  dependent	  and	  share	  a	  similar	  structure.	  Cadherins,	   mainly	   E-­‐Cadherin	   in	   adherens	   junctions	   and	   the	   desmosomal	  cadherins,	   including	   desmocollins	   (Dscs)	   and	   desmogleins	   (Dsgs),	   forms	   the	  physical	   link	  between	   the	  cells.	  The	  cadherins	   in	   turn	   interact	  with	  armadillo	  proteins	   bound	   to	   catenins	   such	   as	   β-­‐,	   α-­‐catenin	   and	   desmosomal	   catenins,	  such	   as	   γ-­‐catenin,	   which	   function	   as	   the	   link	   to	   the	   cytoskeleton	   (Figure	   8).	  	  While	   cell-­‐cell	   junctions	   were	   previously	   considered	   to	   only	   function	   as	  structural	   bonds	   between	   cells,	   it	   is	   now	   clear	   that	   junctional	   complexes	   can	  also	   function	   as	   signalling	   platforms.	   The	   cadherin–catenin	   complex	   can	  interact	   with	   several	   other	   proteins,	   including	   signalling	   proteins	   and	   cell	  surface	   receptors,	   thereby	   functioning	   as	   a	   center	   for	   protein–protein	  interactions	  [146].	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Figure	  8.	  Cell-­cell	  junctions	  in	  epithelial	  cells.	  	  The	   tight	   junctions	   are	   the	  most	   apical	   junctions	   in	   epithelial	   cells	   and	   function	   as	   a	   barrier	  between	   the	   apical	   and	   basal	   side	   and	   are	   also	   important	   cell	   signalling	   platforms.	   The	  adherens	  junctions	  provide	  adherent	  strength	  between	  cells.	  Both	  tight	  junction	  and	  adherens	  junctions	  are	  linked	  to	  the	  actin	  cytoskeleton.	  The	  desmosomes	  provide	  adherent	  strength	  and	  are	  connected	  to	  the	  intermediate	  filaments.	  Abbreviations:	  ZO:	  Zona	  occludens	  	  Loss	   of	   cell-­‐cell	   junctions	   and	   adhesion	   is	   a	   characteristic	   of	   epithelial	   to	  mesenchymal	   transition	   (EMT).	   During	   EMT,	   epithelial	   cells	   acquire	   more	  mesenchymal-­‐like	   morphology	   promoting	   migration	   and	   invasiveness	   of	   the	  tumour	   cells	   through	   the	   basal	   membrane	   and	   the	   extracellular	   matrix.	  Junctional	  proteins	  typical	  for	  epithelial	  cell	  junctions	  such	  as	  β-­‐catenin	  and	  E-­‐cadherin	   are	  downregulated,	  whereas	  mesenchymal	  proteins	   like,	  N-­‐cadherin	  and	  vimentin	  are	  upregulated	  (reviewed	  in	  [147]).	  	  	  	  In	   this	   thesis,	   a	   novel	   role	   of	   Ack1	   in	   TRAIL	   receptor	   signalling	   and	   cell-­‐cell	  junction	  stability	  and	  formation	  is	  presented.	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Research	  Aim	  TRAIL	   receptor	   signalling	   has	   been	   extensively	   studied	   the	   last	   15	   years,	  however	   further	  mechanistic	   insight	   of	   how	   the	   receptors	   are	   regulated	   and	  trafficked	  is	  needed.	  Innate	  and	  acquired	  resistance	  to	  TRAIL	  has	  evolved	  to	  be	  a	   big	   hurdle	   in	   the	   use	   of	   recombinant	  TRAIL	   and	  TRAIL	   receptor	   agonist	   as	  cancer	  therapy.	  	  	  In	  this	  work,	  the	  non-­‐receptor	  tyrosine	  kinase	  Ack1	  is	  reported	  to	  be	  crucial	  for	  TRAIL	  induced	  apoptosis	  in	  human	  epithelial	  cells.	  The	  aim	  with	  this	  thesis	  is	  to	  investigate	  the	  molecular	  mechanisms	  by	  which	  Ack1	  regulates	  TRAIL	  induced	  apoptosis.	  This	  will	  be	  investigated	  specifically	  by	  cell	  biology	  and	  biochemical	  methods	  assessing	  the	  receptor	  cell	  surface	  expression,	  subcellular	  localisation	  of	  the	  TRAIL	  receptors,	  oligomerisation	  and	  DISC	  formation.	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Chapter	  2	  -­	  Materials	  and	  methods	  
3.1 Cell	  culture	  
3.1.1 Cell	  line	  maintenance	  	  The	  non-­‐tumourigenic	  human	  mammary	  epithelial	  cell	  line;	  MCF10A,	  obtained	  from	   American	   Type	   Culture	   Collection	   (ATCC),	   was	   cultured	   in	   DMEM/F12	  (Invitrogen)	  supplemented	  with	  5%	  horse	  serum	  (v/v)	  (Invitrogen),	  20	  ng/ml	  EGF	  (Miltenyi	  Biotech),	  0.5	  mg/ml	  hydrocortisone,	  100	  ng/ml	  cholera	  toxin	  and	  10	  µg/ml	   insulin	   (all	   from	   Sigma).	   HELA	   (human	   cervical	   carcinoma	   cells)	  (from	  Wolfson	   Institute	   for	  Biomedical	  Research	   (WIBR)	   cell	   repository)	  was	  cultured	   in	   DMEM	   (Invitrogen)	   supplemented	   with	   10%	   fetal	   bovine	   serum	  (FBS)	   (v/v)	   (PAA	   clone,	   PAA	   Laboratories	   Ltd.).	   SW480	   cells	   (human	   colon	  carcinoma	  cells)	  (WIBR	  cell	  repository)	  was	  cultured	  in	  Leibovitz’s	  L15	  media	  (Invitrogen)	  supplemented	  with	  10%	  FBS.	  The	  human	  lung	  carcinoma	  cell	  line,	  NCI-­‐H460	  (WIBR	  Cell	  Repository),	  was	  cultured	   in	  RPMI-­‐1460	  with	  10%	  FBS.	  All	  cell	  cultures	  were	  cultivated	  at	  37°C	  with	  5%	  CO2,	  except	  SW480	  cells	  which	  was	  cultured	  in	  100%	  air.	  Cells	  were	  routinely	  passaged	  three	  times	  per	  week	  by	  trypsinisation,	  using	  0.05%	  trypsin-­‐ethylenediaminetetraacetic	  acid	  (EDTA)	  (Invitrogen)	  in	  PBS	  with	  0.02%	  EDTA.	  	  
3.1.2 Cryopreservation	  of	  cultured	  cell	  lines	  All	  cell	  lines	  used	  were	  cryopreserved	  in	  liquid	  nitrogen	  for	  long-­‐term	  storage.	  Cells	  were	  washed	  in	  PBS,	  trypsinised	  and	  thereafter	  centrifuged	  at	  74	  x	  g	  for	  3	  minutes	  (min)	  in	  an	  Eppendorf	  5804	  centrifuge.	  The	  cells	  were	  resuspended	  in	  freezing	   media	   (70%	   FBS,	   20%	   DMEM	   and	   10%	   dimethyl	   sulfoxide	   (DMSO)	  (Sigma),	   (v/v))	   at	   a	   concentration	   of	   approximately	   1-­‐2	  x	  106	  cells/ml	   and	  aliquoted	   in	  cryovials	   (Corning).	  The	  vials	  were	  deposited	   in	  a	  5100	  Cryo	  1°C	  freezing	  container	  (Nalgene)	  with	  isopropanol	  and	  placed	  at	  -­‐80°C,	  allowing	  a	  cooling	   rate	   of	   1°C	  per	  min.	  The	   vials	  were	   transferred	   to	   liquid	  nitrogen	   for	  long-­‐term	  storage	  after	  24	  hours	  (h)	  storage	  at	  -­‐80°C.	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3.1.3 Thawing	  of	  cryopreserved	  cell	  lines	  A	  cryovial	  with	  cells	  was	  quickly	  thawed	  in	  a	  37°C	  water	  bath	  and	  transferred	  to	  a	  tube	  containing	  4	  ml	  pre-­‐warmed	  (37°C)	  complete	  cell	  culture	  media.	  Cells	  were	   centrifuged	   for	   3	  min	   at	   74	   x	   g	   and	   resuspended	   in	   cell	   culture	  media,	  suitable	   for	   the	   specific	   cell	   line,	   and	   plated	   in	   a	   10	  cm	   cell	   culture	   dish	  (Corning).	  	  










Table	  1.	  siRNA	  sequences	  siRNA	  used	  for	  knockdown	  of	  Ack1	  and	  Cdc42.	  Non-­‐targeting	  siRNA	  was	  used	  as	  a	  control.	  	  	  
Target	  gene	  
(name	  of	  oligo)	  
Sequence	  	  
(sense	  5’ 	  3’)	  
siRNA	  ID#	   Manufacturer	  
Ack1(a)	   GGAUGAGGAUGACUUUGAGTT	   103419	   Applied	  Biosystems	  
Ack1(b)	   GGUGUUCAGUGGAAAGCGATT	   s19850	   Applied	  Biosystems	  
Cdc42	  (a)	   n/a	   D-­‐005057-­‐01	   Calbiochem	  
Cdc42	  (b)	   n/a	   D-­‐005057-­‐02	   Calbiochem	  
Cdc42	  (c)	   n/a	   D-­‐005057-­‐04	   Calbiochem	  
Non-­targeting	  
(Ctrl)	  	  
n/a	   AM4636	   Applied	  Biosystems	  	  
Table	  2.	  Volumes	  used	  for	  siRNA	  transfection	  	  MCF10A,	   SW480,	   and	   HELA	   cells	   were	   transfected	   with	   12	  nM	   siRNA.	   NCI-­‐H460	   cells	   were	  transfected	  twice	  with	  30	  nM	  siRNA	  per	  transfection,	  5h	  apart.	  The	  siRNA	  stock	  concentration	  was	  100	  µM.	  The	  cell	  culture	  dish/plate	   format	  used	  was	  depending	  on	   the	  assay	  performed.	  The	  total	  volume	  stands	   for	   transfection	  mixture	  together	  with	  cell	  culture	  media	  per	  dish	  or	  per	  well	  in	  a	  12-­‐well	  plate.	  
Format	   siRNA	  	  
(12nM/30nM)	  
Opti-­MEM	   Lipofectamine	  
RNAiMax	  
Total	  volume	  	  
12-­well	  plate	   0.15	  µl/0.38	  µl	   2	  x	  75	  µl	   1.1	  µl	   1	  ml	  
3.5	  cm	  dish	   0.3	  µl/0.75	  µl	   2	  x	  150	  µl	   2.2	  µl	   2ml	  
6	  cm	  dish	   0.6	  µl/1.5	  µl	   2	  x	  400	  µl	   5.8	  µl	   4ml	  
10	  cm	  dish	   1.2	  µl/3	  µl	   2	  x	  1	  ml	   15	  µl	   8	  ml	  
15	  cm	  dish	   3.9	  µl/9.75	  µl	   2	  x	  2.6	  ml	   39	  µl	   25	  ml	  	  
3.3 Plasmid	  DNA	  transfection	  H460	  cells	  were	  transfected	  with	  full	  length	  (wtAck1)	  or	  kinase	  dead	  Ack1	  (KD-­‐Ack1(K158A)	   cloned	   in	   a	   pcDNA-­‐DEST40	   expression	   vector	   (See	   3.5.2	   and	  3.5.3)	   using	   JetPRIME®	   transfection	   reagent	   (Polyplus	   Transfection™).	   H460	  cells	   were	   seeded	   in	   a	   12-­‐well	   plate	   to	   reach	   a	   confluency	   of	   approximately	  60%	  at	   the	   time	   of	   transfection.	   Following	   concentrations	   and	   volumes	  were	  used	   for	   one	  well	   in	   a	   12-­‐well	   plate:	   0.8µg	   plasmid	  DNA	  was	   diluted	   in	   75µl	  JetPRIME	  buffer	  and	  vortexed	  for	  10s.	  2µl	  JetPRIME	  reagent	  was	  added	  and	  the	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solution	  was	  vortexed	  for	  10s.	  The	  solution	  was	  incubated	  at	  RT	  for	  10min	  and	  thereafter	   added	   drop	  wise	   to	   the	   cells.	   The	  medium	  was	   replaced	   after	   16h	  and	  experiments	  were	  performed	  48h	  post-­‐transfection.	  	  
3.4 DNA	  purification	  
3.4.1 Selective	  antibiotics	  	  Final	   concentrations	   of	   selective	   antibiotics	   used	   for	   bacterial	   cultures	  were;	  100	   µg/ml	   ampicillin,	   100	   µg/ml	   spectinomycin,	   50	  µg/ml	   kanamycin	   and	  50	  µg/ml	  chloramphenicol.	  1000x	  stock	  solutions	  of	  ampicillin,	  kanamycin	  and	  spectinomycin	  were	  prepared	  by	  dissolving	  the	  antibiotics	   in	  H20	  followed	  by	  filter	   sterilisation.	   Chloramphenicol	   was	   dissolved	   in	   ethanol,	   500x	  concentrated.	  	  	  	  
3.4.2 Mini-­prep	  DNA	  purification	  Mini-­‐prep	   DNA	   purification	   was	   performed	   using	   the	   GeneJET™	   plasmid	  miniprep	  kit	  (Fermentas)	  according	  to	  the	  suppliers’	  recommendation.	  A	  single	  colony	   from	   a	   selective	   agar	   plate	   was	   inoculated	   in	   3	  ml	   Luria	   broth	   (LB)	  media	   (20g/l	   LB	   broth	   (Sigma)	   in	   H20)	   containing	   the	   appropriate	   selective	  antibiotics	   and	   incubated	   at	   37°C	   for	   approximately	   6-­‐8h,	   shaking	   at	   200-­‐250	  revolutions	  per	  minute	  (rpm)	  (Inova	  44	  incubator	  shaker,	  New	  Brunswick	  Scientific).	  The	  bacterial	   culture	  was	  harvested	  by	   centrifugation	   for	  5	  min	  at	  6000	  x	  g	   at	   RT	   in	   a	   table	   top	   centrifuge	   (Heraeus	   Biofuge	   Pico).	   The	   pelleted	  bacteria	  was	  resuspended	  in	  250	  µl	  resuspension	  solution	  followed	  by	  addition	  of	  250	  µl	  lysis	  solution	  and	  350	  µl	  neutralisation	  solution.	  After	  the	  addition	  of	  each	  buffer,	  the	  sample	  was	  mixed	  by	  inverting	  the	  tube	  4-­‐6	  times.	  The	  sample	  was	  centrifuged	  for	  10	  min	  at	  16,000	  x	  g.	  The	  supernatant	  was	  transferred	  to	  a	  GeneJET™	  spin	  column	  and	  centrifuged	  for	  1	  min	  at	  16,000	  x	  g	  followed	  by	  two	  washes	   with	   0.5	  ml	   wash	   solution.	   In	   order	   to	   elute	   the	   DNA,	   50	  μl	   elution	  buffer	   was	   added	   to	   the	   column	   and	   centrifuged	   for	   1	  min.	   The	   DNA	  concentration	  was	  determined	  using	  a	  Nano	  drop	  ND1000	  spectrophotometer	  at	  260	  nm	  (Thermo	  Scientific).	  	  	  
48	  	  
3.4.3 Midi-­prep	  DNA	  purification	  Midi-­‐prep	  DNA	  purification	  was	  performed	  using	  the	  QIAprep	  spin	  midiprep	  kit	  (Qiagen).	  A	  single	  colony	  was	  inoculated	  in	  5	  ml	  LB	  media	  supplemented	  with	  appropriate	   selective	   antibiotics	   and	   cultured	   in	   a	   shaking	   incubator,	   at	   200-­‐250	  rpm,	   for	  6-­‐8h	  at	  37°C.	  The	  culture	  was	  diluted	  1:500	   into	  50	  ml	  selective	  LB	  media	  and	  cultured	  o/n	  at	  37°C	  shaking	  at	  200-­‐250	  rpm.	  The	  bacteria	  was	  harvested	  by	  centrifugation	  at	  6000	  x	  g	  for	  15	  min	  at	  4°C	  (Beckman	  Avanti	  J20,	  Beckman	   Coulter™)	   and	   resuspended	   in	   4	  ml	   buffer	   P1.	   In	   order	   to	   lyse	   the	  cells,	  4	  ml	  buffer	  P2	  was	  added	  and	  incubated	  for	  15	  min	  at	  RT.	  The	  DNA	  was	  precipitated	  by	  the	  addition	  of	  4	  ml	  buffer	  P3	  and	  incubated	  on	  ice	  for	  15	  min.	  The	  sample	  was	  centrifuged	  for	  30	  min	  at	  10,000	  x	  g.	  A	  Qiagen-­‐tip	  100	  column	  was	   equilibrated	   by	   adding	   4	  ml	   buffer	   QBT	   to	   the	   column	   and	   emptied	   by	  gravity	  flow.	  The	  supernatant	  was	  added	  to	  the	  column	  followed	  by	  two	  washes	  with	  10	  ml	  buffer	  QC.	  The	  DNA	  was	  eluted	  from	  the	  column	  by	  the	  addition	  of	  5	  ml	   buffer	   QF	   and	   thereafter	   precipitated	   with	   3.5	  ml	   isopropanol	   and	  centrifuged	   immediately	   at	   3220	   x	   g	   for	   1h	   at	   4°C	   (Eppendorf	   centrifuge	  5810R).	  The	  supernatant	  was	  carefully	  removed	  and	  the	  pellet	  was	  washed	  in	  2	  ml	  70%	  ethanol	   and	  centrifuged	  again	   for	  1h	  at	  3220	  x	  g	   at	  4°C.	  The	  pellet	  was	  air	  dried	  for	  5	  min	  and	  thereafter	  dissolved	  in	  200	  µl	  EB	  buffer.	  The	  DNA	  concentration	  was	  determined	  using	  a	  Nano	  drop	  ND1000	  spectrophotometer	  at	  260	  nm.	  
3.4.4 Glycerol	  stock	  Bacterial	   glycerol	   stocks	   for	   long	   term	   storage	   was	   prepared	   in	   cryovials	   by	  combining	  70%	  glycerol	  with	  30%	  bacterial	  culture	  (v/v)	  and	  stored	  at	  -­‐80°C.	  	  
3.5 Molecular	  cloning	  
3.5.1 Preparation	  of	  LB	  agar	  plates	  LB	   agar	   (Sigma)	   was	   dissolved	   in	   dH20	   at	   a	   concentration	   of	   35g/l	   and	  sterilised	   by	   autoclaving.	   The	   LB	   agar	   was	   left	   to	   cool	   down	   to	   55°C	   and	  appropriate	   selective	   antibiotics	   were	   added	   to	   the	   solution	   (see	   3.4.1.)	   The	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agar	  was	  poured	  into	  10	  cm	  Petri	  dishes,	  approximately	  20	  ml/dish	  and	  let	  to	  solidify	  for	  30	  min,	  thereafter	  stored	  at	  4°C.	  	  	  	  
3.5.2 Isolation	  of	  Ack1	  cDNA	  Full-­‐length	   human	   ACK1	   open	   reading	   frame	   (ORF)	   cDNA,	   cloned	   into	   the,	  Gateway®	   compatible,	   entry	   vector	   pENTR223.1	   (Cat.	   #HOC19832,	  Accession#NM_005781)	   was	   purchased	   from	   GeneCopoeia.	   The	   plasmid	   was	  transformed	   into	   one	   shot	   TOP10	   (Invitrogen)	   competent	   Escherichia	   coli	  (E.coli)	  cells	  for	  propagation	  according	  to	  the	  suppliers’	  recommendations	  and	  plated	   on	   a	   spectinomycin	   selective	   agar	   plate	   and	   incubated	   o/n	   at	   37°C.	  Plasmid	   DNA	   was	   isolated	   using	   the	   GeneJET	   plasmid	   mini	   prep	   kit	   as	  previously	  described	  in	  3.4.2.	  The	  accurate	  size	  of	  the	  insert	  was	  confirmed	  by	  restriction	  analysis.	  DNA	  sequencing	  of	  the	  complete	  Ack1	  cDNA,	  performed	  by	  the	  WIBR	   Scientific	   Support	   Services,	   confirmed	   the	   correct	   sequence	   of	   the	  insert.	  For	  sequencing	  primers	  used	  see	  Table	  3.	  
	  
Table	  3.	  Ack1	  sequencing	  primers	  Sequencing	   primers	   used	   for	   nucleotide	   sequencing	   of	   Ack1	   cDNA.	   The	  N-­‐terminal	   region	   of	  Ack1	  was	  sequenced	  using	  a	  primer	  targeting	  the	  polylinker	  in	  the	  pENTR223.1	  vector	  prior	  to	  the	  Ack1	  insert.	  	  
Name	   Starts	  at	  nucleotide	  	   Primer	  sequence	  5’3’	  	  
1	   Polylinker	  in	  pENTR223.1	   CGTTGCAACAAATTGATGAGC	  
2	   121	   GTCAAGAATGAGGACCTGGAG	  
3	   495	   GAGCCAGCCAGAAGCCATG	  	  	  
4	   922	   GCGACACCTGGATGTTCGG	  	  
5	   1390	   CACACAGGGCATGGCGAC	  	  	  
6	   2348	   CCCTGTCCCCTCAAGGCTC	  	  	  
7	   2769	   CTCCACCAACAACAGCAACCC	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3.5.3 Site-­directed	  mutagenesis	  	  Site-­‐directed	  mutagenesis	   is	  a	   technique	   for	  making	  point	  mutations,	  deletion	  or	   insertion	   of	   amino	   acids	   at	   particular	   sites	   of	   the	   DNA.	   This	   is	   done	   by	  several	   temperature	   cycling	   steps.	   The	   first	   step	   is	   to	   denaturate	   a	   double	  stranded	  (dsDNA)	  vector	  containing	  an	  insert	  of	  the	  gene	  to	  be	  altered.	  This	  is	  followed	   by	   annealing	   of	   synthetic	   oligonucleotide	   primers,	   containing	   the	  desired	  mutation.	  The	  primers,	  each	  complementary	  to	  the	  opposite	  strand,	  are	  then	   extended	   by	   DNA	   polymerase,	   and	   a	   plasmid	   with	   the	   incorporated	  mutation	   in	   the	   gene	   is	   generated.	   The	   parental	   DNA	   strand,	   without	   the	  mutation,	  is	  thereafter	  degraded	  by	  endonucleases,	  for	  example	  with	  the	  Dpn	  I	  endonuclease,	   specifically	   cleaving	   methylated	   and	   hemimethylated	   DNA	  (dsDNA	  with	  only	  one	  methylated	  strand).	  	  	  Prior	   to	   sub-­‐cloning	   of	   Ack1	   into	   an	   expression	   vector,	   site-­‐directed	  mutagenesis	  was	  performed.	  A	  stop	  codon	  was	  inserted	  in	  the	  C-­‐terminal	  end	  of	  the	  cDNA,	  to	  be	  able	  to	  express	  non-­‐tagged	  protein.	  Additionally,	  non-­‐sense	  mutations	  in	  the	  Ack1b	  siRNA	  binding	  region	  was	  made,	  making	  it	  possible	  to	  ectopically	  overexpress	  the	  Ack1	  construct	  in	  a	  siRNA	  knockdown	  background	  (See	   Table	   1	   for	   siRNA	   targeting	   sequence).	   Furthermore,	   several	   point	  mutants	  were	  generated,	  either	  affecting	  the	  kinase	  activity	  or	  protein-­‐protein	  interaction	  sites	  in	  Ack1	  (Table	  4).	  	  
Table	  4.	  Ack1	  constructs	  generated	  by	  site	  directed	  mutagenesis	  
Name	  of	  construct	   Mutation/alteration	  
Ack1(stop)	   Insertion	  of	  stop	  codon	  
siR-­Ack1	   siRNA	  resistant,	  Ack1b	  siRNA	  binding	  region,	  	  no	  amino	  acid	  change	  
Kd-­Ack1	   Point	  mutation	  in	  active	  loop,	  kinase	  dead	  
Ca-­Ack1	   Point	  mutation	  resembling	  constitutively	  active	  form	  
CRIB-­Ack1	   Point	  mutation	  abolishing	  binding	  to	  Cdc42	  
Clath-­Ack1	   Point	  mutations	  abolishing	  binding	  to	  Clathrin	  heavy	  chain	  	  Site-­‐directed	   mutagenesis	   was	   performed	   using	   the	   QuikChange®	   XL	   Site-­‐Directed	   Mutagenesis	   kit	   from	   Stratagene.	   Specifically,	   a	   sample	   reaction	  containing	   2.5	   μl	   10x	   reaction	   buffer,	   5	   ng	   pENTR223.1	   vector	   with	   wtAck1	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inserted	  (see	  3.5.2),	  50	  ng	  of	  forward	  and	  reverse	  oligonucleotide	  primer,	  0.5	  μl	  dNTP	  mix,	  1.5	  μl	  QuikSolution,	  ddH2O	   to	  a	   final	  volume	  of	  25	  μl	  and	  0.5	  μl	  of	  PfuTurbo	   DNA	   polymerase	   was	   made.	   The	   oligonucleotide	   primers	   were	  obtained	   from	   Invitrogen	   (Table	   5).	   Each	   sample	   reaction	   was	   cycled	   on	   a	  S1000™	  Thermal	  Cycler	  (BioRad)	  as	  outlined	  in	  Table	  6.	  Following	  temperature	  cycling,	   the	  reaction	  was	  cooled	  to	  ≤	  37°C.	   In	  order	  to	  digest	  the	  non-­‐mutated	  parental	   template,	   0.5	   μl	   Dpn	   I	   restriction	   enzyme	   (Stratagene)	   was	   added	  followed	   by	   incubation	   for	   1h	   at	   37°C.	   The	   DNA	  was	   thereafter	   transformed	  into	  XL	  10-­‐Gold	  E.coli	  cells	  for	  propagation.	  	  
3.5.3.1 XL	  10-­Gold	  transformation	  For	   each	   transformation	   reaction,	   aliquots	   of	   45	   μl	   of	   XL10-­‐Gold	  ultracompetent	  E.coli	   cells	   (Stratagene)	  were	   transferred	   to	  pre-­‐chilled	  14-­‐ml	  BD	  Falcon	  polypropylene	   round-­‐	  bottom	   tubes	   (BD	  Biosciences).	  To	   the	   cells,	  2	  μl	  of	  β-­‐	  mercaptoethanol	  mix	  (Stratgene)	  was	  added	  and	  incubated	  on	  ice	  for	  10	  min.	   Following	   incubation,	   2	   µl	   of	   the	   Dpn	   I	   treated	   DNA,	   from	   the	   site-­‐directed	  mutagenesis	  (see	  3.5.3)	  was	  combined	  with	  the	  cells	  and	  incubated	  on	  ice	   for	   30	  min.	   The	   transformation	   reaction	  was	   thereafter	   heat-­‐shocked	   in	   a	  42°C	   water	   bath	   for	   30	   s,	   incubated	   on	   ice	   for	   2	  min	   and	   0.5	  ml	   preheated	  (42°C)	   NZY	   broth	   media	   (1	   %	   NZ	   amine	   (casein	   hydrolysate),	   0.5	   %	   yeast	  extract,	   0.5	   %	   NaCl,	   (Stratagene))	   was	   added	   to	   each	   reaction.	   The	  transformations	  were	  incubated	  for	  1h	  at	  37°C	  in	  a	  shaking	  incubator	  (225-­‐250	  rpm).	   Finally,	   250	  μl	   of	   the	   transformation	  was	   added	   to	   a	   pre-­‐warmed	   agar	  plate	   with	   suitable	   selective	   antibiotic	   and	   incubated	   over	   night	   at	   37°C.	  Following	  day,	  single	  colonies	  from	  the	  plate	  were	  inoculated	  in	  3	  ml	  LB	  media	  with	   50	   µg/ml	   ampicillin	   and	   cultured	   for	   6-­‐8h	   at	   37°C.	   Plasmid	   DNA	   was	  isolated	   using	   the	   GeneJET™	   miniprep	   kit	   as	   described	   in	   3.4.2.	   Sequence	  analysis	   by	  WIBR	   Scientific	   Support	   Services	   confirmed	   that	   the	  mutagenesis	  was	  successful.	  For	  Ack1	  sequencing	  primers	  used	  see	  Table	  3.	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Table	  5.	  Oligonucleotide	  primer	  sequences	  for	  site-­directed	  mutagenesis	  Oligonucleotide	   primer	   sequences	   used	   for	   site	   directed	   mutagenesis	   of	   Ack1.	   Underlined	  nucleotides	   were	   mutated	   or	   inserted.	   Grey	   highlighted	   residues	   represent	   the	   amino	   acid	  codon	   changed.	  Abbreviations,	  Ack1,	  Activated	  Cdc42-­associated	  kinase	  1,	  KD:	  Kinase	  dead,	  Ca:	  
constitutively	   active,	   Clath:	   Clathrin,	   CRIB:	   Cdc42/Rac	   interactive	   binding	   domain,	   siR:	   siRNA	  
resistant	  
Mutant	   Mutation	   Primer	  sequence	  (5’3’)	  Ack1(stop)	   3114	  +TAA	   CACCACAAGCGCTAATCAGGCCTCATGGGC	  	  	  (Forward)	  GCCCATGAGGCCTGATTAGCGCTTGTGGTG	  (Reverse)	  siR-­‐Ack1	   cagt240-­‐243tttc;	  a246g;	  g249a	  	  	  (no	  amino	  acid	  change)	  
GGATGAGTAAGGTGTTTTTCGGGAAACGACTGGAGGC	  TGAG	  	  (Forward)	  CTCAGCCTCCAGTCGTTTCCCGAAAAACACCTTACTCATCC	  (Reverse)	  KD-­‐Ack1	   K158A	  a472g	  ;	  a473c	   GGTGAGTGTGGCTGTGGCGTGCCTGAAGC	  	  (Forward)	  GCTTCAGGCACGCCACAGCCACACTCACC	  (Reverse)	  Ca-­‐Ack1	   L487F	  c1459t;g1461t	  	   GGATTGACGAACTGTATTTTGGAAACCCCATGGACCC	  (Forward)	  GGGTCCATGGGGTTTCCAAAATACAGTTCGTCAATCC	  (Reverse)	  CRIB-­‐Ack1	   H464D/H467A	  c1390g;	  	  c1399g	  ;	  a1400c	  	  	  
GCTTCATCGACACAGGGGCTGGCGACAGTG	  (Forward)	  	  CACTGTCGCCAGCCCCTGTGTCGATGAAGC	  (Reverse)	  Clat-­‐Ack1	   L571A	  a1711g;t1712c	  	  	  	  SVE496AAA	  	  	  	  
(L571A)	  GCTGAGGTCACGCTCGCCGACTTCGGTGAGG	  (Forward)	  	  CCTCACCGAAGTCGGCGAGCGTGACCTCAGC	  (Reverse)	  	  (SVE496AAA)	  CCCCCGACGCCGCCAGCGTGGAACT	  (Forward)	  	  	  AGTTCCACGCTGGCGGCGTCGGGGG	  (Reverse)	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Table	  6.	  Temperature	  cycling	  parameters	  for	  site-­directed	  mutagenesis	  of	  Ack1	  
Segment	   Cycles	   Temperature	   Duration	  1	   1	   95°C	   3	  minutes	  2	   18	   95°C	  60°C	  68°C	  
50	  seconds	  50	  seconds	  11	  minutes	  3	   1	   68°C	   7	  minutes	  	  
3.5.4 LR-­recombination	  reaction	  for	  subcloning	  of	  Ack1	  cDNA	  into	  
mammalian	  expression	  vector	  A	  Gateway®	  LR	  Recombination	  Reaction	  was	  performed	   in	  order	   to	   combine	  the	  Ack1	  cDNA,	  contained	  in	  the	  entry	  vector	  (pENTR223.1),	  with	  a	  mammalian	  expression	   vector	   (destination	   vector)	   (pcDNA/DEST40)	   (Invitrogen)	   by	  homologous	  recombination,	  generating	  an	  expression	  clone.	  	  Specifically,	   a	   LR-­‐reaction	   containing	   100	   ng	   pENTR223.1,	   with	   wild	   type	   or	  mutated	  Ack1	  inserted	  (see	  3.5.3),	  150	  ng	  pcDNA/DEST40	  vector	  and	  6.5	  μl	  TE-­‐Buffer	   (10	  mM	   Tris-­‐HCl,	   pH	   8.0,	   1	  mM	   EDTA)	   to	   a	   final	   volume	   of	   8	   μl	   was	  made.	  To	  the	  sample,	  2	  µl	  of	  LR	  Clonase™	  II	  enzyme	  mix	  (Invitrogen)	  was	  added	  and	   incubated	   at	   25°C	   for	   2	   h.	   To	   terminate	   the	   reaction,	   1	   µl	   Proteinase	   K	  solution	   (Invitrogen)	   was	   added	   and	   incubated	   for	   10	   min	   at	   37°C.	   The	  construct	  was	   thereafter	   transformed	   into	   one	   shot	   TOP10	   competent	   cells	  and	  DNA	  was	  purified	  as	  previously	  described	  in	  3.4.2	  or	  3.4.3.	  
3.5.5 Generation	  of	  StrepII-­tagged	  Ack1	  An	  N-­‐terminal	  StrepII	  tag	  was	  inserted	  to	  the	  wtAck1	  expression	  construct	  by	  ligation	   of	   annealed	   StrepII	   oligos	   via	   a	   HindIII	   restriction	   site	   in	   the	  pcDNA/DEST40	  vector.	  
3.5.5.1 Insertion	  of	  HindIII	  restriction	  site	  A	   HindIII	   restriction	   site	   was	   inserted	   in	   the	   pcDNA/DEST40	   vector	   by	   site	  directed	  mutagenesis	  as	  described	   in	  3.5.3.	  The	   restriction	   site	  was	  placed	  as	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close	   as	   possible	   to	   the	   ATG	   start	   codon	   of	   the	   wtAck1	   sequence.	   For	   the	  mutagenesis	  primer	  used	  see	  Table	  7.	  	  
3.5.5.2 5’	  Phosphorylation	  and	  annealing	  of	  complimentary	  oligos	  Complimentary	  oligos	  with	  the	  StrepII	  coding	  sequence	  flanking	  the	  N-­‐terminal	  of	  Ack1	  was	  designed	  (Table	  7B).	  The	  primers	  were	  5’	  phosphorylated	  in	  order	  to	  increase	  ligation	  efficiency.	  A	  reaction	  containing	  100	  pmol	  of	  each	  forward	  and	   reverse	   primer,	   2.5	  µl	   10x	  PNK	   buffer,	   2.5	  µl	   ATP	   (stock	   10	  mM),	   0.5	  µl	  (5	  U)	  T4	  polynucleotide	  kinase	  (T4	  PNK)	  (All	  from	  New	  England	  BioLabs)	  and	  18.5	  µl	  H20	  to	  a	  total	  volume	  of	  25	  µl	  was	  made.	  The	  reaction	  was	  incubated	  at	  37°C	  for	  30	  min.	  The	  T4	  PNK	  was	  thereafter	  inactivated	  by	  incubation	  at	  70°C	  for	  10	  min.	  For	   the	  annealing	  of	   the	   complimentary	  oligos,	  15	  µl	   (60	  pmol)	  of	  each	  5’phosphorylated	  oligos	  was	  mixed	  with	  3	  µl	  NEB	  buffer	  2	  and	  thereafter	  incubated	  for	  5	  min	  at	  95°C,	  5	  min	  at	  70°C,	  5	  min	  at	  37°C	  and	  then	  cooled	  down	  to	  RT.	  	  	  	  
Table	  7.	  Primer	  sequences	  for	  the	  insertion	  of	  StrepII	  tag	  in	  pcDNA/DEST40.	  	  	  	  	  
A.	   Oligonucleotide	   primer	   for	   insertion	   of	   a	   HindIII	   restriction	   site	   in	   the	   pcDNA/DEST40	  vector	  by	  site-­‐directed	  mutagenesis.	  B.	  	  Oligonucleotide	  primer	  for	  insertion	  of	  StrepII	  tag.	  	  	  	  
	   Primer	   Primer	  sequence	  
A	   Insertion	  of	  HindIII	  	  restriction	  site	  
5’CGTCAAGGCCCACCAAGCTTCAGCCAGAGGAGG3’	  (Forward)	  5’CCTCCTCTGGCTGAAGCTTGGTGGGCCTTGACG3’	  (Reverse)	  
B	   Strep	  II	  tag	   5’AGCTTACCATGTGGAGCCACCCACAATTCGAGAAGTCAGCAA	  3’	  (Forward)	  5’AGCTTTGCTGACTTCTCGAATTGTGGGTGGCTCCACATGGTA3’	  	  (Reverse)	  	  
3.5.5.3 Digestion	  &	  Ligation	  	  The	   wtAck1-­‐pcDNA/DEST40	   vector,	   with	   the	   HindIII	   restriction	   site,	   was	  digested	   with	   HindIII	   in	   order	   to	   linearise	   the	   vector.	   Specifically,	   500	  ng	  plasmid	   DNA	   was	   incubated	   with	   2	  µl	   NEB	  2	   buffer	   and	   0.5	  µl	   HindIII	  restriction	  enzyme	  (New	  England	  BioLabs)	  in	  H20	  at	  a	  final	  volume	  of	  20	  µl	  for	  1	  h	  at	  37°C.	  The	  digested	  vector	  was	  thereafter	  incubated	  with	  0.5	  µl	  Antarctic	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Phosphatase	  (New	  England	  BioLabs)	  at	  37°C	  for	  1h.	  The	  phosphatase	  was	  then	  inactivated	  at	  65°C	   for	  10	  min.	  The	  DNA	  was	  purified	  with	  a	  PCR	  purification	  kit	  according	  to	  the	  suppliers’	  protocol	  (Qiagen).	  The	  DNA	  was	  eluted	  from	  the	  PCR	  purification	  column	  with	  30	  µl	  H20.	  The	  annealed	  StrepII	  primers	  and	  the	  digested	   pcDNA/DEST40	   vector	   was	   ligated	   by	   incubating	   50	  ng	   digested	  vector	  with	  1	  µl	  annealed	  oligo,	  1	  µl	  T4	  ligation	  buffer,	  0.5	  µl	  T4	  ligase	  (all	  from	  New	   England	   BioLabs)	   and	   H20	   to	   a	   final	   volume	   of	   10	  µl.	   The	   reaction	  was	  incubated	  at	  RT	  for	  1	  h	  and	  0.5	  µl	  of	  the	  ligation	  reaction	  was	  transformed	  into	  TOP10	   competent	   cells	   according	   to	   suppliers’	   recommendations.	   Single	  colonies	   from	  the	   transformation	  were	  cultured	  and	  plasmid	  DNA	  mini	  preps	  was	  made	  as	  previously	  described	  in	  3.4.2.	  Insertion	  of	  the	  correct	  tag	  sequence	  and	  orientation	  of	  the	  insert	  was	  confirmed	  by	  sequencing	  performed	  by	  WIBR	  Scientific	  Support	  Services.	  The	  forward	  sequencing	  primer	  used	  started	  in	  the	  CMV	  promoter	  of	  pcDNA/DEST40	  (5’TGGGCGGTAGGCGTG3’).	  
3.6 Western	  blotting	  
3.6.1 Preparation	  of	  samples	  for	  western	  blotting	  Cells	  were	  washed	  with	  ice-­‐cold	  PBS	  once	  and	  harvested	  with	  1.5	  x	  SDS-­‐sample	  buffer	  (120	  mM	  Tris-­‐HCl	  pH	  6.8,	  3	  %	  SDS,	  15	  %	  glycerol,	  0.03	  %	  bromphenol	  blue,	  75	  mM	  DTT).	  In	  order	  to	  degrade	  the	  genomic	  DNA,	  0.5	  U/µl	  Benzonaze	  (Merk)	  was	  added	  to	  the	  lysate	  and	  incubated	  at	  RT	  for	  approximately	  15	  min	  prior	  to	  3	  min	  incubation	  at	  95°C.	  The	  samples	  were	  cooled	  on	  ice	  and	  directly	  subjected	  to	  SDS-­‐polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE).	  	  	  	  	  	  	  
3.6.2 SDS-­PAGE	  Proteins	  were	  separated	  by	  SDS-­‐PAGE	  according	  to	  size.	  The	  separation	  gel	  was	  prepared	  as	  described	  in	  	  Table	  8	  and	  was	  allowed	  to	  polymerise	   for	  a	  minimum	  of	  30	  min	  prior	   to	   the	  overlay	  of	  the	  stacking	  gel	   	  The	  percentage	  of	  gel	  used	  (7.5%,	  10%	  or	  12.5%)	  was	  depending	   of	  molecular	  weight	   of	   the	   protein	   of	   interest	   being	   resolved.	  Lower	   percentage	   gels	   better	   resolve	   heavier	   proteins	   and	   vice	   versa.	   The	  separation	  gel	  was	  overlaid	  with	  a	  stacking	  gel.	  A	  gel	  comb	  with	  10	  or	  15	  wells	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was	  placed	  in	  the	  stacking	  gel	  directly	  after	  pouring	  it	  onto	  the	  separation	  gel	  and	  the	  gel	  was	  left	  to	  polymerise	  for	  a	  minimum	  of	  30min.	  A	  4%	  stacking	  gel	  was	   used	   for	   10%	   and	   lower	   percentage	   separation	   gels,	   whereas	   the	   6%	  stacking	  gel	  was	  used	  for	  12.5%	  gels	  (Table	  9.).	  The	  gels	  were	  placed	  in	  a	  mini-­‐protein	  running	  module	  and	  the	  module	  was	  placed	  in	  a	  mini-­‐protean	  running	  tank	  (both	  from	  Bio-­‐Rad)	  filled	  with	  SDS-­‐running	  buffer	  (15	  mM	  Tris	  base,	  19.6	  mM	  glycine,	  1%	  SDS).	  The	  comb	  was	  removed	  from	  the	  gel	  and	  protein	  lysates	  were	  loaded	  into	  the	  wells.	  To	  determine	  the	  molecular	  weight	  of	  the	  proteins	  the	  Page	  Ruler	  pre-­‐stained	  protein	  marker	  (Fermentas),	  ranging	  from	  170	  kDa	  to	   10	  kDa	   was	   used	   as	   a	   reference.	   The	   electrophoresis	   was	   run	   at	   100	  V	  (constant	  voltage)	  until	  the	  dye	  front	  had	  run	  out	  the	  gel.	  	  
	  
Table	  8.	  Recipe	  for	  separation	  gel	  used	  in	  SDS-­PAGE	  Volumes	   used	   to	   cast	   two	   SDS-­‐PAGE	   gels.	   The	   percentage	   of	   gel	   used	  was	   depending	   on	   the	  molecular	  weight	  of	  the	  protein	  of	  interest	  being	  resolved.	  Low	  percentage	  gels	  resolve	  larger	  proteins	  more	  efficiently	  and	  vice	  versa.	  The	  gel	  was	  allowed	  to	  polymerise	  for	  a	  minimum	  of	  30	  min.	  Abbreviations:	  APS:	  ammonium	  persulfate	  SDS:	  Sodium	  dodecyl	   sulphate,	  TEMED:	  N,	  N,	  
N',	  N'-­tetramethylethylenediamine,	  	  
Percentage	   7.5%	   10%	   12.5%	  
H20	   5.8	  ml	   4.9	  ml	   3.9	  ml	  
0.5	  M	  Tris-­HCl	  (pH	  8.8)	   3.0	  ml	   3.0	  ml	   3.0	  ml	  
30%	  acrylamide/bis-­acrylamide	   2.95	  ml	   3.7	  ml	   4.75	  ml	  
10%	  SDS	   120	  µl	   120	  µl	   120	  µl	  
TEMED	   16	  µl	   16	  µl	   16	  µl	  












Table	  9.	  Recipe	  for	  stacking	  gel	  used	  in	  SDS-­PAGE	  Volumes	   used	   to	   cast	   two	   SDS-­‐PAGE	   gels.	   4%	   stacking	   gels	   was	   used	   for	   10%	   and	   7.5%	  separation	  gels,	  whereas	  a	  6%	  stacking	  gel	  was	  used	  for	  12.5%	  separation	  gels.	  Abbreviations:	  
APS:	   ammonium	   persulfate,	   SDS:	   Sodium	   dodecyl	   sulphate,	   TEMED;	   N,	   N,	   N',	   N'-­
tetramethylethylenediamine	  
Percentage	  	   4%	   6%	  
H20	   3.6	  ml	   3.6	  ml	  
0.5M	  Tris-­HCl	  (pH	  6.8)	   630	  µl	   630	  µl	  
30%	  Acrylamide/bis-­acrylamide	   660	  µl	   1	  ml	  
20%	  SDS	   25	  µl	   25	  µl	  
TEMED	   10	  µl	   10	  µl	  
25%	  APS	   5	  µl	   5	  µl	  
3.6.3 Immunoblotting	  and	  detection	  Proteins	  were	  transferred	  onto	  Hybond™-­‐P	  PVDF	  membranes	  (GE	  Healthcare)	  using	   the	   Mini	   Trans-­‐Blot®	   wet	   transfer	   system	   (Bio-­‐Rad).	   The	   PVDF	  membrane	  was	  incubated	  in	  methanol,	  fiber	  pads	  and	  filter	  paper	  were	  soaked	  in	   transfer	   buffer	   (25	   mM	   Tris-­‐base,	   19.6	   mM	   Glycine	   with	   10%	   methanol	  added	  prior	  to	  use)	  and	  the	  gel	  sandwich	  was	  thereafter	  assembled	  submerged	  in	   transfer	  buffer.	  The	  proteins	  were	  transferred	  at	  100	  V	   for	  60	  or	  90	  min	   in	  transfer	  buffer,	  depending	  on	   the	  molecular	  weight	  of	   the	  protein	  of	   interest.	  Proteins	  larger	  than	  90	  kDa	  were	  transferred	  for	  90	  min.	  	  	  The	  membranes	  were	  blocked	  in	  4%	  (w/v)	  skimmed	  dry	  milk	  or	  5%	  BSA	  (w/v)	  dissolved	   TBS-­‐T,	   depending	   on	   primary	   antibody	   used,	   for	   1h	   at	   RT.	   The	  membranes	   were	   incubated	   with	   primary	   antibody	   diluted	   in	   milk	   or	   BSA	  blocking	  buffer	  for	  3h	  at	  RT	  or	  o/n	  at	  4°C	  on	  a	  rocker.	  See	  Table	  10	  for	  primary	  antibodies	  used.	  Membranes	  were	  washed	  three	  times	  with	  TBS-­‐T,	  for	  10	  min	  each,	  and	  incubated	  with	  horseradish	  peroxidase	  (HRP)-­‐conjugated	  secondary	  antibody	   (goat	   anti-­‐mouse	  or	   goat	   anti-­‐rabbit	   (Jackson	  Laboratories))	  diluted	  1:3000	  in	  milk	  blocking	  solution	  for	  1h	  at	  RT,	  followed	  by	  three	  more	  washes	  with	   TBS-­‐T.	   The	   protein	   bands	   were	   visualised	   by	   chemiluminescence	   using	  ECL™	  or	  ECL	  plus™	  reagents	  and	  Hyperfilm®	  ECL	  (all	  from	  GE	  Healthcare).	  The	  film	  was	  processed	  using	  a	  Compact-­‐X	  developer	  (X-­‐ograph	  imaging	  systems).	  GAPDH	  or	  α-­‐tubulin	  was	  used	  as	  protein	  loading	  control.	  	  
58	  	  
3.6.4 Stripping	  and	  re-­probing	  of	  PVDF	  membranes	  	  	  The	  membrane	  washed	   in	  TBS-­‐T	   twice	   for	  10	  min	  and	   incubated	   in	   stripping	  buffer	  (62.5	  mM	  Tris-­‐HCl	  (pH	  6.8),	  2%	  SDS	  and	  100	  mM	  of	  2-­‐Mercaptoethanol)	  for	   30	  min	   at	   56°C.	   The	   washing	   step	   was	   repeated	   and	   the	   membrane	   was	  blocked	   in	   4%	  (w/v)	   skimmed	   dry	   milk,	   dissolved	   in	   TBS-­‐T,	   for	   1h	   at	   RT	  followed	   by	   primary	   antibody	   incubation	   and	   all	   the	   subsequent	   steps	  described	  in	  3.6.3.	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Table	  10.	  Primary	  antibodies	  used	  in	  western	  blotting.	  Membranes	  were	  blocked	  and	  antibodies	  were	  diluted	  in	  TBS-­‐Tween	  with	  4%	  dry	  milk	  (w/v)	  unless	  other	  stated.	  	  Abbreviations:	  BSA:	  Bovine	  serum	  albumin,	  M:	  Mouse,	  R:	  Rabbit	  	  
Targeting	  protein	   Clone	   Catalogue	  
number	  
Host	   Manufacturer	   Dilution	  
Ack1	   A-­‐11	   Sc-­‐28336	   M	   Santa	  Cruz	  Technology	   1:200	  
α-­Tubulin	   -­‐	   -­‐	   M	   Home	  made	   1:10	  000	  
β-­catenin	   H-­‐102	   Sc-­‐7199	   R	   Santa	  Cruz	  Biotechnology	   1:5000	  
Caspase-­8	   1-­‐1-­‐37	   MAB4708	   R	   Millipore	   1:500	  
Caveolin-­1	   Polyclonal	   610406	  	   M	   BD	  Transduction	  Laboratories	   1:4000	  
Cdc42	   44	   610928	   M	   BD	  transduction	  Laboratories	   1:1000	  
Cleaved	  Caspase-­3	  
(Asp175)	  
Polyclonal	  	   9661	   R	   Cell	  signaling	  Technology	   1:2000	  
Cleaved	  Caspase-­8	  
(Asp391)	  	  
18C8	   9496	   R	   Cell	  signaling	  Technology	   1:2000	  Blocking:	  Milk	  Antibody:	  5	  %	  BSA	  
FADD	   Polyclonal	   2782	   R	   Cell	  signaling	  Technology	   1:500	  
Keratin	  8/18	   	   5D3	   NCL-­‐5D3	   M	   Novocastra	  Laboratories	  Ltd.	  	   1:5000	  
Na+/K+ATPase	   Polyclonal	   3010	   R	   Cell	  signaling	  Technology	   1:4000	  
Phospho-­Ack1*	  
(Tyr284)	  
Polyclonal	   09-­‐142	  	   R	   Millipore	   1:1000	  
Phospho-­Akt	  
(Thr308)	  
C31E5E	   2965	  	   M	   Cell	  signalling	  Technology	   1:2000	  BSA	  
Phospho-­EGFR	  
(Tyr1068)	  
Polyclonal	   2234	   R	   Cell	  signaling	  Technology	   1:2000	  5	  %	  BSA	  
pNFĸB	  (Ser536)	   93H1	   3033	   R	   Cell	  signalling	  Technology	   1:2000	  5	  %	  BSA	  
Streptavidin-­HRP	   n/a	   FP1047	   n/a	   Perkin	  Elmer	   1:5000	  
TRAIL-­R1	   Polyclonal	   1139	   R	   ProSci	  Incorporated	   1:4000	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TRAIL-­R2	   Polyclonal	   2019	   R	   ProSci	  Incorporated	   1:4000	  
ZO-­1	   Polyclonal	   40-­‐2300	   R	   Zymed	  Laboratories	   1:2000	  *	  Works	  only	  on	  overexpressed	  protein	  
3.7 Immunocytochemistry	  
3.7.1 Collagen	  coating	  of	  coverslips	  Glass	   cover	   slips,	   13	   mm	   in	   diameter,	   thickness	   #1.5,	   0.16	   -­‐	   0.19	  mm	   (VWR	  International)	  was	  used	   for	   all	   immunocytochemistry	   (ICH)	  experiments.	  The	  coverslips	   were	   sterilised	   by	   autoclaving	   and	   thereafter	   coated	   with	   0.01%	  collagen	  type	  I	  (rat	  tail,	  BD	  Biosciences)	  (v/v)	  diluted	  in	  0.02M	  acetic	  acid.	  The	  coverslips	  were	  coated	  for	  2h	  at	  37°C	  and	  washed	  twice	  with	  PBS	  prior	  seeding	  of	  cells.	  	  	  	  
3.7.2 Immunostaining	  	  NCI-­‐H460	   cells	   were	   cultured	   on	   collagen	   I	   coated	   coverslips	   and	   thereafter	  fixed	  with	  ice-­‐cold	  methanol	  for	  10	  second	  at	  RT.	  The	  cells	  were	  blocked	  with	  5%	  normal	   goat	   serum	   in	   TBS-­‐T	   (TBS	   (100	  mM	  Tris	   base	   pH	  7.6,	   1.5M	  NaCl)	  with	  0.1%	  Tween-­‐20	  (v/v))	  for	  30	  min	  at	  RT.	  Primary	  antibodies	  were	  diluted	  1:100	   in	   blocking	   solution	   and	   30	  µl	   antibody	   solution	   was	   added	   to	   each	  coverslip	  and	  incubated	  for	  2h	  at	  RT.	  For	  primary	  antibodies	  used	  see	  Table	  11.	  The	  coverslips	  were	  briefly	  washed	  five	  times	  with	  TBS-­‐T,	  thereafter	  incubated	  with	  secondary	  antibody,	  diluted	  1:300	  in	  blocking	  solution,	  for	  1h	  at	  RT	  in	  the	  dark.	  Secondary	  antibodies	  used	  were	  donkey-­‐anti-­‐rabbit	  Cy3	  (gift	   from	  Taija	  Makinen,	   LRI)	   and	   donkey-­‐anti-­‐mouse	   Alexa	   488	   (Invitrogen).	   The	   coverlips	  were	  washed	  an	  additional	  five	  times	  with	  TBS-­‐T	  and	  stained	  with	  1	  µg/ml	  4',6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI)	  (Sigma),	  diluted	  in	  PBS,	  for	  5	  min	  at	  RT	  in	  the	  dark.	   Finally,	   the	   coverslips	   were	   washed	   twice	   in	   PBS	   and	   mounted	   with	  Vectashield	  H-­‐1000	  mounting	  media	   (Vector	   Laboratories,)	   on	   a	   Superfrost®	  microscope	   slide	   (Thermo	   Scientific).	   The	   coverslips	   were	   sealed	   to	   the	  microscope	  slide	  with	  nail	  polish	  around	  the	  edges	  of	   the	  coverslip	  and	   let	   to	  dry	   at	   RT,	   prior	   to	   storage	   at	   4°C.	   Confocal	   microscopy	   acquisitions	   were	  acquired	   at	   London	   Research	   Institute,	   Lincoln's	   Inn	   Fields,	   Cancer	   Research	  UK	  with	  the	  technical	  assistance	  of	  Andres	  Vicente.	  The	  images	  were	  acquired	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using	  a	  Zeiss	  LSM	  inverted	  confocal	  microscope	  (Carl	  Zeiss)	  at	  a	  magnification	  of	  63x	  using	  the	  software	  LSM	  510.	  Orthogonal	  views	  were	  obtained	  using	  the	  LSM	  Image	  Browser	  software.	  	  	  
Table	  11.	  Primary	  antibodies	  used	  for	  immunocytochemistry	  Primary	   antibodies	   used	   for	   immunocytochemistry	   staining	   of	  NCI-­‐H460	   cells.	   All	   antibodies	  were	  diluted	  1:100	  in	  TBS-­‐T	  (TBS	  with	  0.1	  %	  Tween-­‐20).	  Abbreviations:	  Ack1:	  Activated	  Cdc42-­
associated	  kinase	  1,	  Na+/K+	  ATPase:	  Sodium-­potassium	  adenosine	  triphosphatase	  TRAIL-­R1:	  TNF-­
related	  apoptosis-­inducing	  ligand	  receptor	  1,	  ZO-­1:	  Zona	  occludens	  1	  
Targeting	  protein	   Clone	   Catalogue	  number	   Host	   Manufacturer	  
Ack1	   A-­‐11	   Sc-­‐28336	   M	   Santa	  Cruz	  Biotechnology	  
β-­catenin	   H-­‐102	   Sc-­‐7199	   R	   Santa	  Cruz	  Biotechnology	  
Caveolin-­1	   Polyclonal	   610406	  	   M	   BD	  Transduction	  Laboratories	  
γ-­catenin	   15F11	  	   Ab12083	   M	   Abcam	  
Na+/K+	  ATPase	  	  
α1	  subunit	  
Polyclonal	   3010	   M	   Cell	  Signaling	  Technology	  
TRAIL-­R1	   Polyclonal	   1139	   R	   ProSci	  Incorporated	  
ZO-­1	   Polyclonal	   40-­‐2300	   R	   Zymed	  Laboratories	  	  
3.8 Generation	  and	  purification	  of	  recombinant	  TRAIL	  	  The	  construct	   for	  generating	   recombinant	  human	  TRAIL	  was	  a	  kind	  gift	   from	  Dr	  Marion	   Macfarlane,	   University	   of	   Leicester.	   TRAIL	   (residues	   95-­‐281)	   was	  cloned	   into	   the	   expression	   vector	   pET28b	   containing	   an	   in-­‐frame	  N-­‐terminal	  His-­‐6	  and	  T7	  tag.	  	  
3.8.1 IPTG	  Induction	  The	  pET28b-­‐TRAIL	  construct	  was	   transformed	   into	  BL21(DE3)RIL	  competent	  
E.	  coli	  cells	   for	  propagation	  according	  to	  the	  suppliers’	  recommendations.	  The	  transformation	   reaction	  was	   spread	  out	   on	  kanamycin	   containing	   agar	  plates	  and	  incubated	  o/n	  at	  37°C.	  One	  single	  colony	  was	  inoculated	  in	  20	  ml	  LB-­‐media	  supplemented	  with	  50	  mg/ml	  kanamycin	  and	  50	  mg/ml	  chloramphenicol	  and	  incubated	  o/n	  at	  37°C,	   shaking	  at	  250	   rpm.	  The	  20	  ml	   culture	  was	   thereafter	  diluted	  in	  1	  l	  LB	  media	  supplemented	  with	  50	  mg/ml	  kanamycin	  and	  50	  mg/ml	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chloramphenicol	   and	   cultured	   at	   37°C	   for	   2	  h,	   shaking	   at	   250	  rmp.	  To	   induce	  protein	  expression	  of	  the	  recombinant	  TRAIL,	  1	  mM	  IPTG	  was	  added	  to	  the	  1	  l	  culture	  and	  cultured	  for	  3	  h	  at	  27°C	  at	  250	  rpm.	  The	  culture	  was	  centrifuged	  at	  3220	   x	   g	   for	   15	  min	   at	   4°C	   (Eppendorf	   centrifuge	   5810R)	   and	   the	   pellet	  was	  washed	  once	  in	  ice	  cold	  PBS	  and	  stored	  at	  -­‐80°C	  until	  purification.	  In	  order	  to	  control	  the	  induction	  efficiency,	  1	  ml	  aliquots	  were	  taken	  from	  the	  non-­‐induced	  and	  induced	  culture,	  pelleted	  and	  resuspended	  in	  50	  µl	  3	  x	  SDS-­‐sample	  buffer	  (240	  mM	  Tris-­‐HCl	  (pH	  6.8),	  6%	  SDS,	  30%	  glycerol,	  0.06	  %	  bromophenol	  blue,	  150	  mM	  DTT)	  and	  subjected	  to	  SDS-­‐PAGE.	  The	  gel	  was	  stained	  with	  coomassie	  brilliant	   blue	   (0,1%	   Coomasssie	   brilliant	   blue	   R250	   (w/v),	   25%	   2-­‐propanol	  (v/v),	   10	  %	  acetic	   acid	   (v/v))	   o/n	   on	   a	   rocker	   and	   thereafter	   destained	  with	  (10%	  (v/v)	  acetic	  acid,	  40%	  (v/v)	  methanol)	  until	  the	  background	  staining	  was	  removed.	  	  
3.8.2 Purification	  Induced	  bacterial	  pellets	  were	  lysed	  in	  Triton	  lysis	  buffer	  (20	  mM	  Tris-­‐HCl	  (pH	  7.5),	   150	   mM	   NaCl,	   10%	   glycerol,	   1%	   Triton-­‐X,	   1	   mM	   phenylmethylsulfonyl	  fluoride	   (PMSF))	   for	   30	   min	   on	   ice	   and	   thereafter	   sonicated.	   Lysates	   were	  cleared	  by	  centrifugation	  at	  3220	  x	  g	  for	  45	  min	  at	  4°C	  and	  then	  supplemented	  with	  Imidazole	  (Sigma)	  at	  a	  final	  concentration	  of	  20	  mM,	  to	  prevent	  unspecific	  binding	   to	   the	   nickel	   beads.	   His-­‐TRAIL	   was	   thereafter	   batch	   purified	   with	  1.5	  ml	   (dry	   volume)	   Ni2+-­‐NTA	   agarose	   beads	   (Qiagen)	   for	   1.5	   h	   at	   4°C	   on	   a	  spinning	  wheel,	   followed	  by	   three,	   10	  min,	  washes	  with	  Triton	   lysis	   buffer	   at	  4°C.	   As	   a	   control	   of	   the	   purification	   steps	   performed,	   20	   µl	   aliquots	   were	  collected	  after	  each	  centrifugation	  step	  and	  resuspended	  in	  40	  µl	  3x	  SDS	  SB	  and	  subjected	   to	   SDS-­‐PAGE	   and	   commassie	   staining	   as	   previously	   described	   in	  3.8.1.	  	  
3.8.3 Elution	  	  TRAIL	  was	  eluted	   from	   the	  beads	  by	   the	  addition	  of	  1	  ml	  elution	  buffer	   (300	  mM	  NaCl,	  100	  mM	  Imidazole	  dissolved	  in	  PBS).	  The	  beads	  were	  incubated	  with	  the	   elution	   buffer	   on	   a	   spinning	   wheel	   for	   15	  min	   at	   4°C,	   the	   beads	   were	  centrifuged	  at	  500	  x	  g	  and	  the	  supernatant	  with	  the	  eluted	  TRAIL	  was	  collected.	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The	  elution	  step	  was	  repeated	  an	  additional	  five	  times,	  leading	  to	  the	  collection	  of	   4	   elution	   fractions	   in	   total.	   The	   fractions	   with	   the	   highest	   and	   purest	  concentration	  of	  TRAIL	  were	  pooled.	  Aliquots	  from	  the	  eluted	  fractions	  where	  resuspended	  1:1	  in	  3X	  SDS-­‐Sample	  buffer	  and	  run	  on	  a	  12	  %	  SDS-­‐PAGE	  gel	  as	  described	  in	  3.6.2.	  The	  gel	  was	  thereafter	  stained	  with	  coomassie	  brilliant	  blue	  as	  described	  in	  3.8.1.	  The	  fractions	  with	  the	  highest	  purified	  yield	  were	  pooled	  and	   thereafter	   aliquoted,	   snap	   freezed	   in	   liquid	  nitrogen	   and	   stored	   at	   -­‐80°C.	  The	   death	   inducing	   activity	   was	   assessed	   by	   cleaved	   caspase-­‐8	   levels	   by	  western	  blotting.	  	  	  
3.8.4 Biotinylation	  of	  recombinant	  TRAIL	  Recombinant	   TRAIL	   were	   generated	   and	   purified	   as	   previously	   described	   in	  3.8.1	  and	  3.8.2.	  Prior	  to	  elution,	   the	  beads	  were	  resuspended	  in	  1	  ml	  PBS	  and	  labelled	   with	   0.4	   mg	   D-­‐biotinoyl-­‐ε-­‐aminocaproic	   acid-­‐N-­‐hydroxysuccinimide	  ester	  (biotin-­‐7-­‐NHS),	  dissolved	  in	  DMSO	  (Roche)	  for	  1h	  at	  4°C.	  Excess	  labelling	  solution	  was	   quenched	   by	   the	   addition	   of	   2	  ml	   1	  M	   Tris-­‐HCl	   (pH	   8.0)	   for	   an	  additional	  15	  min	  at	  4°C.	  The	  beads	  were	  thereafter	  washed	  in	  lysis	  buffer	  and	  eluted	  with	   100	  mM	   Imidazole	   as	   previously	   described.	   The	   incorporation	   of	  biotin	   and	   the	   apoptotic	   inducing	   activity	   was	   assessed	   by	   western	   blotting	  with	   a	   HRP	   conjugated	   streptavidin	   antibody	   and	   cleaved	   caspase-­‐8	   levels	  respectively.	  
3.9 Induction	  of	  apoptosis	  via	  the	  TRAIL	  induced	  pathway	  TRAIL	  induced	  apoptosis	  was	  induced	  by	  treating	  cells,	  approximately	  70-­‐80%	  confluent,	  with	  30U/ml	  recombinant	  TRAIL	  for	  the	  time	  points	  indicated.	  	  
3.10 Induction	  of	  apoptosis	  via	  the	  Fas	  induced	  pathway	  For	  activation	  of	  the	  Fas	  ligand	  induced	  pathway,	  2	  μg/μl	  of	  the	  activating	  anti-­‐FAS	   antibody,	   clone	   C11	   (#05-­‐201	  Millipore,	   Billerica,	  MA,	   US)	  was	   added	   to	  cells,	  approximately	  70%	  confluent	  and	  incubated	  for	  time	  points	  specified.	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3.11 Cell	  cycle	  profiling	  with	  PI	  staining	  	  MCF10A	   cells	   were	   trypsinised,	   washed	   in	   PBS	   and	   counted	   using	   a	  hemocytometer.	   Each	   sample	   was	   diluted	   in	   1	   ml	   PBS	   at	   a	   concentration	   of	  1.5	  x	  106	   cells/ml.	  The	   cells	  were	   centrifuged	   at	   200	   x	   g	   at	  RT	   for	  5	  min	   and	  resuspended	  in	  0.5	  ml	  PBS.	  The	  cells	  were	  fixed	  by	  the	  addition	  of	  4.5	  ml	  of	  ice-­‐cold	  70%	  ethanol	  and	  were	  incubated	  on	  ice	  for	  a	  minimum	  of	  30	  min.	  After	  the	  fixation,	  the	  cells	  were	  centrifuged	  at	  400	  x	  g	  for	  5	  min	  and	  washed	  in	  5	  ml	  PBS	  followed	  by	  another	  centrifugation	  step.	  	  The	  cells	  were	  resuspended	  in	  0.5	  ml	  PBS	  and	  0.5	  ml	  DNA	  extraction	  buffer	   (0,2	  M	  Na2HPO4,	  0,004%	  Triton	  X-­‐100,	  pH	  7.8)	  The	  sample	  was	  incubated	  at	  RT	  for	  5	  min	  and	  centrifuged	  at	  400	  x	  g	  for	  5	  min.	  The	  supernatant	  was	  removed	  and	  the	  cells	  were	  resuspended	  in	  1	  ml	   freshly	  prepared	  DNA	  staining	   solution	   (50	  µg/ml	  PI,	   0.2	  mg/ml	  RNAse	  A	  (dissolved	   in	  10	  mM	  Sodium	  acetate	   (pH	  7.4)	   in	  PBS)	   for	  30	  min	   in	   the	  dark.	  The	   cell	   cycle	   profile	   was	   analysed	   with	   flow	   cytometry	   (CyAn	   ADP	   High-­‐Performance	   Flow	   Cytometer)	   at	   an	   excitation	   of	   488	   nm.	   Side	   scatter	   and	  emission	  at	  >600	  nm	  was	  measured.	  A	  minimum	  of	  10	  000	  events/sample	  was	  collected	   and	   the	   hypodiploid	   and	   diploid	   DNA	   peaks	   was	   measured.	   The	  Summit	  4.3	  software	  was	  used	  to	  analyse	  the	  data.	  	  
3.12 FACS	  analysis	  of	  apoptosis	  with	  Annexin	  V/PI	  labelling	  MCF10A	   cells	   cultured	   in	   6	  cm	   dishes,	   approximately	   80%	   confluent,	   were	  treated	  with	  30U/ml	  TRAIL	  for	  2h.	  The	  cells	  were	  therafter	  washed	  in	  PBS	  and	  trypsinised.	   Extra	   care	   was	   taken	   to	   ensure	   the	   cells	   were	   in	   single	   cell	  suspension.	  The	  cells	  were	  washed	  twice	  in	  Annexin	  V	  binding	  buffer	  (10	  mM	  Hepes	   (pH	  7.4),	  150	  mM	  NaCl,	  5	  mM	  KCl,	  1	  mM	  MgCl2	  and	  1.8	  mM	  CaCl2)	  and	  10	  µl	  Annexin	  V-­‐FITC	   (Miltenyi	  Biotec)	  was	  added	   followed	  by	   incubation	   for	  15	  min	   in	   the	   dark	   at	   room	   temperature.	   The	   cells	   were	   washed	   twice	   in	  Annexin	  V	  binding	  buffer	  and	  1	  mg/ml	  of	  PI	   solution	  was	  added	   immediately	  prior	  to	  analysis	  by	  flow	  cytometry.	  The	  software	  Summit	  version	  4.3	  was	  used	  to	   analyse	   the	   data.	   10	   000	   events/sample	   were	   collected	   and	   three	  independent	  experiments	  were	  performed.	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3.13 FACS	  analysis	  of	  TRAIL	  receptor	  cell	  surface	  expression	  Cell	   surface	   expression	   of	   TRAIL-­‐R1	   and	   -­‐R2	   was	   analysed	   as	   previously	  described	   [148].	  MCF10A	   cells	  were	   trypsinised,	   washed	   once	   in	   cell	   culture	  media	   and	   counted	   using	   a	   hemocytometer.	   The	   cells	   were	   diluted	   in	   1	   ml	  medium/sample	   at	   a	   concentration	   of	   2.5	   x	   105	   cells/ml	   and	   were	   left	   to	  recover	   at	   37°C	   for	   30	  min.	   The	   cells	  were	   pelleted	   and	   blocked	   in	   40-­‐45	  µl	  normal	  goat	  serum,	  and	   incubated	  on	   ice	   for	  5	  min.	  PE-­‐conjugated	  antibodies	  against	  the	  extracellular	  region	  of	  TRAIL-­‐R1	  and	  TRAIL-­‐R2	  was	  used	  to	  detect	  TRAIL	  receptors	  expressed	  on	  the	  cell	  surface.	  10	  µl	  PE-­‐TRAIL-­‐R1	  (Clone:	  DJR1,	  eBioscienses)	  or	  5	  µl	  PE-­‐TRAIL-­‐R2	  (Clone:DJR2,	  eBiosciences)	  was	  added	  to	  the	  cells	   to	   a	   final	   volume	   of	   50	   µl.	   10	   µl	   PE-­‐Mouse	   IgG1	   isotype	   control	  (eBiosciences)	  was	  used	  as	  a	  negative	  control.	  The	  samples	  were	  incubated	  for	  1h	   on	   ice	   in	   the	   dark	   and	   thereafter	   washed	   3	   times	   in	   PBS	   and	   finally	  resuspended	  in	  1	  ml	  PBS.	  The	  mean	  fluorescent	  intensity	  (MFI)	  was	  measured	  by	   flow	  cytometry	  using	  an	  excitation	  of	  488	  nm	  and	  an	  emission	  of	  575	  nm.	  The	  experiment	  was	  repeated	  independently	  three	  times.	  	  	  
3.14 Cell	  surface	  expression	  of	  the	  TRAIL	  receptors-­	  Biotin	  IP	  NCI-­‐H460	  cells,	  cultured	  in	  10	  cm	  dishes	  were	  washed	  twice	  with	  ice-­‐cold	  PBS.	  In	   order	   to	  biotin	   label	   all	   cell	   surface	  proteins,	   1	  ml	  biotinylation	  buffer	   (50	  
µg/ml	  Biotin-­‐7-­‐NHS,	   50	  mM	  sodium	  borate,	   150	  mM	  NaCl)	  was	   added	   to	   the	  cells	  and	  incubated	  at	  4°C	  for	  30	  min.	  The	  cell	  culture	  dish	  was	  rocked	  every	  10	  min	   in	   order	   to	   ensure	   even	   distribution	   of	   biotinylation	   buffer.	   The	  biotinylation	  reaction	  was	  quenched	  by	  the	  addition	  of	  50	  µl	  500	  mM	  NH4Cl	  to	  a	   final	   concentration	  of	  50	  mM	   for	  15	  min.	  The	   cells	  were	   thereafter	  washed	  with	   ice-­‐cold	   PBS,	   1	  ml	   lysis	   buffer	   (20	  mM	  Tris-­‐HCl	   (pH	  7.5),	   150	  mM	  NaCl,	  10%	  glycerol,	   1%	  Triton	  X-­‐100,	  HALT	  protease/phosphatase	   inhibitor,	   1	  mM	  Vanadate,	  1	  mM	  PMSF)	  was	  added	  to	  the	  dish	  and	  the	  cells	  were	  collected	  using	  a	   cell	   scraper.	   The	   lysates	   were	   incubated	   on	   ice	   for	   30	   min	   and	   were	  centrifuged	  at	  16	  000	  x	  g	  at	  4°C	  for	  30	  min.	  A	  40	  µl	  aliquot	  of	  the	  cleared	  lysate	  was	  mixed	  with	  20	  µl	   lysis	  buffer	  and	  60	  µl	  3x	  SDS	  sample	  buffer	  and	  used	  as	  input	   control.	  The	  cleared	   lysate	  was	  added	   to	  40	  µl	   streptavidin	  bead	  slurry	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(beads	   and	   lysis	   buffer,	   1:1)	   in	   order	   to	   immunoprecipitate	   biotin	   labeled	  proteins.	   The	   lysate	   was	   incubated	  with	   the	   beads	   o/n	   at	   4°C	   on	   a	   spinning	  wheel.	  The	  beads	  was	  washed	  three	  times	  with	  lysis	  buffer	  for	  10	  min	  at	  4°C	  on	  a	  spinning	  wheel	  and	  resuspended	  in	  40	  µl	  lysis	  buffer	  and	  70	  µl	  3x	  SDS	  sample	  buffer.	  The	  samples	  were	  incubated	  at	  95°C	  for	  3	  min,	  centrifuged	  at	  16,000	  x	  g	  for	  20	  s	  and	  the	  supernatant	  was	  transferred	  to	  a	  new	  tube.	  	  The	  input	  and	  the	  IP	  samples	  were	  subjected	  to	  SDS-­‐PAGE	  and	  blotted	  for	  the	  protein	  of	  interest	  (ie.	   TRAIL-­‐R1	   and	   TRAIL-­‐R2).	   Non-­‐biotinylated	   cells	   were	   used	   as	   negative	  control	   for	   the	   immunoprecipitation	   of	   unspecific	   proteins	   binding	   to	   the	  streptavidin	  beads.	  	  
3.15 DISC	  formation	  assay	  The	   TRAIL	   DISC	   complex	  was	   isolated	   by	   the	   use	   of	   biotinylated	   TRAIL	   (see	  3.8.4)	   and	   streptavidin-­‐sepharose	   beads.	   Cells	   was	   treated	   with	   30U/ml	  biotinylated	   TRAIL	   for	   30	  min	   at	   37°C	   ,	   thereafter	   collected	   and	   lysed	   for	   30	  min	  on	  ice	  in	  Triton	  lysis	  buffer	  (20	  mM	  Tris-­‐HCl	  (pH	  7.5),	  150	  mM	  NaCl,	  1	  mM	  EDTA,	   10%	   glycerol,	   1%	   Triton-­‐X-­‐100,	   1	   mM	   vanadate,	   complete,	   protease	  inhibitor	   cocktail	   (Roche)	   and	   1mM	  NaF).	   50	  µl	   aliquots	   of	   the	   lysates	   were	  taken	  as	  input	  samples.	  Lysates	  were	  cleared	  by	  centrifugation	  at	  16	  000	  x	  g	  for	  30	   min	   in	   a	   table	   top	   centrifuge	   at	   4°C.	   In	   order	   to	   analyse	   the	   total	   TRAIL	  receptor	   levels,	   3U/ml	   biotin-­‐TRAIL	  was	   instead	   added	   to	   the	   cleared	   lysate,	  allowing	   TRAIL	   to	   bind	   all	   receptors	   in	   the	   cells.	   One	   sample	   without	   any	  addition	  of	  TRAIL	  was	  used	  as	  a	  negative	  control	  for	  the	  immunoprecipitation.	  TRAIL-­‐receptors	   with	   bound	   biotinylated	   TRAIL	   were	   precipitated	   with	  Streptavidin-­‐Sepharose™	  beads	  (Streptavidin	  Plus	  UltraLink	  Resin,	  Pierce)	  over	  night	  at	  4°C.	  Beads	  were	  washed	  three	  times	  with	  lysis	  buffer,	  resuspended	  in	  60	   µl	   SDS-­‐sample	   buffer,	   incubated	   at	   95°C	   for	   3	  min	   and	   centrifuged	   at	  16,000	  x	  g	  for	  20	  s.	  The	  supernatant	  was	  subject	  to	  western	  blotting	  (3.6)	  and	  blotted	  for	  proteins	  of	  interest.	  	  
3.16 Sucrose	  gradient	  for	  isolation	  of	  lipid	  rafts	  Lipid	   rafts	  were	   isolated	   by	   sucrose	   gradient	   and	  ultracentrifugation.	  One	  15	  cm	  cell	  culture	  dish	  with	  MCF10A	  cells,	  at	  a	  confluency	  of	  approximately	  80%,	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was	  used	  per	  sample.	  Cells	  were	  treated	  with	  30U/ml	  TRAIL	  for	  1h.	  The	  cells	  were	  washed	  once	  with	  ice-­‐cold	  PBS	  and	  collected	  and	  lysed	  in	  1	  ml	  lysis	  buffer	  (10	  mM	  Tris-­‐HCl	   (pH	   7.5),	   150	  mM	  NaCl,	   5	  mM	  EDTA	   and	   1%	  Triton	   x-­‐100,	  supplemented	   with	   1	   mM	   vanadate,	   1	   mM	   NaF	   and	   HALT	  phosphatase/protease	   inhibitor).	   50	   µl	   aliquots	   of	   the	   lysate	   were	   taken	   as	  input	   control.	   The	   lysates	  were	   incubate	   on	   ice	   for	   30	  min	   and	  homogenized	  with	  10	  strokes	  using	  a	  tissue	  grinder	  and	  mixed	  with	  1	  ml	  85%	  Sucrose	  ((w/v)	  dissolved	  in	  lysis	  buffer	  without	  Triton	  x-­‐100).	  The	  lysate	  and	  sucrose	  mixture	  was	   transferred	   to	   the	   bottom	   of	   a	   pre-­‐cooled	   14	   ml	   open	   top	   thin-­‐wall	  ultracentrifuge	   tube	   (cat	   no:	   644060,	   14x95mm,	   Beckman)	   and	   carefully	  overlayed	  with	  7.5	  ml	  35%	  sucrose	  and	  3.5	  ml	  5%	  sucrose.	  The	  samples	  were	  centrifuged	   at	   38	  000	   rpm	   for	   18h	   at	   4°C	   in	   a	   swing	   out	   SW40	   rotor	   in	   an	  optima	   L-­‐100XP	   Beckman	   centrifuge	   (acceleration	   8,	   deceleration	   8).	   1	   ml	  fractions	   were	   carefully	   collected	   from	   the	   top	   to	   bottom	   of	   the	   tube	   and	  resuspended	   1:1	   with	   3x	   SDS-­‐sample	   buffer.	   Samples	   were	   subjected	   to	  western	  blotting	  as	  described	  in	  3.6.	  	  
3.17 TRAIL	  receptor	  clustering	  assay	  TRAIL	   receptor	   clustering	   was	   analysed	   by	   SDS-­‐PAGE	   with	   lysate	   without	  reducing	   agent.	   One	   6	   cm	   cell	   culture	   dish	   was	   used	   per	   sample.	   Cells	   were	  treated	  with	  30U/ml	  TRAIL	  for	  15min	  or	  1h,	  washed	  in	  PBS	  and	  lysed	  in	  0.4	  ml	  cell	  lysis	  buffer	  (20	  mM	  Tris-­‐HCl	  pH	  7.5,	  150	  mM	  NaCl,	  10%	  Glycerol,	  1%	  Triton	  X-­‐100	   supplemented	   with	   HALT	   phosphatase/protease	   inhibitor,	   1mM	  vanadate	   and	   1	  mM	   NaF).	   The	   lysates	   were	   incubated	   on	   ice	   for	   30	  min,	  thereafter	  centrifuged	  at	  16	  000	  x	  g	  at	  4°C.	  The	  cleared	   lysate	  was	  divided	   in	  two	   aliquots	   and	  diluted	   1:1	  with	   3x	   SDS	   sample	   buffer	  with	   or	  without	   150	  mM	  of	  the	  reducing	  agent	  DTT.	  The	  samples	  with	  DTT	  were	  incubated	  at	  95°C	  for	   3	  min	  whereas	   the	  non-­‐reduced	   samples	  were	   kept	   on	   ice.	   Samples	  were	  run	  on	  a	  7.5%	  SDS-­‐PAGE	  gel	  as	  described	  in	  3.6.	  
3.18 Inhibition	  of	  clathrin	  mediated	  endocytosis	  Clathrin	   mediated	   endocytosis	   was	   inhibited	   with	   10	   µg/ml	   Chlorpromazine	  Hydrochloride	  (CPZ),	  (Sigma)	  for	  1h	  prior	  to	  treatment	  with	  TRAIL	  for	  2h.	  The	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inhibitor	  was	   dissolved	   in	   DMSO.	   DMSO	   alone	  was	   added	   to	   the	   non	   treated	  samples.	  	  	  
3.19 Inhibition	  of	  lysosomal	  degradation	  H460	  cells	  were	  treated	  with	  the	   lysosomal	   inhibitor	  Chloroquine	  (Sigma)	   for	  16h	   at	   a	   final	   concentration	   of	   50	   µM	   or	   100	   µM.	   The	   cells	   were	   thereafter	  treated	  with	  30U/ml	  TRAIL	  for	  1.5h.	  	  	  	  
3.20 Inhibition	  of	  kinase	  activity	  of	  EGFR	  and	  ErbB2	  MCF10A	  cells	  were	  washed	  with	  PBS	  and	  DMEM/F12	  medium,	  supplemented	  with	   20	  ng/ml	   EGF,	   was	   added.	   Lapatinib	   (GlaxoSmithKline),	   an	   inhibitor	   of	  EGFR	   and	   ErbB2	   activity,	   was	   added	   at	   a	   final	   concentration	   of	   1	   μM	   and	  incubated	  for	  1	  h	  prior	  to	  treatment	  with	  TRAIL	  for	  2h.	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Chapter	  4	  -­	  Results	  
4.1 Ack1	  is	  required	  for	  TRAIL	  induced	  apoptosis	  
4.1.1 Background	  and	  aims	  The	   focus	   of	   our	   research	   group	   has	  mainly	   been	   on	   the	   tumour	   suppressor	  Mitogen	   inducible	   gene	   6	   (Mig6).	   Mig6	   is	   an	   adaptor	   protein	   that	   can	   bind	  directly	   to	   the	   kinase	   domain	   of	   the	   ErbB	   receptors	   and	   thereby	   inhibit	   the	  dimerisation	  and/or	  phosphorylation	  of	  the	  receptors	  [149].	  Gene	  targeting	  of	  Mig6	   in	   mice	   have	   shown	   that	   Mig6	   is	   a	   specific	   negative	   regulator	   of	   ErbB	  mediated	   signalling	   during	   development	   and	   carcinogenesis	   [150].	   The	   non-­‐receptor	  tyrosine	  kinase,	  Ack1,	  has	  a	  proline	  rich,	  ErbB	  receptor	  binding	  region	  highly	  similar	  to	  the	  one	  of	  Mig6.	  	  	  Mig6	  has	  been	  shown	  to	  be	  a	  key	  regulator	  of	  apoptosis	  in	  mammary	  epithelial	  cells	   (S.	  Hopkins	  et	  al.,	  2012	  Dev	  cell).	  This	   raised	   the	  question	  whether	  Ack1	  also	  may	  regulate	  apoptosis.	  In	  this	  work,	  we	  have	  identified	  Ack1	  as	  a	  crucial	  protein	  for	  TRAIL	  induced	  apoptosis.	  	  
	  
The	  aims	  were	  to:	  	  a) Generate	  recombinant	  TRAIL	  for	  the	  use	  in	  subsequent	  experiments.	  	  	  b) Analyse	   the	   cell	   death	   response	   in	   a	   panel	   of	   epithelial	   cells	   following	  TRAIL	  treatment,	  in	  the	  presence	  or	  absence	  of	  Ack1	  expression.	  c) Investigate	  if	  Ack1	  regulates	  apoptosis	  via	  other	  death	  receptors.	  	  d) Examine	  if	  Ack1	  is	  required	  for	  the	  mitochondrial	  cell	  death	  pathway.	  e) Study	  whether	   TRAIL	   induced	   survival	   signalling	   is	   increased	   in	   Ack1	  knockdown	  cells.	  f) Study	  the	  mechanism	  by	  which	  Ack1	  regulates	  TRAIL	  induced	  apoptosis	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4.1.2 Generation	  and	  purification	  of	  recombinant	  TRAIL	  	  Due	   to	   the	   large	   quantities	   of	   TRAIL	   required	   for	   experiments	   we	   sought	   to	  generate	  our	  own	  recombinant	  TRAIL.	  An	  expression	  construct	  containing	  the	  extracellular	   region	   of	   TRAIL	   (residues	   95-­‐281)	   was	   expressed	   in	  BL21(DE3)RIL	  E.	   Coli	   cells.	   Expression	   of	  His-­‐tagged	   recombinant	  TRAIL	  was	  induced	  by	  IPTG	  and	  TRAIL	  was	  thereafter	  batch	  purified	  with	  nickel	  agarose	  beads	  and	  eluted	  with	  100	  mM	  imidazole.	  The	  yield	  and	  purity	  was	  assessed	  by	  SDS-­‐PAGE	  and	  coomassie	  brilliant	  blue	  staining.	  Samples	  from	  several	  steps	  of	  the	  purification	  were	   run	   in	   order	   to	   assess	   the	   efficiency	  of	   the	  purification.	  The	   purity	   of	   the	   protein	   was	   satisfactory	   and	   elution	   fractions	   1	   to	   4	   were	  pooled	   and	   aliquoted	   (Figure	   9A).	   In	   order	   to	   control	   the	   apoptosis	   inducing	  activity	  of	   the	  purified	  TRAIL,	  MCF10A	  cells	  were	   treated	  with	   three	  doses	  of	  TRAIL	   for	   3h	   and	   caspase-­‐8	   cleavage	   was	   used	   to	   assess	   the	   apoptotic	  response.	   Commercially	   produced	   TRAIL	   (ENZO	   Life	   Sciences,	   cat	   no.	   BML-­‐SE722)	   was	   used	   as	   a	   positive	   control	   at	   a	   final	   concentration	   of	   1	   μg/ml.	  Western	   blotting	   results	   showed	   that	   the	   purified	   TRAIL	   was	   active	   and	  induced	  an	  adequate	  amount	  of	  cleaved	  caspase-­‐8,	  in	  MCF10A	  cells,	  in	  a	  dose-­‐dependent	   manner.	   The	   concentration	   chosen	   to	   use	   in	   subsequent	  experiments,	  defined	  as	  30U/ml,	  induced	  approximately	  one	  third	  of	  the	  death	  response	  compared	  to	  commercial	  TRAIL	  (100U/ml).	  Elution	  buffer	  alone	  did	  not	  induce	  caspase-­‐8	  cleavage	  (Figure	  9B).	  	  
4.1.3 Biotinylation	  of	  recombinant	  TRAIL	  In	   order	   to	   perform	   DISC	   co-­‐immunoprecipitation	   assays	   (see	   3.15)	   some	  recombinant	  TRAIL	  was	  labelled	  with	  biotin.	  TRAIL	  was	  purified	  as	  previously	  described	  and	  conjugated	  with	  biotin	  prior	   to	  elution	  of	   the	  protein	   from	   the	  nickel	   agarose	   beads.	   The	   biotinylation	   of	   TRAIL	   was	   assessed	   by	   western	  blotting	   and	   biotinylated	   protein	  was	   detected	   using	   streptavidin	   conjugated	  with	   HRP.	   As	   a	   positive	   control,	   1	   mg	   of	   a	   biotin-­‐conjugated	   antibody	   was	  loaded	  to	  one	  of	  the	  wells.	  The	  purified	  TRAIL	  was	  successfully	  labelled	  (Figure	  9C).	  The	  apoptosis	   inducing	  activity	  was	  assessed	  by	  cleaved	  caspase-­‐8	   levels	  and	  was	  also	  satisfactory.	  Two	  freezing	  conditions	  were	  tested;	  with	  or	  without	  the	  addition	  of	  20%	  glycerol.	  Results	  show	  that	  storage	  of	  biotinylated	  TRAIL	  at	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-­‐80°C	   without	   glycerol	   conserves	   the	   highest	   death	   inducing	   activity	   (Figure	  9D).	   Freeze	   thawing	   of	   the	   recombinant	   TRAIL	   significantly	   reduced	   the	  activity	  and	  was	  therefore	  avoided.	  	  	  
	  	  
Figure	  9.	  Purification	  and	  cell	  death	  inducing	  activity	  of	  recombinant	  TRAIL	  
A.	  SDS-­‐PAGE	  analysis	  of	  the	  purification	  and	  expression	  of	  recombinant	  TRAIL.	  Electrophoresis	  was	  performed	  using	  a	  12.5	  %	  acrylamide	  gel,	   and	   the	  proteins	  were	  stained	  with	  coomassie	  brilliant	  blue.	  His-­‐TRAIL	  protein	  expression	  was	   induced	  with	  1	  mM	  IPTG	  for	  3h	  at	  27°C.	  The	  cleared	  lysate	  was	  purified	  with	  Ni2+-­‐agarose	  beads	  and	  eluted	  with	  100	  mM	  imidazole.	  B.	  The	  apoptotic	   inducing	  activity	  of	   the	  purified	  TRAIL	  was	  assessed	   in	  MCF10A	  cells	  by	   treatment	  with	  TRAIL	  for	  3h.	  Cleavage	  of	  caspase-­‐8	  was	  dose	  dependent.	  As	  a	  positive	  control,	  cells	  were	  treated	  with	  1	  μg/ml	  commercially	  made	  TRAIL	  (ENZO	  Life	  Sciences).	  Elution	  buffer	  alone	  did	  not	  induce	  cleavage	  of	  caspase-­‐8.	  C.	  TRAIL	  was	  labelled	  with	  biotin	  by	  the	  addition	  of	  Biotin-­‐7-­‐NHS.	   The	   biotinylation	   was	   assessed	   by	   western	   blot	   using	   HRP-­‐conjugated	   streptavidin.	   A	  biotin-­‐conjugated	   antibody	  was	   used	   as	   positive	   control	   (lane	   1).	  D.	   The	   cell	   death	   inducing	  activity	   of	   the	   biotin	   conjugated	   recombinant	   TRAIL	  was	   assessed	   by	   cleavage	   of	   caspase-­‐8.	  Storage	   of	   the	   biotinylated	   TRAIL	   at	   -­‐80°C,	   without	   the	   addition	   of	   glycerol,	   preserves	   the	  activity	  more	  efficiently	  compared	  to	  addition	  of	  20%	  glycerol.	  Abbreviations:	  Biotin-­7-­NHS:	  D-­
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biotinoyl-­ε-­aminocaproic	   acid-­N-­hydroxysuccinimide	   ester	   His:	   histidine,	   HRP:	   horseradish	  
peroxidase,	  IPTG:	  Isopropyl-­β-­D-­thio-­galactoside,	  TRAIL:	  TNF-­related	  apoptosis	  inducing	  ligand	  	  
4.1.4 Ack1	  knockdown	  inhibits	  TRAIL	  induced	  apoptosis	  In	   order	   to	   investigate	   if	   Ack1	   has	   a	   role	   in	   TRAIL	   induced	   apoptosis,	   the	  expression	   of	   Ack1	   was	   silenced,	   in	   human	   epithelial	   cells,	   using	   siRNA	   and	  thereafter	   treated	   with	   TRAIL.	   The	   apoptotic	   response	   following	   TRAIL	  treatment	   was	   analysed	   by	   measuring	   the	   expression	   of	   phosphatidylserine	  (PS)	  on	  the	  cell	  surface	  by	  flow	  cytometry	  analysis.	  Healthy	  cells	  express	  PS	  in	  the	  inner	  leaflet	  of	  the	  plasma	  membrane,	  however	  during	  apoptosis;	  the	  PS	  is	  translocated	  to	  the	  outer	  membrane	  of	  the	  dying	  cell.	  The	  PS	  exposure	  can	  be	  detected	  using	  a	   fluorescently	   labelled	  phospholipid	  binding	  protein,	  Annexin	  V,	  with	   a	   high	   affinity	   to	   PS	   located	   only	   on	   the	   outer	  membrane.	   Annexin	   V	  positive	   cells	   function	   as	   an	   early	   marker	   for	   apoptosis.	   Late	   apoptotic	   and	  necrotic	  cells,	  which	  have	  lost	  their	  membrane	  integrity,	  are	  distinguished	  from	  early	  apoptotic	  cells	  by	  propidium	  iodide	  (PI)	  staining.	  	  	  The	  TRAIL	  sensitive	  mammary	  epithelial	  cell	  line	  MCF10A	  was	  transfected	  with	  siRNA	  targeting	  Ack1	  (siAck1)	  or	  non-­‐targeting	  siRNA	  (siCtrl).	  The	  cells	  were	  treated	   with	   2	   doses	   (30U/ml	   or	   60U/ml)	   of	   TRAIL	   for	   3h,	   trypsinised	   and	  thereafter	   stained	   with	   FITC-­‐Annexin	   V	   and	   PI.	   The	   percentage	   of	   early	  apoptotic	  (Annexin	  V	  positive/PI	  negative)	  cells	  in	  Ack1	  knockdown	  cells	  were	  significantly	  lower	  than	  in	  control	  cells	  with	  both	  doses	  of	  TRAIL	  used;	  5.4	  and	  11.5%	  in	  Ack1	  knockdown	  cells	  as	  compared	  to	  24.8	  and	  39.4%	  in	  control	  cells	  (p<0.006,	   students	   t-­‐test).	   The	   experiment	   was	   repeated	   three	   times	   and	   a	  representative	   dot	   plot	   from	  one	   of	   the	   experiments	   is	   shown	   in	   Figure	   10A.	  The	  graph	  in	  Figure	  10B	  is	  an	  average	  of	  the	  three	  independent	  experiments.	  	  	  To	  further	  confirm	  that	  Ack1	  knockdown	  inhibits	  TRAIL	  induced	  apoptosis,	  the	  levels	   of	   cleaved	   and	   activated	   caspase-­‐8	   and	   -­‐3	   was	   analysed	   by	   western	  blotting.	   Results	   clearly	   show	   that	   Ack1	   knockdown	   leads	   to	   lower	   levels	   of	  both	  cleaved	  caspases.	  Two,	  non-­‐overlapping,	  siRNA	  targeting	  Ack1	  (Ack1a	  and	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Ack1b)	  were	  used	  to	  confirm	  the	  phenotype	  (Figure	  10C).	  The	  cells	  underwent	  apoptosis	  in	  a	  time	  and	  dose	  dependent	  manner.	  	  	  	  In	   order	   to	   investigate	   how	   general	   this	   observed	   phenotype	   is,	   the	   TRAIL	  treatment	  experiments	  were	  repeated	  in	  a	  panel	  of	  human	  epithelial	  cell	  lines,	  all	  known	  to	  be	  TRAIL	  sensitive.	  Cells	  were	  treated	  with	  TRAIL	  for	  30	  min	  –	  3h,	  depending	   on	   the	   sensitivity	   of	   the	   cell	   line,	   and	   the	   apoptotic	   response	  was	  analysed	  by	  western	  blotting.	  Results	  show	  that	  the	  epithelial	  cell	   lines	  tested	  (SW480,	   HELA	   and	   NCI-­‐H460)	   all	   had	   lower	   levels	   of	   cleaved	   caspase-­‐8	  following	   TRAIL	   treatment	   (Figure	   10D-­‐F),	   suggesting	   that	   the	   phenotype	   is	  more	  general	  for	  TRAIL-­‐sensitive	  epithelial	  cells	  and	  not	  just	  cell	  line	  specific.	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Figure	  10.	  Ack1	  is	  required	  for	  TRAIL	  induced	  apoptosis	  in	  human	  epithelial	  cells	  
A.	  MCF10A	  cells	  transfected	  with	  non-­‐targeting	  (siCtrl)	  or	  Ack1	  siRNA	  (siAck1)	  were	  either	  left	  untreated	   or	   treated	   with	   30U/ml	   or	   60U/ml	   TRAIL	   for	   3h.	   Cells	   were	   stained	   with	   FITC-­‐conjugated	   Annexin	   V	   and	   PI	   followed	   by	   flow	   cytometry	   analysis.	   The	   percentage	   of	   early	  apoptotic	   (Annexin	   V	   positive/PI	   negative)	   cells	  was	   significantly	   lower	   in	   Ack1	   knockdown	  cells.	  Necrotic	  and	  late	  apoptotic	  cells	  were	  positively	  stained	  with	  PI.	  A	  representative	  dot	  plot	  from	  one	  out	  of	  thee	  independent	  experiments	  are	  shown.	  B.	  An	  average	  of	  three	  independent	  Annexin	   V/PI	   flow	   cytometry	   experiments.	   Ack1	   knockdown	   cells	   undergo	   significantly	   less	  apoptosis	   following	   TRAIL	   treatment	   (p>0.006,	   Students	   t-­‐test).	   The	   error	   bars	   represent	  standard	  deviation.	  C.	  MCF10A	  cells	  were	  transfected	  with	  two	  non-­‐overlapping	  siRNA	  (Ack1a	  or	   Ack1b)	   for	   the	   knockdown	   of	   Ack1,	   or	   transfected	   with	   non-­‐targeting	   siRNA	   (Ctrl).	   Cells	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were	  treated	  with	  TRAIL	  for	  the	  time	  points	  indicated.	  Western	  blot	  analysis	  show	  lower	  levels	  of	  cleaved	  and	  activated	  caspase-­‐8	  and	  -­‐3	  in	  Ack1	  knockdown	  cells	  as	  compared	  to	  control	  cells.	  
D-­F.	  A	  panel	  of	   epithelial	   cells	  was	   treated	  with	  30U/ml	  TRAIL	   for	   the	   time	  points	   indicated.	  Cleaved	  caspase-­‐8	   levels	  were	   lower	   following	  Ack1	  knockdown	  in	  HELA	  (D)	  SW480	  (E)	  and	  NCI-­‐H460	  cells	  (F).	  Abbreviations:	  Ack1:	  Activated	  Cdc42-­associated	  kinase	  1,	   FITC:	   fluorescein	  
isothiocyanate,	   PI:	   Propidium	   Iodide,	   PS:	   phosphatidylserine,	   TRAIL:	   TNF-­related	   apoptosis-­
inducing	  ligand	  	  
	  








Figure	  11.	  Decreased	  proliferation	  rate	  in	  Ack1	  knockdown	  cells	  MCF10A	   cells	   were	   transfected	   with	   non-­‐targeting	   siRNA	   (siCtrl)	   or	   siRNA	   targeting	   Ack1	  (siAck1)	  48h	  prior	  to	  the	  experiment.	  Cells	  were	  trypsinised,	  fixed	  in	  ethanol	  and	  stained	  with	  propidium	   iodide.	   The	   cell	   cycle	   profile	   was	   analyzed	   by	   flow	   cytometry.	   Ack1	   knockdown	  resulted	  in	  a	  13%	  increase	  of	  cells	  in	  G1	  as	  compared	  to	  control	  transfected	  cells.	  Abbreviations:	  
Ack1:	  Activated	  Cdc42-­associated	  kinase	  1,	  PI:	  propidium	  iodide	  	  	  
4.1.6 Regulation	  of	  Fas-­mediated	  apoptosis	  by	  Ack1	  To	   elucidate	   the	   specificity	   of	   Ack1	   on	   regulating	   apoptosis	   via	   the	   death	  receptor	   pathway,	  we	  wanted	   to	   investigate	   if	   Ack1	   knockdown	   also	   inhibits	  Fas-­‐induced	  apoptosis.	  MCF10A	  cells	  were	  treated	  with	  2	  µg/ml	  Fas	  receptor-­‐activating	  antibody	  for	  24	  to	  48h.	  Cell	  death	  was	  assessed	  by	  western	  blotting	  of	  cleaved	  caspase-­‐8.	  Results	  show	  that	  there	  was	  a	  slight	  decrease	  in	  the	  levels	  of	  cleaved	  caspase-­‐8	  in	  Ack1	  knockdown	  cells,	  suggesting	  that	  Ack1	  might	  play	  a	  role	  in	  the	  regulation	  of	  Fas	  induced	  apoptosis.	  The	  ~50	  kDa	  band	  detected	  in	  the	   cleaved	   caspase-­‐8	   blot	   is	   most	   likely	   the	   heavy	   chain	   of	   IgG	   from	   the	  antibody	  used	  for	  the	  treatment	  (Figure	  12).	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Figure	  12.	  Ack1	  regulates	  Fas-­induced	  apoptosis	  MCF10A	  cells	  were	  transfected	  with	  non-­‐targeting	  (Ctrl)	  or	  Ack1	  siRNA	  and	  cultured	  for	  48h.	  The	  cells	  were	   treated	  with	  2	  µg/ml	  Fas-­‐activating	  antibody	   for	  24	   to	  48h	  and	   the	  cell	  death	  response	  was	   analysed	   by	  western	   blotting	   of	   cleaved	   caspase-­‐8	   levels.	   A	   slight	   decrease	   in	  cleaved	  caspase-­‐8	  was	  seen	  in	  Ack1	  knockdown	  cells	  as	  compared	  to	  control	  transfected	  cells.	  *	  The	  ~50	  kDa	  band	  detected	  in	  the	  cleaved	  caspase-­‐8	  blot	  is	  most	  likely	  IgG	  from	  the	  antibody	  used	  for	  the	  treatment.	  Abbreviations:	  Ack1:	  Activated	  Cdc42-­associated	  kinase	  1	  	  
4.1.7 Ack1	  is	  not	  required	  for	  apoptosis	  via	  the	  mitochondrial	  pathway	  In	  order	  to	  investigate	  if	  Ack1	  only	  regulate	  the	  death	  receptor	  pathway	  or	  if	  it	  also	   plays	   a	   role	   in	   the	   mitochondrial	   pathway,	   experiments	   activating	   the	  mitochondrial	   pathway	  were	   performed.	   Serum	   starvation	   and	   growth	   factor	  deprivation	   is	   thought	   to	   induce	   cell	   death	   via	   the	   mitochondrial	   pathway.	  MCF10A	  cells	  were	  cultured	  without	  serum	  and	  growth	  factors	  for	  48h	  to	  72h	  and	  apoptosis	  was	  assessed	  by	  cleaved	  caspase-­‐3	  levels	  using	  western	  blotting.	  The	   cleaved	   caspase-­‐3	   levels	   were	   equal	   or	   even	   elevated	   in	   the	   Ack1	  knockdown	   cells	   compared	   to	   control	   transfected	   cells	   (Figure	   13).	   These	  results	  suggest	  that	  Ack1	  promotes	  apoptosis	  specifically	  via	  the	  death	  receptor	  pathway.	  The	  increase	  of	  caspase-­‐3	  cleavage	  seen	  in	  Ack1	  knockdown	  cells	  was	  not	  further	  investigated.	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Figure	  13.	  Ack1	  is	  not	  required	  for	  apoptosis	  via	  the	  mitochondrial	  pathway	  Ack1	   expression	  was	   silenced	  with	   siRNA	  and	  non-­‐targeting	   siRNA	  was	  used	   as	   control.	   The	  experiment	  was	  performed	  48h	  post-­‐transfection.	  MCF10A	  cells	  were	  cultured	  devoid	  of	  serum	  and	   growth	   factors	   for	   48	   to	   72h.	   Apoptosis	   was	   assessed	   by	   western	   blotting	   of	   cleaved	  caspase-­‐3	   levels.	   Ack1	   knockdown	   does	   not	   inhibit	   the	   apoptotic	   response	   via	   the	  mitochondrial	  pathway.	  Abbreviations:	  Ack1:	  Activated	  Cdc42-­associated	  kinase	  1	  	  
4.1.8 Ack1	  knockdown	  does	  not	  promote	  survival	  signalling	  pathways	  
via	  the	  TRAIL	  receptors	  Following	   TRAIL	   ligand	   binding,	   alternative	   signalling	   pathways	   promoting	  anti-­‐apoptotic	  activities,	   such	  as	  migration,	   invasion	  and	   inflammation	  can	  be	  activated,	  via	  the	  formation	  of	  a	  second	  complex	  following	  the	  assembly	  of	  the	  DISC.	  Two	  proteins	  known	  to	  be	  activated	  are	  NfkB	  and	  Akt	  [151,	  152].	  In	  order	  to	  investigate	  if	  Ack1	  knockdown	  leads	  to	  a	  shift	  from	  death	  inducing	  signalling	  towards	   survival	   signalling,	   MCF10A	   cells	   were	   serum	   starved	   for	   4h	   and	  thereafter	   treated	   with	   TRAIL	   for	   3h.	   The	   levels	   of	   phosphorylated	   NfkB	  (pNfkB)	   and	  Akt	   (pAkt)	  was	   analysed	   by	  western	   blotting.	   Results	   show	   that	  there	  is	  no	  increase	  in	  phosphorylation	  of	  NfkB	  or	  Akt	  in	  response	  to	  TRAIL	  in	  MCF10A	  cells.	  In	  addition,	  there	  was	  no	  difference	  in	  the	  pNfkB	  levels	  in	  Ack1	  knockdown	   cells	   as	   compared	   to	   control	   transfected	   cells	   (Figure	   14).	   In	  contrast,	   Ack1	   knockdown	   leads	   to	   significantly	   lower	   levels	   of	   pAkt	   both	   in	  non-­‐treated	  and	  TRAIL	  treated	  cells.	  Ack1	  is	  known	  to	  phosphorylate	  Akt	  [116],	  so	  the	  decrease	  was	  therefore	  expected	  and	  independent	  of	  TRAIL	  (Figure	  14).	  These	   results	   suggest	   that	   Ack1	   knockdown	   does	   not	   lead	   to	   an	   increase	   in	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survival	  signalling	  via	  NfkB	  and	  Akt	  signalling	  pathways	  in	  response	  to	  TRAIL	  treatment.	  	  	  	  
	  
Figure	   14.	   Ack1	   knockdown	   does	   not	   lead	   to	   increased	   TRAIL	   induced	   NfkB	   and	   Akt	  
activation	  MCF10A	   cells	   were	   transfected	   with	   control	   siRNA	   (C)	   or	   siRNA	   targeting	   Ack1	   (A).	  Experiments	   were	   performed	   48	   h	   post	   transfection.	   Cells	   were	   serum	   starved	   for	   4h	   and	  thereafter	   treated	   with	   30U/ml	   TRAIL	   for	   3h.	   Western	   blot	   analysis	   shows	   no	   increased	  phosphorylation	  of	  NfkB	  in	  the	  absence	  of	  Ack1.	  The	  phosphorylation	  levels	  of	  Akt	  were	  lower	  in	   Ack1	   knockdown	   cells,	   independently	   of	   TRAIL	   treatment.	   	  Abbreviations:	   Ack1:	   Activated	  
Cdc42-­associated	   kinase	   1,	   NfkB:	   Nuclear	   factor-­ĸB,	   p:	   phosphorylation,	   TRAIL:	   TNF-­related	  
apoptosis-­inducing	  ligand	  	   	  
4.1.9 Ack1	  is	  dephosphorylated	  in	  response	  to	  TRAIL	  In	  order	  to	   investigate	  the	  activity	  of	  Ack1	  in	  response	  to	  TRAIL,	  wild	  type	  or	  kinase	  dead	  (KD)	  Ack1	  was	  ectopically	  expressed	  in	  H460	  cells	  and	  thereafter	  serum	   starved	   for	   6h	   and	   treated	   with	   TRAIL	   for	   the	   time	   points	   indicated.	  Significant	  levels	  of	  phosphorylated	  Ack1	  were	  still	  detected	  in	  serum	  starved	  cells.	   Interestingly,	   TRAIL	   treatment	   reduced	   the	   phosphorylation	   levels	   in	   a	  time	  dependent	  manner,	  suggesting	  that	  Ack1	  is	  dephosphorylated	  in	  response	  to	  TRAIL.	   Phosphorylation	   of	   kinase	   dead	  Ack1	  was	   not	   detected,	   confirming	  the	  specificity	  of	  the	  pAck1	  antibody	  (Figure	  15A).	  	  	  A	   decrease	   of	   the	   total	   levels	   of	   Ack1	   following	   TRAIL	   treatment	   have	   been	  detected	  in	  many	  experiments	  performed	  (for	  example	  in	  Figure	  10	  and	  Figure	  18).	  In	  addition,	  knockdown	  of	  Ack1	  in	  some	  cases	  leads	  to	  a	  decreased	  level	  of	  TRAIL-­‐R1,	   it	   is	   unclear	   why	   this	   difference	   is	   only	   detected	   in	   some	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experiments	   and	   not	   in	   others.	   One	   possible	   explanation	   is	   that	   Ack1	  transiently	   regulates	   TRAIL-­‐R1	   stability	   and/or	   trafficking.	   In	   order	   to	  investigate	   the	   stability	   and	   degradation	   of	   Ack1	   and	   TRAIL-­‐R1,	   lysosomal	  degradation	  was	  inhibited	  using	  the	  inhibitor	  Chloroquine	  at	  a	  concentration	  of	  50	  µM	  to	  100	  µM	  for	  16h.	  Ack1	  and	  TRAIL-­‐R1	  levels	  were	  analysed	  by	  western	  blotting.	  Results	   show	   that	   lysosomal	   inhibition	   increased	  both	   the	  TRAIL-­‐R1	  and	   Ack1	   levels,	   suggesting	   that	   both	   proteins	   are	   degraded	   via	   a	   lysosome	  dependent	   pathway.	   Non-­‐treated	   Ack1	   knockdown	   cells	   had	   slightly	   lower	  levels	   of	   TRAIL-­‐R1	   compared	   to	   control	   transfected	   cells,	   which	   have	   been	  observed	  in	  other	  experiments	  performed.	  The	  difference	  in	  protein	  levels	  are	  however	  restored	  by	  the	  higher	  dose	  of	  Chloroquine	  (Figure	  15B).	  	  	  
	  
	  
Figure	  15.	  Ack1	  is	  dephosphorylated	  in	  response	  to	  TRAIL.	  	  
A.	  H460	  cells	  were	  either	  transfected	  with	  an	  empty	  vector	  (-­‐),	  with	  an	  Ack1	  wilt	  type	  (+)	  or	  an	  Ack1	   kinase	   dead	   (+KD)	   expression	   vector.	   The	   cells	  were	   serum	   starved	   for	   6h	   and	   treated	  with	  TRAIL	  for	  the	  time	  points	  indicated.	  B.	  Lysosomal	  degradation	  was	  inhibited	  with	  50	  µM	  or	   100	   µM	   Chloroquine	   for	   16h,	   where	   indicated.	   Protein	   levels	   of	   TRAIL-­‐R1	   and	   Ack1	   are	  increased	  after	  lysosome	  inhibition	  with	  Chloroquine.	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4.1.10 Ack1	  promotes	  TRAIL	  induced	  apoptosis	  independently	  of	  ErbB	  
signalling	  Ack1	   has	   previously	   been	   described	   to	   interact	   with	   and	   regulate	   EGFR	  signalling,	  we	  therefore	  wanted	  to	   investigate	   if	  Ack1	  controls	  TRAIL	   induced	  apoptosis	  via	  an	  ErbB	  signalling	  dependent	  mechanism.	  This	  was	  addressed	  by	  treating	  the	  cells	  with	  the	  epidermal	  growth	  factor	  receptor	  (EGFR)	  and	  ErbB2	  inhibitor	  Lapatinib	  followed	  by	  TRAIL	  treatment	  for	  2h.	  Lapatinib	  inhibited	  the	  phosphorylation	  of	  EGFR	  effectively,	  visualised	  by	  the	  loss	  of	  phospho-­‐EGFR	  in	  Lapatinib	   treated	   cells	   analysed	   by	   western	   blotting	   (Figure	   16	   lane	   7-­‐9).	  Inhibition	   of	   ErbB	   signalling	   failed	   to	   restore	   the	   levels	   of	   cleaved	   caspase-­‐8	  and	   -­‐3	   in	   Ack1	   knockdown	   cells	   following	   TRAIL	   treatment	   suggesting	   that	  Ack1	   regulates	   TRAIL	   induced	   apoptosis	   independently	   of	   ErbB	   signalling	  (Figure	  16).	  	  
	  
	  Figure	  16.	  Ack1	  promotes	  TRAIL	   induced	  apoptosis	   independently	  of	  EGFR	  and	  ErbB2	  
activity.	  	  Ack1	  expression	  was	  silenced	  in	  MCF10A	  cells	  by	  two	  independent	  siRNA	  (Ack1a	  and	  Ack1b),	  non-­‐targeting	  siRNA	  was	  used	  as	  control.	  The	  kinase	  activity	  of	  EGFR	  and	  ErbB2	  was	  inhibited	  with	  1	  μM	  Lapatinib,	  where	   indicated,	  and	  thereafter	   treated	  with	  TRAIL	   for	  2h.	   Inhibition	  of	  ErbB	  signalling	  did	  not	  restore	  the	  cleaved	  casapase-­‐8	  and	  -­‐3	  levels	  in	  Ack1	  knockdown	  cells.	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4.1.11 Cdc42	  is	  required	  for	  TRAIL	  induced	  apoptosis	  	  Ack1	   is	   a	   downstream	  effector	   of	   Cdc42.	   Striking	  morphological	   changes	  was	  seen	   in	   HELA	   cells	   when	   Ack1	  was	   silenced,	   although	   not	   in	   other	   cell	   lines	  examined	   (data	   not	   shown).	   The	   cells	   were	   elongated	   and	   resembled	   the	  phenotype	   described	   for	   Cdc42	   knockdown	   cells.	   We	   therefore	   wanted	   to	  investigate	   if	   the	   Ack1	   function	   in	   TRAIL	   induced	   apoptosis	   is	   Cdc42	  dependent.	  	  MCF10A	   cells	   were	   transfected	   with	   siRNA	   targeting	   Ack1,	   Cdc42	   or	   with	   a	  non-­‐targeting	   control.	   The	   Cdc42	   expression	   was	   silenced	   with	   three	  independent	  non-­‐overlapping	  siRNA	  (Cdc42	  a,	  b,	  c).	  The	  cells	  were	  treated	  with	  TRAIL	   for	   3h	   and	   samples	  were	   subjected	   to	  western	   blotting.	   Results	   show	  that	  cleaved	  caspase-­‐8	   levels	  were	   lower	   in	  both	  Cdc42	  and	  Ack1	  knockdown	  cells	  compared	  to	  control	  cells	  (Figure	  17).	  This	  data	  suggest	  that	  Cdc42	  also	  is	  required	   for	   TRAIL	   induced	   apoptosis,	   either	   directly	   or	   indirectly	   by	  regulating/activating	  Ack1.	  	  	  
	  
Figure	  17.	  Cdc42	  knockdown	  inhibits	  TRAIL	  induced	  apoptosis	  MCF10A	  cells	  were	  transfected	  with	  non-­‐targeting	  control,	  Ack1	  and	  Cdc42	  siRNA.	  Expression	  of	   Cdc42	   was	   knocked	   down	   with	   three	   non-­‐overlapping	   siRNA.	   The	   cells	   were	   thereafter	  treated	  with	  30U/ml	  TRAIL	  for	  3h.	  Lower	  levels	  of	  caspase-­‐8	  were	  detected	  in	  both	  Ack1	  and	  Cdc42	   knockdown	   cells	   compared	   with	   cells	   transfected	   with	   non-­‐targeting	   siRNA.	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Abbreviations:	   Ack1:	   Activated	   Cdc42-­associated	   kinase	   1,	   Cdc42:	   Cell	   division	   cycle	   42,	   GTP	  
binding	  protein,	  TRAIL:	  TNF-­related	  apoptosis-­inducing	  ligand	  
	  
4.1.12 Discussion	  In	   this	   work,	   a	   novel	   role	   of	   Ack1	   in	   death	   receptor	   signalling	   has	   been	  discovered;	   demonstrating	   that	   the	   non-­‐receptor	   tyrosine	   kinase,	   Ack1,	   is	  required	  for	  TRAIL	  induced	  apoptosis	  in	  human	  epithelial	  cells.	  	  Recombinant	   TRAIL	   was	   generated	   in	   order	   to	   perform	   several	   assays	  requiring	  large	  quantities	  of	  TRAIL	  and	  the	  death-­‐inducing	  activity	  determined	  empirically.	  Ack1	  expression	  was	  silenced	  by	  transient	  siRNA	  transfection	  and	  more	   than	   ~80%	   knockdown	   of	   Ack1	   was	   achieved,	   confirmed	   by	   western	  blotting.	   This	   degree	   of	   knockdown	  was	  necessary	   to	  prevent	  TRAIL	   induced	  apoptosis	   (data	  not	   shown).	  The	   levels	  of	  Ack1	  varied	  between	   cell	   lines	   and	  hence	  the	  amount	  of	  siRNA	  that	  needed	  to	  be	  used:	  12	  mM	  for	  most	  of	  the	  cell	  lines	  (MCF10A,	  HELA	  and	  SW480)	  but	  30	  nM	  for	  the	  high	  expressing	  NCI-­‐H460	  cell	  line.	  	  A	  decreased	  proliferation	  rate	  was	  observed	  upon	  Ack1	  knockdown.	  Cell	  cycle	  analysis	  by	  PI	  staining	  of	  genomic	  DNA	  and	  flow	  cytometry	  confirmed	  that	  the	  Ack1	  knockdown	  population	  had	  more	  cells	   in	  G1	  (75%)	  compared	  to	  control	  transfected	   cells	   (62%)	   (Figure	   11).	   The	   effect	   on	   cell	   proliferation	   following	  Ack1	  knockdown	  has	  been	  described	  previously	  and	  it	  has	  been	  suggested	  that	  Ack1	  promotes	  proliferation	  by	  activating	  mitogenic	  signalling	  pathways	  such	  as	   the	   Akt	   signalling	   cascade	   [153].	   Due	   to	   the	   decreased	   proliferation	   rate	  following	   Ack1	   knockdown,	   25%	  more	   cells	   were	   transfected	   with	   the	   Ack1	  siRNA	   oligo	   in	   order	   to	   ensure	   that	   the	   cell	   confluency	   at	   the	   time	   of	   TRAIL	  treatment	  was	  similar	  in	  control	  and	  knockdown	  cells.	  	  	  	  Apoptosis	   via	   the	   TRAIL	   signalling	   pathway	  was	   induced	   in	   a	   time	   and	   dose	  dependent	   manner	   using	   the	   recombinant	   TRAIL	   produced.	   The	   apoptotic	  response	  was	  assessed	  by	  Annexin	  V/PI	  staining	  and	  flow	  cytometry	  analysis.	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The	   results	   showed	   that	   Ack1	   knockdown	   leads	   to	   a	   significant	   decrease	   in	  early	   apoptotic	   (Annexin	   V	   positive/PI	   negative)	   cells	   following	   TRAIL	  treatment	  in	  the	  mammary	  epithelial	  cell	  line	  MCF10A	  (Figure	  10A-­‐B).	  The	  cell	  death	   response	   was	   also	   analysed	   with	   western	   blotting	   of	   cleaved	   and	  activated	   caspase-­‐8	   and	   caspase-­‐3,	   considered	   to	   be	   key	   caspases	   in	   death	  receptor	  signalling.	  Ack1	  was	  silenced	  in	  MCF10A	  cells	  using	  two	  independent	  non-­‐overlapping	  siRNA	  and	  treated	  with	  TRAIL	  for	  3h.	  Results	  show	  that	  Ack1	  knockdown	   leads	   to	   significantly	   lower	   levels	   of	   both	   cleaved	   caspase-­‐8	   and	  caspase-­‐3	   (Figure	   10C).	   The	  phenotype	  was	   confirmed	   in	   an	   additional	   three	  human	  epithelial	   cell	   lines	   (SW480,	  HELA	  and	  NCI-­‐H460),	   suggesting	   that	   the	  role	   of	   Ack1	   in	   TRAIL	   induced	   apoptosis	   is	  more	   general	   for	   TRAIL-­‐sensitive	  epithelial	  cells	  (Figure	  10D-­‐F).	  The	  cell	  lines	  used	  in	  this	  work	  were	  mainly	  the	  MCF10A	  cell	   line	  and	  the	  human	  lung	  carcinoma	  cell	   line,	  NCI-­‐H460.	  Both	  cell	  lines	  are	  sensitive	  to	  TRAIL	  and	  NCI-­‐H460	  express	  relatively	  high	  levels	  of	  Ack1	  and	  TRAIL-­‐R1	  compared	   to	  MCF10A	  cells,	   assessed	  by	  western	  blotting	   (data	  not	  shown).	  	  	  A	  direct	  role	  of	  Ack1	  in	  apoptosis	  has	  not	  previously	  been	  reported.	  However	  in	  contrast	   to	   our	   results,	   Ack1	   has	   been	   described	   to	   promote	   cell	   survival	   of	  cancer	   cells.	   Ack1	   was	   identified	   as	   a	   survival	   kinase	   in	   a	   large-­‐scale	   RNAi	  screen	   targeting	   all	   known	   kinases	   [130].	   Apoptosis	   was	   induced	   by	   DNA	  damaging	  drugs,	  activating	  the	  mitochondrial	  pathway.	  When	  Ack1	  is	  knocked	  down	   2.5	   fold	   more	   cell	   death	   is	   observed	   compared	   to	   control	   transfected	  cells.	   However	   the	   underlying	  molecular	  mechanism	   and	   the	   phenotype	  was	  not	   characterised	   further.	  These	  results	  agree	  with	   the	  starvation	  experiment	  performed	  here	  where	  cleaved	  caspase-­‐3	  levels	  were	  slightly	  elevated	  in	  Ack1	  knockdown	  cells	  demonstrating	  that	  Ack1	  is	  not	  required	  for	  apoptosis	  via	  the	  mitochondrial	  pathway,	  instead	  rather	  might	  prevent	  cell	  death	  (Figure	  13).	  	  To	  address	  if	  Ack1	  specifically	  regulates	  TRAIL	  induced	  apoptosis	  or	  whether	  it	  also	   can	   regulate	   other	   death	   receptor	   pathways,	   such	   as	   FasL	   induced	  apoptosis,	   MCF10A	   cells	   were	   treated	   with	   a	   Fas-­‐activating	   antibody.	   The	  antibody	  induced	  apoptosis	  in	  MCF10A	  cells,	  although	  not	  as	  efficiently	  as	  with	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TRAIL	   treatment.	   There	   was	   a	   slight	   decrease	   of	   cleaved	   caspase-­‐8	   in	   Ack1	  knockdown	  cells	  after	  24h	  of	  TRAIL	  treatment,	  suggesting	  that	  Ack1	  may	  also	  regulate	   Fas	   induced	   apoptosis	   to	   some	   extent	   (Figure	   12).	   The	   effect	   was	  however	  more	  striking	  with	  TRAIL	  treatment	  and	  that	  pathway	  will	  be	  further	  studied	  in	  this	  work.	  	  	  TRAIL	  is	  able	  to	  activate	  anti-­‐apoptotic	  signalling	  pathways	  promoting	  cellular	  events	   such	   as	   proliferation,	   migration	   and	   inflammation	   in	   some	  circumstances.	  Two	  proteins	  known	  to	  be	  activated	  by	  TRAIL	  are	  Akt	  and	  NfkB.	  Western	   blot	   analysis	   of	   phosphorylated	   forms	   of	   Akt	   and	   NfkB	   were	  performed	  in	  order	  to	  investigate	  if	  Ack1	  knockdown	  might	  lead	  to	  a	  diversion	  of	   the	   TRAIL	   receptor	   signalling,	   from	   death	   inducing,	   to	   an	   anti-­‐apoptotic	  signalling	   mode.	   MCF10A	   cells	   were	   starved	   for	   4h,	   treated	   with	   TRAIL	   and	  subjected	  to	  western	  blotting.	  TRAIL	  did	  not	  activate	  either	  Akt	  or	  NfkB	  in	  the	  MCF10A	   cells,	   since	   the	   phosphorylation	   levels	   in	   TRAIL	   treated	   cells	   were	  comparable	   to	   serum	   starved	   cells.	   Moreover,	   Ack1	   knockdown	   did	   not	  influence	   the	   phosphorylation	   status	   of	   NfkB.	   pAkt	   levels	   were	   significantly	  decreased	   in	  Ack1	  knockdown	   cells,	   independent	   of	  TRAIL	   treatment	   (Figure	  14).	  This	  may	  be	  consistent	  with	  a	  previous	  report	  showing	  that	  Akt	  is	  a	  direct	  phosphorylation	   substrate	   of	   Ack1.	   Ack1	   phosphorylates	   Akt	   at	   Tyr176	  resulting	   in	   plasma	   membrane	   translocation	   of	   Akt	   and	   promotes	  Thr308/Ser473-­‐phosphorylation	  leading	  to	  Akt	  activation	  [116].	  	  	  Overexpressed	   Ack1	   was	   still	   to	   a	   large	   extent	   phosphorylated	   even	   after	  serum	  starvation	  for	  6h.	  It	  has	  previously	  been	  reported	  that	  one	  pool	  of	  Ack1	  is	   constitutively	   activated	   in	   the	   cell	   even	   in	   the	   absence	   of	   stimuli	   [110]	  alternatively	   that	   the	   overexpression	   itself	   caused	   auto	   activation	   of	   the	  protein.	   Although,	   the	   phosphorylation	   of	   Ack1	   decreased	   after	   TRAIL	  treatment	   in	   a	   time	   dependent	   manner	   (Figure	   15A),	   it	   is	   still	   unclear	   if	   it	  mainly	   depends	   on	   a	   reduction	   in	   total	   Ack1	   levels	   or	   a	   specific	  dephosphorylation	   of	   the	   protein.	   It	   could	   suggest	   that	   Ack1	   needs	   to	   be	  inactive	  in	  order	  to	  perform	  its	  regulatory	  role	  in	  TRAIL	  induced	  apoptosis.	  To	  further	  investigate	  the	  reduction	  in	  protein	  levels	  of	  both	  TRAIL-­‐R1	  after	  Ack1	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knockdown	   and	   reduction	   in	   Ack1	   in	   TRAIL	   treated	   cells,	   cells	   were	   treated	  with	  the	  lysosomal	  inhibitor,	  Chloroquine.	  Both	  TRAIL-­‐R1	  and	  Ack1	  levels	  were	  increased	   after	   Chloroquine	   treatment	   (Figure	   15B).	   These	   results	   confirm	  another	   study	   claiming	   that	  Ack1	   is	   degraded	   via	   the	   lysosome	   [129].	  Others	  have	  although	  reported	  that	  Ack1	  are	  degraded	  by	  the	  proteasome	  [128].	  	  	  Ack1	   interacts	   with	   the	   EGFR	   and	   regulates	   ErbB	   signalling,	   potentially	   by	  inducing	  degradation	  of	  EGFR	  or	  preserving	  EGFR	  on	  the	  cell	  surface,	  however	  the	  mechanism	  is	  not	  yet	  fully	  understood	  [119-­‐121].	  We	  therefore	  wanted	  to	  investigate	   whether	   the	   role	   of	   Ack1	   is	   dependent	   on	   ErbB	   signalling.	   The	  inhibitor	  Lapatinib	  was	  used	   to	   inhibit	   the	  kinase	  activity	  of	  EGFR	  and	  ErbB2	  followed	  by	  TRAIL	   treatment	   for	  2h.	  Results	   show	   that	  Ack1	   regulates	  TRAIL	  induced	  apoptosis	  independently	  of	  EGFR/ErbB2	  activity	  since	  treatment	  with	  the	   inhibitors	  Lapatinib	  did	  not	  restore	  the	   levels	  of	  cleaved	  caspases	   in	  Ack1	  knockdown	   cells	   (Figure	   16).	   Ack1	   is	   also	   a	   known	   downstream	   effector	   of	  Cdc42	  and	  experiments	  were	  therefore	  performed	  in	  order	  to	  investigate	  if	  the	  role	   of	   Ack1	   in	   TRAIL	   induced	   apoptosis	   is	   Cdc42	   dependent.	   Indeed,	  knockdown	   of	   Cdc42	   resulted	   in	   lower	   levels	   of	   cleaved	   caspase-­‐8	   following	  TRAIL	   treatment,	   suggesting	   that	   Cdc42	   also	   is	   important	   for	   TRAIL	   induced	  apoptosis	   (Figure	   17).	   The	   Cdc42	   expression	   was	   silenced	   with	   three	  independent,	   non-­‐overlapping,	   siRNA,	   in	   order	   to	   rule	   out	   possible	   off-­‐target	  effects.	  	  	  Ideally,	  to	  verify	  the	  target	  specificity	  of	  the	  Ack1	  siRNAs	  a	  rescue	  experiment	  should	   be	   performed	   and	   was	   attempted.	   By	   ectopic	   expression	   of	   siRNA	  resistant	   Ack1	   in	   an	   Ack1	   knockdown	   background	   the	   cell	   death	   response	  should	  be	  restored.	  Several	  point	  mutants	  of	  Ack1	  have	  been	  generated	  by	  site-­‐directed	  mutagenesis.	  The	  mutations	  either	  impair	  the	  tyrosine	  kinase	  activity	  or	   disrupt	   protein-­‐protein	   interaction	   domains,	   such	   as	   Cdc42	   and	   clathrin	  binding	  (3.5.3).	  	  	  The	  point	  mutants	  would	  serve	  as	  a	  useful	  tool	  to	  determine	  if	  kinase	  activity	  or	   interactions	  with	  other	  proteins,	  such	  as	  Cdc42,	   is	  required.	  Unfortunately,	   due	   to	   technical	   difficulties,	   ectopic	   expression	   of	   the	  mutants	  has	   not	   been	   successful.	   Transient	   transfection	  with	   both	   siRNA	   and	  plasmid	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DNA	   were	   either	   cytotoxic	   or	   an	   inadequate	   amount	   of	   overexpression	   was	  obtained.	  Another	  approach	  was	  to	  generate	  stable	  cell	  lines	  expressing	  siRNA	  resistant	   Ack1,	   however	   this	   also	   failed,	   presumably	   due	   to	   selection	   against	  Ack1	  expressing	  cells.	  	  	  
4.2 Trafficking	  and	  sub-­cellular	  localisation	  of	  the	  TRAIL	  receptors	  
4.2.1 Background	  and	  aims	  Trafficking	   and	   sub-­‐cellular	   localisation	   of	   the	   TRAIL	   receptors	   have	   been	  shown	   to	   be	   important	   for	   the	   cell	   death	   response.	   For	   example,	   loss	   of	   cell	  surface	  expression	  of	  the	  TRAIL	  receptors	  due	  to	  constitutive	  endocytosis	  is	  a	  know	  mechanism	  of	  TRAIL	   resistance	   [74].	  Ack1	   is	   suggested	   to	   regulate	   the	  trafficking	   and	   endocytosis	   of	   ErbB	   receptors	   and	   Ack1	   interacts	   with	   the	  heavy	   chain	   of	   clathrin	   and	   the	   adaptor	   protein	   AP-­‐2	   [124].	   However	   the	  mechanism	   by	   which	   Ack1	   regulates	   endocytosis	   and	   trafficking	   is	   not	   fully	  understood.	  A	  potential	  role	  for	  Ack1	  in	  the	  trafficking	  of	  the	  TRAIL	  receptors	  has	   been	   investigated.	   In	   addition,	   Ack1	  was	   found	   to	   be	   crucial	   for	   cell-­‐cell	  junction	  stability,	  although	  this	  did	  not	  seem	  to	  be	  directly	  linked	  to	  the	  role	  of	  Ack1	  in	  TRAIL	  induced	  death	  response.	  	  
The	  aims	  were	  to:	  a) Examine	   the	   putative	   role	   of	   clathrin	   mediated	   endocytosis	   in	   TRAIL	  induced	   apoptosis	   and	   a	   potential	   regulatory	   role	   of	   Ack1	   in	  endocytosis.	  	  	  b) Investigate	   if	   Ack1	   regulates	   the	   cell	   surface	   expression	   of	   the	   TRAIL	  receptors	  by	  studying	  subcellular	  localisation	  of	  the	  TRAIL	  receptors	  in	  the	  absence	  and	  presence	  of	  Ack1.	  c) Elucidate	  whether	   cell-­‐cell	   junctions	   are	   important	   for	  TRAIL	   receptor	  dynamics	  and	  cell	  death	  response.	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4.2.2 Inhibition	  of	  clathrin	  mediated	  endocytosis	  does	  not	  affect	  the	  
TRAIL	  cell	  death	  response	  In	   order	   to	   elucidate	   if	   Ack1	   control	   the	   TRAIL	   response	   by	   regulating	   the	  endocytosis	   of	   the	   TRAIL	   receptors,	   clathrin	   mediated	   endocytosis	   was	  inhibited	   with	   the	   established	   inhibitor	   Chlorpromazine	   (CPZ)	   followed	   by	  treatment	  with	  TRAIL	  for	  2.5h.	  Western	  blotting	  results	  show	  that	  the	  cleaved	  caspase-­‐8	   levels	   were	   equal	   in	   the	   cells	   treated	   with	   CPZ	   compared	   to	   cells	  treated	   only	   with	   TRAIL.	   In	   addition,	   the	   reduction	   of	   caspase-­‐8	   cleavage	   in	  Ack1	  knockdown	  cells	  were	  not	   restored	   in	  CPZ	   treated	  cells,	   suggesting	   that	  Ack1	   regulates	   TRAIL	   induced	   apoptosis	   independently	   of	   clathrin	   mediated	  endocytosis	  (Figure	  18).	  	  
	  
	  
Figure	  18.	  Ack1	  regulates	  TRAIL	  induced	  apoptosis	  independently	  of	  clathrin	  mediated	  
endocytosis.	  	  	  MCF10A	   cells	   transfected	  with	   control	   siRNA	  or	   siRNA	   targeting	  Ack1,	  were	   treated	  with	   10	  µg/ml	   Chlorpromazine	   for	   1h	  where	   indicated,	   followed	   by	   TRAIL	   treatment	   for	   2.5h.	   There	  was	  no	  difference	  in	  cell	  death	  response,	  assessed	  by	  the	  cleavage	  of	  caspase-­‐8,	  in	  cells	  treated	  with	  Chlorpromazine,	  in	  either	  control	  or	  Ack1	  knockdown	  cells,	  compared	  to	  cell	  treated	  with	  TRAIL	   alone.	   Abbreviations:	   CPZ:	   Chlorpromazine,	   Ack1:	   Activated	   Cdc42-­associated	   kinase,	  
TRAIL:	  TNF-­related	  apoptosis-­inducing	  ligand	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4.2.3 Ack1	  knockdown	  does	  not	  alter	  the	  cell	  surface	  expression	  of	  the	  
TRAIL	  receptors	  The	   cell	   surface	   expression	   of	   TRAIL-­‐R1	   and	   -­‐R2	   was	   compared	   between	  control	  and	  Ack1	  knockdown	  cells	  to	  elucidate	  whether	  Ack1	  is	  required	  for	  the	  membrane	  localisation	  of	  the	  receptors.	  MCF10A	  cells,	  transfected	  with	  control	  or	   Ack1	   siRNA,	   were	   trypsinised	   and	   blocked	   in	   goat	   serum.	   The	   cells	   were	  thereafter	   incubated	  with	  phycoerythrin	   (PE)	   conjugated	  antibodies	   targeting	  the	  extracellular	  domain	  of	  TRAIL-­‐R1,	  -­‐R2	  or	  incubated	  with	  a	  PE-­‐IgG1	  isotype	  control	  for	  1h.	  Cell	  surface	  expression	  of	  the	  TRAIL	  receptors	  was	  analysed	  by	  flow	  cytometry	  using	  excitation	  and	  emission	  wavelengths	  of	  488	  and	  575	  nm	  respectively.	  The	  mean-­‐fluorescence	   intensity	  (MFI)	  value	  was	  analysed	  using	  the	   Summit	   4.3	   software	   and	   the	   PE-­‐intensity	   from	   the	   TRAIL	   receptor	  antibodies	  binding	  cell	  surface	  receptors	  was	  compared	  to	  the	  intensity	  of	  the	  isotype	   negative	   control.	   The	  MCF10A	   cells	   express	   both	  TRAIL	   receptors	   on	  the	   cell	   surface	   (Figure	   19).	   Furthermore,	   no	   difference	   in	   cell	   surface	  expression	   following	   Ack1	   knockdown	  was	   detected,	   since	   the	   PE-­‐intensities	  were	   comparable.	   The	   data	   presented	   is	   a	   representative	   graph	   from	   three	  independent	   experiments.	   Successful	   knockdown	   was	   confirmed	   by	   western	  blotting	  (data	  not	  shown).	  	  To	   further	   confirm	   that	   the	   cell	   surface	   expression	   is	   not	   effected	   in	   Ack1	  knockdown	  cells	  a	  Biotin-­‐IP	  of	  cell	  surface	  protein	  was	  performed.	  Cell	  surface	  proteins	   were	   labelled	   with	   biotin-­‐7-­‐NHS,	   binding	   free	   amine	   groups.	   The	  biotinylated	   proteins	   were	   thereafter	   immunoprecipitated	   with	   streptavidin	  beads,	  subjected	  to	  western	  blotting	  and	  probed	  for	  the	  protein	  of	  interest	  (ie.	  TRAIL-­‐R1	   and	   -­‐R2).	   Input	   samples	   with	   total	   protein	   content	   were	   run	   as	   a	  control.	  Comparable	  levels	  of	  biotinylated	  TRAIL-­‐R2	  were	  immunoprecipitated	  in	  control	  and	  Ack1	  knockdown	  cells,	  confirming	  that	  the	  TRAIL-­‐R2	  cell	  surface	  expression	   is	   equal	   in	   Ack1	   knockdown	   cells	   compared	   to	   control	   cells.	   The	  total	  levels	  of	  TRAIL-­‐R1	  varied	  between	  the	  control	  and	  Ack1	  knockdown	  cells	  so	   it	   is	   therefore	   not	   feasible	   to	   draw	   conclusion	   regarding	   the	   cell	   surface	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expression	   of	   TRAIL-­‐R1	   in	   these	   experiments.	   Na+/K+	   ATPase	   was	   used	   as	   a	  loading	  control	  (Figure	  19C).	  	  	  
	  
Figure	   19.	   Ack1	   knockdown	   does	   not	   alter	   the	   cell	   surface	   expression	   of	   the	   TRAIL	  
receptors	  	  
A.	   Flow	   cytometry	   analysis	   of	   cell	   surface	   expression	   of	   TRAIL-­‐R1	   and	  TRAIL-­‐R2	   in	  MCF10A	  cells.	  Cells	  were	  incubated	  with	  PE-­‐conjugated	  antibodies	  targeting	  the	  ligand-­‐binding	  domain	  of	  TRAIL-­‐R1	  and	  R2	  or	  with	  an	  IgG	  isotype	  control.	  There	  was	  no	  difference	  in	  the	  cell	  surface	  expression	  in	  Ack1	  knockdown	  cells	  compared	  to	  control	  transfected	  cells.	  Na+/K+	  ATPase	  was	  used	   as	   a	   loading	   control.	  B.	   Cell	   surface	  proteins	  were	   labelled	  with	  biotin	   and	  precipitated	  with	  streptavidin	  beads.	  Total	  cell	  lysates	  were	  used	  as	  input	  control.	  Samples	  were	  subjected	  to	  SDS	  PAGE	  and	  Western	  blot	  and	  probed	  for	  TRAIL-­‐R1	  and	  R2.	  Abbreviations:	  Ack1:	  Activated	  
Cdc42-­associated	   kinase,	   Biotin-­7-­NHS:	   D-­biotinoyl-­ε-­aminocaproic	   acid-­N-­hydroxysuccinimide	  
ester,	  PE:	  phycoerythrin,	  TRAIL-­R:	  TNF-­related	  apoptosis-­inducing	  ligand	  receptor	  	  
	  
4.2.4 TRAIL-­R1	  is	  localised	  at	  cell-­cell	  contacts	  In	   addition	   to	   previous	   experiments	   presented	   in	   4.2.3,	   the	   cell	   surface	  expression	   of	   the	   TRAIL	   receptors	   was	   also	   investigated	   by	  immunocytochemistry	   (ICH).	   NCI-­‐H460	   cells	   were	   plated	   on	   collagen	   coated	  glass	   coverslips	   and	   thereafter	   stained	   for	   TRAIL-­‐R1	   and	   the	  sodium/potassium	  adenosine	  triphosphatase	  (Na+/K+	  ATPase),	  commonly	  used	  as	  a	  plasma	  membrane	  marker,	   localised	  mainly	  on	   the	  basolateral	   surface	  of	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most	   epithelial	   cells.	   Confocal	   imaging	   of	   the	   cells	   show	   the	   Na+/K+	   ATPase	  primarily	   located	   at	   the	   plasma	   membrane	   at	   cell-­‐cell	   contacts	   with	   limited	  staining	   where	   cell-­‐cell	   contacts	   are	   absent.	   TRAIL-­‐R1	   share	   highly	   similar	  staining	   pattern	   and	   co-­‐localise	   with	   the	   Na+/K+	   ATPase	   at	   cell-­‐cell	   borders	  (Figure	  20).	  	  Single	  plane	  confocal	  images	  were	  acquired	  at	  63x	  magnification.	  	  
	  
	  	  
Figure	  20.	  TRAIL-­R1	  is	  mainly	  localised	  at	  cell-­cell	  contacts	  Single	  plane	  confocal	  images	  of	  NCI-­‐H460	  cells	  stained	  with	  TRAIL-­‐R1	  (red)	  and	  the	  membrane	  marker	  Na+/K+	  ATPase	  (green)	  at	  63x	  magnification.	  TRAIL-­‐R1	  and	  Na+/K+	  ATPase	  co-­‐localise	  at	  cell-­‐cell	  contacts.	  	  	  	  	  
4.2.5 Ack1	  knockdown	  leads	  to	  impaired	  cell-­cell	  junction	  
formation/stability	  and	  mislocalisation	  of	  TRAIL-­R1	  In	  order	  to	  investigate	  whether	  the	  sub-­‐cellular	  localisation	  of	  TRAIL-­‐R1	  were	  altered	   in	   the	   absence	   of	   Ack1,	   ICH	   experiments	   were	   repeated	   with	   Ack1	  knockdown	   cells.	   The	   adherens/desmosomal	   protein	   γ-­‐catenin	  was	   used	   as	   a	  cell-­‐cell	   junction	   marker.	   Interestingly,	   it	   was	   observed	   that	   the	   Ack1	  knockdown	  cells	  had	  a	  disrupted	  sub	  cellular	  localisation	  of	  both	  TRAIL-­‐R1	  and	  
γ-­‐catenin	  (Figure	  21).	  The	  expression	  of	  the	  proteins	  on	  the	  cell	  surface	  was	  to	  a	   large	   extent	   lost	   and	   the	   proteins	  were	  more	   internalised	   and	   present	   in	   a	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disorganised	  pattern.	  By	  analysing	  the	  confocal	  images	  in	  an	  orthogonal	  view	  it	  was	  possible	   to	   see	   that	  both	  γ-­‐catenin	  and	  TRAIL-­‐R1	  were	   localised	  more	  at	  the	   apical	   side	   of	   the	   cells	   after	   Ack1	   knockdown.	  Moreover,	   the	   sub-­‐cellular	  localisation	  of	  NA+/K+	  ATPase	  was	  also	  mislocalised	   in	  a	  similar	  manner	   to	  γ-­‐catenin	   (Figure	   21B).	   The	   apical	   localisation	   of	   junctional	   protein	   observed	  could	  suggest	  that	  epithelial	  cell	  polarity	  is	  disrupted	  in	  Ack1	  knockdown	  cells.	  	  	  Knockdown	   of	   Ack1	   in	   NCI-­‐H460	   cells	   also	   resulted	   in	   a	   significant	  mislocalisation	  of	  β-­‐catenin	  and	  ZO-­‐1,	  an	  important	  adaptor	  protein	  mainly	  in	  tight	  junctions.	  β-­‐catenin	  was	  significantly	  mislocalised	  and	  showed	  a	  staining	  pattern	   similarly	   to	   the	   staining	   pattern	   of	   γ-­‐catenin	   (Figure	   21C).	   The	   total	  protein	   levels	   of	   β-­‐catenin	   did	   not	   change,	   confirmed	   by	   western	   blotting	  (Figure	  21E).	  In	  contrast,	  knockdown	  of	  Ack1	  leads	  to	  a	  downregulation	  of	  ZO-­‐1	  protein	  levels	  (Figure	  21C-­‐D)	  	  These	   observations	   lead	   to	   further	   investigations	   of	   a	   possible	   link	   between	  disrupted	   cell-­‐cell	   junction	   and	   decreased	   sensitivity	   of	   TRAIL	   induced	  apoptosis	  in	  Ack1	  knockdown	  cells.	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Figure	  21.	  Ack1	  knockdown	  cells	  lead	  to	  mislocalisation	  of	  TRAIL-­R1	  and	  impaired	  cell-­
cell	  junction	  stability/formation	  
A.	  Single	  plane	  confocal	   images	  of	  NCI-­‐H460	  cells	   stained	  with	  TRAIL-­‐R1	  (red)	  and	  γ-­‐catenin	  (green)	   at	   63x	  magnification.	   Orthogonal	   view	   shows	   apical	   staining	   of	   the	   receptor	   in	  Ack1	  knockdown	   cells,	   which	   is	   not	   seen	   in	   control	   cells.	  B.	   Stainings	   of	   TRAIL-­‐R1	   (red)	   and	   the	  
94	  	  
membrane	  marker	   Na+/K+	   ATPase	   (green).	  C.	   Cell-­‐cell	   junction	   proteins	   are	  mislocalised	   in	  Ack1	  knockdown	  cells.	  Single	  plane	  confocal	  images	  of	  NCI-­‐H460	  cells	  stained	  with	  ZO-­‐1	  (red),	  Na+/K+	   ATPase	   (green)	   and	   β-­‐catenin	   (red).	   D.	   Western	   blotting	   of	   ZO-­‐1	   levels.	   ZO-­‐1	   is	  downregulated	  in	  Ack1	  knockdown	  cells.	  B.	  Western	  blotting	  of	  β-­‐catenin	  levels.	  Abbreviations:	  
Ack1:	   Activated	   Cdc42-­associated	   kinase	   1,	   TRAIL-­‐R:	   TNF-­related	   apoptosis-­inducing	   ligand	  
receptor	  
4.2.6 Ack1	  regulates	  cell-­cell	  junctions	  independently	  of	  the	  regulation	  
of	  TRAIL	  induced	  apoptosis	  	  The	   observation	   of	   the	   co-­‐localisation	   of	   TRAIL-­‐R1	   and	   junctional	   protein	   as	  well	  as	  the	  mislocalisation	  of	  catenins	  and	  NA+/K+	  ATPase	  in	  Ack1	  knockdown	  cells,	  raised	  the	  question	  whether	  cell-­‐cell	  junction	  stability	  and	  integrity	  could	  be	   important	   for	  TRAIL	   induced	   apoptosis.	   In	   efforts	   to	  determine	   a	   possible	  role	   of	   cell-­‐cell	   junctions	   in	   TRAIL	   induced	   apoptosis,	   different	   assays	  disturbing	  the	  cell	  contacts	  were	  used.	  	  	  Cell-­‐cell	   junctions	   are	   highly	   dependent	   on	   calcium.	   By	   depleting	   the	   cell	  culture	  media	  of	  calcium,	  cell-­‐cell	  junctions	  are	  disrupted.	  NCI-­‐H460	  cells	  were	  let	   to	   adhere	   for	   48h,	   to	   allow	   the	   junctions	   fully	   form.	   EDTA	  was	   thereafter	  added	   to	   the	   culture	   media	   for	   3h,	   chelating	   calcium.	   Following	   calcium	  depletion,	   the	   cells	  were	   treated	  with	  TRAIL	   and	   the	   apoptotic	   response	  was	  assessed.	  Western	   blot	   results	   of	   cleaved	   caspase-­‐8	   levels	   show	   that	   calcium	  withdrawal	  did	  not	  affect	  the	  apoptotic	  response	  (Figure	  22C).	  	  	  	  	  Another	  way	  of	   investigating	   if	   TRAIL-­‐R	   localisation	  on	   cell-­‐cell	   contacts	   	   are	  important	   for	  TRAIL	   induced	  cell	  death	   is	   to	   compare	   the	  apoptotic	   response	  between	   cells	   adhered	   for	   a	   short	   time	  with	   cells	   adhered	   for	   a	   longer	   time.	  	  NCI-­‐H460	   cells	  were	   left	   to	   attach	   to	   a	   cell	   culture	   plate	   for	   72h	   so	   the	   cells	  reached	   an	   approximate	   confluency	   of	   80%.	   The	   cells	  were	   thereafter	   either	  left	   adhered	   or	   trypsinised	   and	   plated	   again	   and	   allowed	   to	   attach	   for	   3h.	  Following	  the	  72	  or	  3h	  attachment	  time,	  the	  cells	  were	  treated	  with	  TRAIL	  for	  2h.	  Immunocytochemistry	  staining	  show	  that	  the	  γ-­‐catenin-­‐containing	  cellular	  junctions	   are	   forming	   after	   3h	   of	   attachment,	   however	   TRAIL-­‐R1	   has	   not	  translocated	   back	   to	   the	   junctional	   compartments	   (Figure	   22A).	   Western	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blotting	   results	   show	   that	   there	   is	   no	   difference	   in	   the	   cell	   death	   response	  depending	  on	   the	   time	  adhered	  (Figure	  22B).	  These	   two	  experiments	  suggest	  that	  the	  cell-­‐cell	  junctions	  are	  not	  important	  for	  the	  cell	  death	  response.	  	  	  
	  
	  
Figure	   22.	   Cell-­cell	   contact	   localisation	   of	   TRAIL-­R1	   is	   not	   required	   for	  TRAIL	   induced	  
apoptosis.	  	  	  
A.	  Immunocytochemistry	  of	  γ-­‐catenin	  (green)	  and	  TRAIL-­‐R1	  (red)	  in	  sparse	  compared	  to	  dense	  plated	  cells.	  B.	  Apoptotic	  response	  between	  cells	  attached	  for	  3h	  and	  72h	  was	  compared.	  The	  duration	   of	   cell	   attachment	   did	   not	   affect	   caspase-­‐8	   cleavage	   after	   TRAIL	   treatment	   C.	   NCI-­‐H460	  cells	  were	  cultured	  in	  cell	  culture	  containing	  EDTA,	  chelating	  calcium,	  for	  3h	  followed	  by	  TRAIL	  treatment	  for	  2h.	  Calcium	  depletion	  did	  not	  affect	  the	  amounts	  of	  cleaved	  caspase-­‐8	   in	  TRAIL	  treated	  cells.	  Abbreviations:	  TRAIL-­R:	  TNF-­related	  apoptosis-­inducing	  ligand	  receptor	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4.2.7 Discussion	  Studies	  have	  shown	  that	  receptor	  compartmentalisation	  and	  internalisation	  is	  important	   for	   responsiveness	   to	   TRAIL.	   Both	   clathrin	   dependent	   and	  independent	  mechanisms	   for	   the	   internalisation	   of	   the	   TRAIL-­‐receptors	   have	  been	   suggested	   [74,	   86,	   154].	   However	   the	   results	   published	   have	   been	  conflicting	   and	   the	   trafficking	   of	   the	   TRAIL	   receptors	   is	   still	   not	   fully	  understood.	  Ack1	  is	  known	  to	  interact	  with	  the	  heavy	  chain	  of	  clathrin	  and	  the	  adaptor	  protein	  AP-­‐2.	  A	  role	  for	  Ack1	  in	  clathrin	  induced	  apoptosis	  of	  the	  ErbB	  receptors	   have	   previously	   been	   suggested	   by	   others	   [120].	   We	   therefore	  wanted	   to	   investigate	   if	   Ack1	   controls	   the	   internalisation	   of	   the	   TRAIL	  receptors	   via	   clathrin	   mediated	   endocytosis.	   The	   widely	   used	   drug	  Chlorpromazine	  was	  used	  to	  inhibit	  clathrin	  mediated	  endocytosis	  followed	  by	  TRAIL	  treatment	  with	  TRAIL	  for	  2.5h.	  Chlorpromazine	  treatment	  alone	  did	  not	  induce	   caspase-­‐8	   cleavage.	   The	   reduced	   sensitivity	   to	   TRAIL	   in	   Ack1	  knockdown	   cells	  was	  not	   restored	  upon	  CPZ	   treatment,	   suggesting	   that	  Ack1	  regulates	   TRAIL	   induced	   apoptosis	   independently	   of	   clathrin	   mediated	  endocytosis	  (Figure	  18).	  These	  results	  agree	  with	  one	  previous	  report	  claiming	  that	   the	   internalisation	   of	   the	   TRAIL	   receptors	   is	   not	   required	   for	   cell	   death	  [86].	  	  	  A	  correlation	  between	  low	  cell	  surface	  expression	  of	   the	  TRAIL	  receptors	  and	  TRAIL	  resistance	  has	  been	  confirmed	  in	  human	  breast	  epithelial	  cells	  (34).	  We	  therefore	  wanted	  to	  investigate	  if	  Ack1	  knockdown	  may	  affect	  the	  cell	  surface	  expression	  of	  the	  TRAIL	  receptors.	  The	  cell	  surface	  expression	  was	  investigated	  by	   flow	   cytometry	   analysis	   using	   PE-­‐conjugated	   antibodies	   binding	   to	   the	  extracellular	   domain	   of	   TRAIL-­‐R1	   and	   -­‐R2	   respectively.	   In	   addition,	   biotin	  labelling	   of	   cell	   surface	   protein,	   followed	   by	   immunoprecipitation	   using	  streptavidin	   beads	   and	   immunoblotting	   was	   used	   to	   confirm	   the	   flow	  cytometry	   data.	   Results	   show	   that	   there	   is	   no	   difference	   in	   the	   cell	   surface	  expression	   of	   the	  TRAIL	   receptors	   in	  Ack1	   knockdown	   cells	   (Figure	   19).	   The	  total	   level	   of	   TRAIL-­‐R1	   was	   not	   equal	   in	   the	   Biotin-­‐IP	   experiment	   so	   it	   was	  therefore	  not	  possible	  to	  confirm	  the	  flow	  cytometry	  data	  in	  this	  case.	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  To	  further	  investigate	  the	  sub-­‐cellular	  localisation	  of	  the	  TRAIL	  receptors,	  ICH	  experiments	  were	  performed.	  The	  TRAIL	   sensitive,	   lung	   cancer	   cell	   line,	  NCI-­‐H460	  was	  used	   for	  all	   ICH	   in	   this	  work.	  The	   cells	   are	   suitable	  due	   to	   the	   fact	  that	   they	   express	   relatively	   high	   levels	   of	   Ack1	   and	   TRAIL-­‐R1,	   estimated	   by	  western	  blotting	  (data	  not	  shown).	   ICH	  staining	  of	  TRAIL-­‐R1	  showed	  that	   the	  receptor	  is	  mainly	  localised	  at	  cell-­‐cell	  contacts	  or	  in	  perinuclear	  compartments	  (Figure	  20).	  The	  NA+/K+	  ATPase	  was	  used	  as	  a	  basolateral	  membrane	  marker	  and	  has	  previously	  been	  shown	  to	  co-­‐localise	  with	  cell-­‐cell	  junctional	  proteins	  [155].	   Co-­‐staining	   shows	   that	   TRAIL-­‐R1	   co-­‐localises	   with	   NA+/K+	   ATPase	   at	  cell-­‐cell	  contacts,	  which	  has	  not	  previously	  been	  reported	  (Figure	  20).	  The	  sub-­‐cellullar	  localisation	  of	  TRAIL-­‐R1	  in	  control-­‐transfected	  cells	  was	  compared	  to	  Ack1	  knockdown	  cells,	  and	  γ-­‐catenin	  and	  NA+/K+	  ATPase	  were	  used	  as	  markers	  for	  the	  cell-­‐cell	  junctions.	  Results	  show	  that	  TRAIL-­‐R1	  co-­‐localises	  with	  both	  γ-­‐catenin	   and	  NA+/K+	   ATPase	   in	   control	   cells,	   whereas	   all	   three	   proteins	  were	  mislocalised	  in	  Ack1	  knockdown	  cells.	  The	  γ-­‐catenin	  positive	  junctions	  appear	  disorganised,	  ZO-­‐1	  positive	   tight	   junctions	  disrupted	  and	  TRAIL-­‐R1	  no	   longer	  localize	  distinctly	  at	  cell-­‐cell	  contacts	  (Figure	  21A-­‐B).	  	  Since	  the	  flow	  cytometry	  data	   show	   that	   the	   cell	   surface	   expression	   of	   TRAIL-­‐R1	   is	   normal	   in	   Ack1	  knockdown	  cells,	  the	  TRAIL-­‐R1	  is	  most	  likely	  localised	  more	  diffusely	  over	  the	  plasma	  membrane,	   compared	   to	   control	   cells	   which	   seem	   to	   have	   TRAIL-­‐R1	  concentrated	  at	  cell-­‐cell	  contact	  areas.	  By	  analysing	   the	  confocal	   images	   in	  an	  orthogonal	   view	   it	   was	   possible	   to	   see	   that	   γ-­‐catenin	   and	   TRAIL-­‐R1	   were	  localised	   at	   the	   apical	   side	   of	   the	   cells	   in	   Ack1	   knockdown	   cells.	   Control	  transfected	   cells	   show	   γ-­‐catenin	   mainly	   at	   the	   basolateral	   side	   of	   the	   cell	  (Figure	   21A).	  Mislocalisation	   of	   junctional	   protein	   is	   a	   hallmark	   of	   disrupted	  polarity	  in	  epithelial	  cells	  (reviewed	  by	  [156]),	  suggesting	  that	  Ack1	  may	  play	  a	  role	  in	  maintaining	  polarity.	  	  A	  role	  for	  Ack1	  in	  regulating	  cell-­‐cell	  junctions	  or	  polarity	   has	   not	   previously	   been	   described	   and	   would	   therefore	   be	   very	  interesting	   to	   investigate	   further.	   Cdc42	   is	   a	   known	   regulator	   of	   polarity,	   for	  example	  by	  directing	  vesicle	   trafficking	  of	  proteins	   to	  distinct	  domains	  of	   the	  plasma	   membrane	   [136-­‐138].	   Additionally,	   Cdc42	   has	   been	   suggested	   to	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regulate	  cell-­‐cell	  junction	  stability	  or	  formation,	  however	  the	  exact	  mechanism	  is	  not	  understood	  (Reviewed	  by	  [157].	  Activation	  of	  Cdc42	  in	  endothelial	  cells	  promotes	   reannealing	   of	   adherens	   junctions	   [158]	   and	   stabilises	   AJs	   by	  regulation	   of	   apical	   endocytosis	   in	   drosophila	   [142].	   It	   could	   therefore	   be	  possible	   that	   Ack1	   regulates	   cell-­‐cell	   junctions,	   and	   potentially	   polarity,	  downstream	  of	  Cdc42.	  The	  junctions	  were	  further	  investigated	  by	  ICH.	  Staining	  of	  the	  tight	  junction	  marker	  ZO-­‐1	  show	  that	  the	  protein	  was	  considerably	  down	  regulated	   in	   Ack1	   knockdown	   cells	   (Figure	   21C)	   also	   confirmed	   by	   western	  blotting	   (Figure	   21D).	   In	   addition	   β-­‐catenin	   was	   clearly	   localised	   at	   cell-­‐cell	  contact	   at	   the	   lateral	   side	   of	   the	   cells	   in	   control	   cells,	  whereas	  β-­‐catenin	  was	  significantly	  mislocalised	  in	  Ack1	  knockdown	  cells.	  The	  junctions	  appear	  to	  be	  destabilised	  with	  a	  more	  irregular	  and	  spiky	  appearance.	  	  β-­‐catenin	  is	  known	  to	  be	  degraded	  when	  cell-­‐cell	   junctions	  are	  disrupted,	  however	   the	   total	  protein	  level	   of	  β-­‐catenin	  was	   however	   not	   affected	   by	   the	   Ack1	   knockdown	   (Figure	  21E)	  indicating	  that	  β-­‐catenin	  containing	  junctional	  complexes	  are	  still	  formed.	  From	   the	   experiments	   performed	   it	   is	   not	   clear	   how	  Ack1	   regulates	   stability	  and	  formation	  of	  adherence	  and	  tight	  junctions	  respectively.	  	  	  Furthermore,	   assays	   where	   the	   junctions	  were	   disrupted	  were	   performed	   in	  effort	   to	   elucidate	   whether	   intact	   cell-­‐cell	   junctions	   are	   required	   for	   TRAIL	  induced	   apoptosis.	   To	   start	   with,	   the	   cell	   death	   response	   was	   compared	  between	   cells	   adhered	   for	   72h	   with	   cells	   only	   plated	   for	   3h.	   There	   was	   no	  difference	  in	  cleaved	  caspase-­‐8	  levels	  depending	  on	  the	  adhesion	  time	  (Figure	  22B).	   ICH	   staining	   comparing	   the	   cells	   attached	   for	   72	   or	   3h,	   show	   clear	  staining	  of	  both	  TRAIL-­‐R1	  and	  γ-­‐catenin	  at	   cell-­‐cell	   contracts	   in	   cells	  adhered	  for	  72h.	  In	  contrast,	  the	  cells	  plated	  for	  3h	  display	  a	  much	  more	  diffuse	  staining	  pattern	  of	  TRAIL-­‐R1	  although	  the	  γ-­‐catenin	  containing	   junctions	  were	   formed	  (Figure	  22A).	  In	  addition,	   junctions	  were	  also	  disrupted	  by	  Calcium	  depletion,	  since	  many	   of	   the	   protein-­‐protein	   interactions	   forming	   the	   cellular	   junctions	  are	  highly	  dependent	  on	  calcium.	  EDTA	  was	  added	  to	  the	  cell	  culture	  media	  in	  order	   to	   deplete	   the	   cells	   of	   Calcium,	   the	   cells	   were	   thereafter	   treated	   with	  TRAIL.	   No	   difference	   in	   cell-­‐death	   was	   detected	   after	   calcium	   depletion	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compared	  to	  cells	  cultured	  with	  calcium	  containing	  media	  (Figure	  22C).	  These	  two	  assays	  suggest	  that	  localisation	  of	  TRAIL-­‐R1	  on	  cell-­‐cell	   junctions	  and	  the	  junctions	  themselves	  are	  not	  required	  for	  TRAIL-­‐induced	  apoptosis.	  	  	  
4.3 Ack1	  is	  required	  for	  DISC	  formation,	  receptor	  clustering	  and	  
lipid	  raft	  translocation	  of	  the	  TRAIL-­receptors	  
4.3.1 Background	  and	  aims	  In	   order	   to	   further	   investigate	   the	   molecular	   mechanism	   by	   which	   Ack1	  regulates	   TRAIL	   induced	   apoptosis	   a	   series	   of	   biochemical	   assays,	   exploring	  events	   occurring	   after	   TRAIL	   ligand	   binding,	   such	   as	   clustering	   and	   DISC	  formation	  were	  performed.	  
	  
The	  aims	  were:	  a) Analyse	  the	  formation	  of	  the	  DISC	  complex	  in	  the	  presence	  or	  absence	  of	  Ack1.	  	  b) Study	   the	   oligomerisation	   of	   the	   TRAIL	   receptors	   following	   ligand	  binding.	  	  c) Elucidate	   the	   lipid	   raft	   localisation	   of	   the	  TRAIL	   receptors	   and	   further	  elucidate	   if	   Ack1	   might	   regulate	   the	   lipid	   raft	   localisation	   of	   the	  receptors.	  
4.3.2 Ack1	  knockdown	  leads	  to	  impaired	  DISC	  formation	  The	  formation	  of	  the	  DISC	  is	  crucial	  for	  the	  initiation	  of	  the	  apoptotic	  response	  in	  a	  cell	   following	   ligand	  binding	   to	  a	  death	  receptor.	  A	  DISC	   formation	  assay	  was	   performed	   to	   investigate	   if	   Ack1	   is	   required	   for	   the	   assembly	   of	   the	  complex.	  MCF10A	  cells	  were	  treated	  with	  biotin-­‐conjugated	  TRAIL	  for	  30	  min	  at	   37°C,	   allowing	   TRAIL	   to	   bind	   to	   the	   receptors	   on	   the	   cell	   surface	   and	   the	  subsequent	  formation	  of	  the	  DISC.	  The	  cells	  were	  thereafter	  lysed	  and	  the	  DISC	  was	  co-­‐immunoprecipitated	  (co-­‐IP)	  with	  streptavidin	  beads	  binding	  biotin	  with	  high	   affinity.	   In	   order	   to	   detect	   the	   total	   receptor	   levels,	   TRAIL	   was	   instead	  added	  after	  the	  cell	  lysis	  in	  some	  samples,	  allowing	  TRAIL	  to	  bind	  all	  receptors	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present	   in	   the	   cells,	   without	   the	   formation	   of	   DISCs	   (Figure	   23A	   Lane	   1-­‐2).	  Additionally,	   as	   a	   negative	   control,	   TRAIL	   was	   omitted	   completely	   in	   one	  sample	  in	  order	  to	  rule	  out	  unspecific	  binding	  to	  the	  beads	  alone.	  Input	  samples	  were	  also	  collected	  directly	  after	  lysis	  prior	  to	  immunoprecipitation.	  The	  co-­‐IP	  and	  input	  samples	  were	  subject	  to	  SDS-­‐PAGE	  and	  western	  blotting.	  No	  protein	  was	   detected	   in	   the	   control-­‐IP,	   confirming	   that	   the	   immunoprecipitation	  worked	  satisfactory	  without	  unspecific	  binding	  of	  protein	   to	   the	  beads.	  There	  was	  a	  slight	  decrease	   in	  the	  total	   levels	  of	  TRAIL-­‐R1	  in	  Ack1	  knockdown	  cells	  Figure	  23A	  Lane	  1-­‐2),	  and	  less	  TRAIL-­‐R1	  were	  therefore	  immunoprecipitated.	  The	  recruitment	  of	  the	  adaptor	  protein	  FADD,	  which	  is	  crucial	  for	  the	  formation	  of	   the	   DISC	   complex,	   was	   not	   altered	   in	   Ack1	   knockdown	   cells.	   However	   an	  impaired	   recruitment	  of	   full-­‐length	   caspase-­‐8	   to	   the	   complex	  was	   seen	   in	   the	  Ack1	  knockdown	  cells,	   indicating	   that	  Ack1	   is	  required	   for	   the	  recruitment	  of	  caspase-­‐8	  and	  complete	  formation	  of	  the	  DISC	  (Figure	  23A	  Lane	  3-­‐4).	  	  
4.3.3 Ack1	  is	  required	  for	  oligomerisation	  of	  TRAIL-­R1	  The	   oligomerisation	   and	   clustering	   of	   the	   TRAIL	   receptors	   are	   important	   for	  the	  DISC	  formation	  and	  subsequent	  downstream	  signalling	  (reviewed	  in	  [159]).	  Since	   the	  DISC	   formation	  was	   impaired	   in	   the	  absence	  of	  Ack1,	  we	  wanted	   to	  investigate	  whether	   this	  defect	   could	  be	  due	   to	  a	  defective	  oligomerisation	  of	  the	   receptors.	   TRAIL	   induced	   oligomerisation	   of	   the	   TRAIL	   receptors	   were	  investigated	  by	  western	  blotting.	  By	  omitting	  the	  reducing	  agent	  DTT	  from	  the	  SDS	  sample	  buffer	  and	  avoid	  boiling	  of	  the	  cell	  lysates,	  oligomeric	  forms	  of	  the	  TRAIL	  receptors	  can	  be	  detected.	  MCF10A	  cells,	  either	  transfected	  with	  control	  or	  Ack1	  siRNA,	  were	  treated	  with	  TRAIL	  for	  the	  time	  points	  indicated.	  The	  cells	  were	  harvested,	   lysed	  and	  resuspended	   in	  SDS-­‐sample	  buffer	  with	  or	  without	  DTT.	  Samples	  were	  run	  on	  a	  SDS-­‐PAGE	  gel	   followed	  by	  western	  blotting.	  The	  non-­‐reduced	   samples	   were	   blotted	   for	   TRAIL-­‐R1	   and	   -­‐R2	   (Figure	   23B).	   The	  monomeric	  form	  of	  TRAIL-­‐R1,	  around	  43kDa,	  was	  detected	  as	  well	  as	  a	  larger	  Mw	  band	  around	  100	  kDa	  constituting	  oligomeric	  receptor	  complexes.	  Results	  show	  that	  a	  weak	  band	  representing	   the	  oligomeric	   form	  of	  TRAIL-­‐R1	  can	  be	  detected	   already	   after	   15	  min	   of	   TRAIL	   treatment	   in	   control	   transfected	   cells	  (Figure	   23A,	   lane	   3).	   Furthermore,	   after	   1h	   of	   TRAIL	   treatment	   there	   is	   a	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notably	   increased	   amount	   of	   oligomerised	   TRAIL-­‐R1	   in	   control	   cells.	   In	  contrast,	   significantly	   lower	   levels	   of	   oligomerised	   forms	   of	   TRAIL-­‐R1	   is	  detected	   in	   Ack1	   knockdown	   cells.	   In	   addition,	   total	   levels	   of	   TRAIL-­‐R1	   are	  reduced	   in	   the	   Ack1	   knockdown	   cells	   following	   TRAIL	   treatment,	   suggesting	  that	   the	   stability	   of	   the	   receptor	  may	   be	   decreased.	   These	   results	   show	   that	  Ack1	   is	   required	   for	   the	   oligomerisation	   of	   TRAIL-­‐R1.	   On	   the	   other	   hand,	  TRAIL-­‐R2	  oligomerisation	  seems	  to	  be	  un-­‐affected	  by	  Ack1	  knockdown	  (Figure	  23B).	  Two	  oligomeric	  complexes	  are	  seen,	  the	  bands	  are	  however	  also	  detected	  in	   non-­‐treated	   samples,	   suggesting	   that	   these	   form	  are	   not	   solely	   induced	  by	  TRAIL.	  	  	  	  	  
	  
	  
Figure	   23.	   Ack1	   knockdown	   impair	   the	   recruitment	   of	   caspase-­8	   to	   the	   DISC	   and	   the	  
clustering	  of	  TRAIL-­R1	  
A.	  The	  DISC	  was	  co-­‐immunoprecipitated	  by	  treating	  MCF10A	  cells	  with	  biotin-­‐TRAIL	  for	  30	  min	  thereafter	   lysed	   and	   purified	   with	   streptavidin	   beads.	   In	   lane	   1-­‐2,	   TRAIL	   was	   added	   to	   the	  cleared	   lysate.	   No	   TRAIL	   was	   added	   to	   the	   Control	   IP.	   The	   recruitment	   of	   FADD	   was	   not	  affected	  however	  recruitment	  of	  caspase-­‐8	  is	  impaired	  in	  Ack1	  knockdown	  cells.	  B.	  Monomeric	  and	  oligomeric	  forms	  of	  the	  TRAIL	  receptors	  were	  detected	  after	  TRAIL	  treatment	  by	  running	  SDS-­‐PAGE	  samples	  without	  the	  reducing	  agent	  DTT.	  Reduced	  samples	  were	  run	  as	  a	  control	  of	  the	   total	   receptor	   levels.	   Abbreviations:	   DISC:	   Death	   inducing	   signalling	   complex,	   DTT:	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Ditiotreitol,	   FADD:	   Fas-­Associated	   protein	  with	   death	   domain,	   IP:	   Immunoprecipitation,	   TRAIL:	  
TNF-­related	  apoptosis-­inducing	  ligand,	  TRAIL-­R:	  TRAIL	  Receptor	  
	  
4.3.4 Ack1	  knockdown	  leads	  to	  impaired	  TRAIL	  induced	  lipid	  raft	  
translocation	  of	  TRAIL-­R1	  and	  TRAIL-­R2	  The	  sub-­‐cellular	   localisation	  of	   the	  TRAIL-­‐receptors	  on	  the	  plasma	  membrane	  has	  been	   shown	   to	  be	  of	   significant	   importance	   for	  TRAIL	   induced	   signalling.	  Dynamic	  micro-­‐domains	  in	  the	  plasma	  membrane,	  enriched	  with	  sphingolipids	  and	  cholesterol,	   called	   lipid	   rafts,	  have	  been	   suggested	   to	  be	  essential	   for	   the	  regulation	  of	  TRAIL	  receptor	  signalling	  and	  a	  link	  between	  receptor	  clustering	  and	   lipid	   raft	   localisation	   of	   the	   receptors	   have	   been	   proposed	   [99-­‐101].	   In	  order	   to	   investigate	   the	  membrane	   localisation	   of	   the	   TRAIL	   receptors,	   lipid	  rafts	  were	  isolated	  using	  sucrose	  gradient	  and	  ultracentrifugation.	  Cell	   lysates	  were	  mixed	  with	   a	   85%	  sucrose	   solution	   and	   thereafter	   overlayed	  with	  35%	  and	  5%	  sucrose	  followed	  by	  ultra-­‐centrifugation	  at	  38	  000	  rpm	  for	  18	  h	  at	  4°C.	  During	  ultracentrifugation	  the	  lipid	  rafts	  “float”	  to	  the	  lighter	  fractions	  whereas	  non-­‐raft	  compartments	  stay	   in	   the	  heavier	   fractions.	  After	  ultra-­‐centifugation,	  10	  fractions	  from	  top	  to	  bottom	  were	  collected.	  The	  fractions	  were	  mixed	  with	  sample	  buffer	  and	  subjected	  to	  western	  blotting.	  Caveolin-­‐1	  was	  used	  as	  a	  lipid	  raft	  marker	  and	  was	  detected	  in	  fraction	  2-­‐4	  which	  were	  considered	  to	  be	  the	  raft	   fractions	  (Figure	  24A).	  Some	  Caveolin-­‐1	  was	  also	  detected	  in	  the	  non-­‐raft	  fractions,	   possible	   due	   to	   excessive	   shearing	   of	   the	   raft	   when	   using	   the	  homogeniser.	  Results	  show	  that	  in	  the	  non-­‐treated	  cells;	  both	  TRAIL-­‐R1	  and	  R2	  were	  present	  in	  the	  lipid	  raft	  fractions	  similarly	  in	  the	  control	  and	  knockdown	  cells.	  A	  significant	  translocation	  of	  the	  receptors	  towards	  the	  lipid	  raft	  fraction	  after	  1h	  TRAIL	  treatment	  was	  seen	  in	  the	  control	  transfected	  cells.	  In	  contrast,	  the	   raft	   localisation	   of	   the	   TRAIL-­‐Rs	   was	   completely	   lost	   and	   the	   receptors	  were	   only	   detected	   in	   the	   heavier	   non-­‐raft	   fractions	   in	   the	   Ack1	   knockdown	  cells	  following	  TRAIL	  treatment.	  These	  results	  suggest	  that	  Ack1	  is	  required	  for	  TRAIL	   dependent	   translocation	   of	   TRAIL-­‐R1	   and	   R2	   to	   the	   lipid	   rafts.	   In	  addition,	   a	   TRAIL	   dependent	   translocation	   of	   Ack1	   towards	   the	   lipid	   raft	  enriched	  fractions	  was	  also	  observed.	  A	  slight	  up-­‐shift	  in	  the	  molecular	  weight	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of	  Ack1	  in	  the	  lighter	  fractions	  was	  also	  noticed,	  suggesting	  that	  Ack1	  might	  be	  post-­‐translationally	   modified	   in	   the	   lipid	   rafts,	   possibly	   by	   tyrosine	  phosphorylation,	  although	  this	  remains	  to	  be	  demonstrated	  (Figure	  24A).	  	  	  To	   further	   confirm	   the	   translocation	   of	   the	   TRAIL	   receptors	   to	   lipid	   rafts,	  MCF10A	   cells	   were	   fractionated	   into	   sub-­‐cellular	   fractions	   using	   a	   kit	  containing	   buffers	  with	   increasing	   detergent	   strength.	   The	   cells	  were	   treated	  with	   TRAIL	   for	   1	   or	   2h.	   The	   total	   protein,	   the	   membrane	   fraction	   and	   the	  cytoskeleton/lipid	   raft	  associated	   fraction	  were	  analysed	  by	  western	  blotting.	  Caveolin-­‐1	   was	   used	   as	   a	   lipid	   raft	   marker	   and	   was	   enriched	   in	   the	  cytoskeleton/raft	  fraction	  as	  compared	  to	  the	  membrane	  fraction	  (Figure	  25D).	  In	   control	   cells,	   TRAIL	   treatment	   leads	   to	   decreased	   levels	   of	   both	   TRAIL-­‐R1	  and	   R2	   in	   the	   membrane	   fraction,	   whereas	   an	   increase	   is	   seen	   in	   the	  cytoskeleton/raft	   fraction.	   An	   increase	   of	   TRAIL-­‐R2	   in	   the	   cytoskeleton/raft	  fraction	   was	   only	   seen	   after	   1h	   of	   treatment,	   suggesting	   that	   the	   lipid	   raft	  localisation	   is	   transiently	   trafficked.	   In	  Ack1	  knockdown	  cells,	   the	  decrease	  of	  the	  TRAIL	  receptors	  in	  the	  membrane	  fraction	  was	  comparable	  to	  control	  cells.	  However,	  the	  increase	  of	  TRAIL-­‐R1	  in	  the	  cytoskeleton/raft	  fraction	  was	  not	  as	  high	   as	   compared	   to	   control	   cells	   (Figure	   25B).	   The	   TRAIL-­‐R2	   levels	   in	   the	  cytoskeleton/lipid	  raft	   fraction	  were	  similar	   to	   the	  one	  of	   control	   cells.	  These	  results	  further	  support	  the	  model	  that	  Ack1	  promotes	  lipid	  raft	  localisation,	  of	  at	  least	  of	  TRAIL-­‐R1,	  after	  TRAIL	  ligand	  binding.	  	  	  
104	  	  
	  
Figure	   24.	   TRAIL	   induced	   translocation	   of	   the	   TRAIL	   receptors	   to	   lipid	   rafts	   are	  
dependent	  of	  Ack1	  	  
A.	  MCF10A	  cells	  were	   transfected	  with	  control	  or	  Ack1	  siRNA	  and	   treated	  with	  TRAIL	   for	  1h	  where	   indicated.	   Lipid	   rafts	   were	   isolated	   using	   sucrose	   gradient	   ultracentrifugation.	   The	  detergent	  resistant	   lipid	  raft	   fractions	  were	  enriched	   in	   fraction	  1-­‐3.	  Soluble	  proteins	  were	   in	  the	   last	  heavy	  fractions.	  Cav1	  was	  used	  as	  a	  raft	  marker.	  B.	  Confirmation	  of	  Ack1	  knockdown	  efficiency.	  D.	  MCF10A	  cells	  in	  the	  absence	  of	  presence	  of	  Ack1	  were	  treated	  with	  TRAIL	  for	  1-­‐2h	   and	   thereafter	   subject	   to	   subcellular	   fractionation	   using	   a	   detergent	   kit.	   TRAIL	   treatment	  leads	   to	  a	  decrease	  of	  both	  TRAIL-­‐R1	  and	  TRAI-­‐R2	   in	   the	  membrane	   fraction.	  TRAIL-­‐R1,	   and	  TRAIL-­‐R2	   to	   some	   extent,	   was	   translocated	   to	   the	   cytoskeleton/raft	   associated	   fraction	  following	  TRAIL	  treatment.	  Cav1	  was	  used	  as	  a	  lipid	  raft	  marker.	  Abbreviations:	  Cav1:	  Caveolin	  




4.3.5 TRAIL-­R1	  and	  Caveolin-­1	  co-­localise	  following	  TRAIL	  treatment	  To	  further	  elucidate	  the	  role	  of	  Ack1	  in	  lipid	  raft	  dynamics	  and	  translocation	  of	  the	  TRAIL-­‐R1,	  ICH	  co-­‐staining	  of	  TRAIL-­‐R1	  and	  Caveolin-­‐1	  were	  performed.	  In	  non-­‐treated	   control	   cells,	   TRAIL-­‐R1	   is	   mainly	   localised	   at	   cell-­‐cell	   contacts	  whereas	   the	   staining	   pattern	   in	   Ack1	   knockdown	   cells	   is	  more	   dispersed,	   as	  previously	   shown	   in	   (Figure	  20).	  Caveolin-­‐1	   is	  partially	   located	  near	   the	   cell-­‐cell	   contacts	   and	   in	   the	   cytosol	   in	   both	   control	   and	   knockdown	   cells	   and	   a	  partial	  co-­‐localisation	  of	  TRAIL-­‐R1	  and	  Caveolin-­‐1	  was	  seen.	  Following	  30	  min	  TRAIL	   treatment,	   both	   Caveolin-­‐1	   and	   TRAIL-­‐R1	   are	   accumulated	   at	   cell	  contact	  areas	  and	  co-­‐localisation	  of	  the	  two	  proteins	  is	  notably	  increased	  in	  the	  control	  cells.	   In	  contrast,	   in	  Ack1	  knockdown	  cells	  both	  proteins	  show	  diffuse	  staining	   in	   the	   whole	   cell	   (Figure	   25).	   These	   results	   confirm	   that	   TRAIL-­‐R1	  translocates	  to	  Caveolin-­‐1	  containing	  compartments	  after	  TRAIL	  treatment	  and	  that	  Ack1	  is	  required	  for	  this	  event.	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Figure	  25.	  TRAIL-­R1	   and	  Caveolin-­1	   accumulate	   on	   the	  plasma	  membrane	   after	  TRAIL	  
treatment.	  NCI-­‐H460	   cells	   were	   transfected	   with	   non-­‐targeting	   siRNA	   or	   siRNA	   targeting	   Ack1	   and	  thereafter	  left	  untreated	  or	  treated	  with	  TRAIL	  for	  30min.	  ICH	  staining	  of	  Caveolin-­‐1	  (Red)	  and	  TRAIL-­‐R1	   (Green)	   was	   performed.	   Confocal	   single	   plane	   images	   were	   acquired	   at	   63x	  magnification.	  Abbreviations:	   Ack1:	  Activated	   Cdc42-­associated	   kinase	   1,	  TRAIL-­R:	   TNF-­related	  
apoptosis-­inducing	  ligand	  receptor,	  ICH:	  Immunohistochemistry	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4.3.6 Discussion	  In	   this	   section,	   the	   mechanism	   by	   which	   Ack1	   may	   regulate	   TRAIL	   induced	  apoptosis	  has	  been	   investigated.	  Results	   show	   that	  Ack1	  knockdown	   leads	   to	  an	   impairment	   of	   several	   early	   events	   during	   TRAIL	   ligand	   binding	   to	   the	  receptors.	  	  	  	  The	   DISC	   formation	   assay	   is	   a	   useful	   assay	   when	   investigating	   the	   most	  upstream	   events	   in	   death	   receptor	   signalling	   pathways.	   The	   recruitment	   of	  FADD	   to	   the	  DISC	  was	   comparable	   in	   control	   and	   knockdown	   cells.	  However	  the	   binding	   of	   full-­‐length	   caspase-­‐8	   to	   FADD	   is	   impaired	   in	  Ack1	   knockdown	  cells.	   Since	  biotinylated	  TRAIL,	   binding	  both	  TRAIL-­‐R1	  and	  R2,	   is	  used	   in	   the	  DISC	  assay,	   it	   is	  not	  possible	   to	  distinguish	   from	   the	  DISC	   formation	  of	  homo	  and	   heteromeric	   complexes	   of	   the	   receptors.	   In	   order	   to	   be	   able	   to	   do	   that,	  receptor	  selective	  antibodies	  binding	  the	  extracellular	  domain	  of	  the	  receptors	  need	   to	   be	   used.	   The	   reduced	   recruitment	   of	   caspase-­‐8	   to	   the	   DISC	   suggests	  that	  Ack1	  regulates	  TRAIL	  induced	  apoptosis	  at	  an	  early	  stage	  of	  the	  signalling	  cascade	   (Figure	   23B).	   Clustering	   and	   oligomerisation	   of	   the	   TRAIL	   receptors	  has	   been	   shown	   to	   be	   crucial	   for	   the	   efficient	   formation	   of	   the	   DISC	   and	  subsequent	  downstream	  apoptotic	  signalling	  [98,	  101].	  The	  oligomerisation	  of	  the	   receptors	  was	   investigated	  by	  western	  blotting	  of	  protein	   lysates	  without	  the	   addition	   of	   reducing	   agent.	   Oligomeric	   complexes	   of	   TRAIL-­‐R1	   were	  beginning	   to	  be	   formed	  already	  after	  15min	  of	  TRAIL	   treatment	   and	  after	  1h	  significant	  levels	  were	  detected.	  In	  contrast,	  considerably	  less	  oligomeric	  forms	  were	  detected	  in	  the	  Ack1	  knockdown	  cell,	  suggesting	  that	  Ack1	  is	  required	  for	  the	   oligomerisation	   of	   the	   receptor,	   possibly	   causing	   the	   impaired	   caspase-­‐8	  recruitment	   to	   the	  DISC	  complex	  (Figure	  23A).	  The	  oligomerisation	  of	  TRAIL-­‐R2	  does	  not	  seem	  to	  be	  affected	  by	  Ack1	  knockdown,	  suggesting	  that	   the	  two	  receptors	  might	  be	  regulated	  differently.	  Little	  is	  known	  about	  whether	  TRAIL-­‐R1	  and	  R2	  have	  distinct	  roles;	  it	  is	  however	  known	  that	  the	  two	  receptors	  are	  differentially	   modified	   post-­‐translationally.	   TRAIL-­‐R1	   can	   be	   palmiotyolated	  and	   the	  modification	   has	   been	   shown	   to	   be	   crucial	   for	   lipid	   raft	   localisation,	  receptor	  oligomerisation	  and	  subsequent	  apoptosis	  [107].	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  The	  disrupted	  DISC	  and	  impairment	  of	  the	  oligomerisation	  of	  TRAIL-­‐R1	  in	  Ack1	  silenced	  cells	  lead	  to	  the	  question	  of	  whether	  the	  lipid	  raft	  could	  be	  involved.	  A	  link	  between	  oligomerisation/clustering	  of	  the	  receptors	  and	  the	  lipid	  rafts	  has	  been	   suggested	   although	   it	   is	   not	   yet	   fully	   understood.	   Others	   have	   reported	  that	  clustering	  and	  localisation	  in	  lipid	  rafts	  do	  correlate,	  however	  it	  is	  not	  clear	  if	   increased	   clustering	   leads	   to	   lipid	   raft	   localisation,	   or	   conversely,	   that	   the	  receptors	   need	   to	   be	   in	   the	   lipid	   rafts	   in	   order	   to	   effectively	   oligomerise	   and	  cluster[82,	  101].	  The	  discrepancy	  in	  clustering	  between	  TRAIL-­‐R1	  and	  R2	  may	  suggest	  that	  TRAIL-­‐R1	  is	  more	  dependent	  on	  lipid	  raft	   localisation	  in	  order	  to	  fully	  oligomerise	  (Figure	  23B).	  	  	  The	  lipid	  rafts	  were	  investigated	  by	  ultra-­‐centrifugation	  of	  protein	  lysates	  in	  a	  sucrose	  gradient.	  This	  is	  the	  most	  widely	  used	  biochemical	  method	  to	  study	  the	  lipid	  rafts.	  The	  lipid	  rafts	  are	  detergent	  resistant	  at	  low	  temperatures	  (4°C)	  and	  can	  thereby	  be	  isolated	  from	  other	  soluble	  membrane	  compartments.	  The	  lipid	  rafts	  “float”	  to	  the	  low	  density	  fractions	  formed,	  whereas	  the	  non-­‐raft	  fractions	  are	   found	   in	  heavy	  density	   fractions.	  The	   fractions	   from	   the	   sucrose	  gradient	  were	  analysed	  by	  SDS-­‐PAGE	  and	  western	  blotting.	  In	  the	  non-­‐treated	  cells,	  the	  majority	  of	   the	  TRAIL	  receptors	  were	   located	   in	   the	  soluble	  non-­‐raft	   fraction,	  although	   there	  were	  also	   receptors	  detected	   in	   the	   lipid	   rafts	   to	   some	  degree	  (Figure	   24A).	   The	   localisation	   of	   both	   TRAIL-­‐R1	   and	   R2	   was	   comparable	   in	  control	   and	  Ack1	   knockdown	   cells.	   After	   1h	   of	   TRAIL	   treatment,	   there	  was	   a	  clear	  translocation	  of	  TRAIL-­‐R1	  and	  R2	  toward	  the	  lipid	  raft	  enriched	  fractions,	  showing	  that	  TRAIL	  induces	  the	  relocation	  of	  the	  receptors	  to	  the	  rafts.	  These	  results	  confirm	  the	  reports	  by	  others	  claiming	  that	  redistribution	  of	  the	  TRAIL	  receptors	  to	  lipid	  raft	  is	  TRAIL	  dependent	  and	  leads	  to	  increased	  sensitivity	  to	  TRAIL	  [103].	  	  In	  contrast,	  knockdown	  of	  Ack1	  lead	  to	  a	  complete	  loss	  of	  TRAIL-­‐R1	  and	  R2	  in	  the	  lipid	  raft	  fractions	  after	  TRAIL	  treatment	  (Figure	  24).	  There	  is	  also	  an	  up-­‐shift	  of	  the	  Ack1	  protein	  in	  the	  lighter	  lipid	  raft	  fractions,	  suggesting	  that	   Ack1	   localised	   in	   lipid	   raft	   is	   post-­‐translationally	   modified,	   possibly	   by	  phosphorylation.	  It	  would	  have	  been	  interesting	  to	  also	  blot	  for	  phosphorylated	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Ack1;	   unfortunately	   the	   available	   pAck1	   antibody	   does	   not	   work	   on	  endogenous	  protein.	  	  	  	  In	   addition,	   immunocytochemistry	   experiments	   analysing	   TRAIL-­‐R1	   and	  Caveolin-­‐1	  localisation	  in	  NCI-­‐H460	  cells	  with	  or	  without	  TRAIL	  treatment	  was	  performed.	   Confocal	   imaging	   shows	   that	   after	   a	   short	   TRAIL	   treatment	  (30min),	   both	   TRAIL-­‐R1	   and	   Caveolin-­‐1	   accumulate	   at	   or	   close	   to	   the	   cell	  surface	   and	   a	   considerably	   higher	   percentage	   of	   the	   proteins	   co-­‐localise.	   The	  accumulation	  of	  TRAIL-­‐R1	  and	  Caveolin-­‐1	  at	   cell-­‐cell	   contacts	   is	  most	   likely	  a	  transient	   effect	   since	   decreased	   membrane	   localisation	   of	   the	   receptors	   was	  seen	  after	  1h	  or	  longer	  in	  the	  sub-­‐cellular	  fractionation	  experiment	  performed	  (Figure	  24D).	  	  	  It	  would	  have	  been	  very	  interesting	  to	  investigate	  whether	  Ack1	  and	  TRAIL-­‐R1	  interacts.	  ICH	  experiments	  have	  been	  performed	  where	  the	  Ack1	  and	  TRAIL-­‐R1	  have	   been	   co-­‐stained.	   Unfortunately,	   the	   Ack1	   antibody	   is	   not	   ideal	   for	   ICH	  staining	   of	   endogenous	   protein	   so	   no	   conclusion	   could	   be	   made	   from	   the	  staining.	   The	   Ack1	   antibody	   detects	   overexpressed	   protein	   much	   more	  efficiently,	   however	   due	   to	   poor	   transfection	   efficiency	   the	   ICH	   experiments	  with	  ectopically	  expressed	  Ack1	   failed.	  An	  alternative	  way	   to	   show	   that	  Ack1	  and	   TRAIL-­‐R1	   interacts	   would	   be	   to	   perform	   an	   IP.	   However,	   technical	  problems	  with	  the	  IPs	  using	  the	  Ack1	  or	  DR4	  antibody	  as	  a	  capturing	  antibody	  limited	  the	  possibility	  to	  perform	  IP	  with	  endogenous	  protein.	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Chapter	  4	  –	  Final	  Discussion	  
4.4 Summary	  This	  work	  show	  that	  Ack1	   is	   required	   for	  TRAIL	   induced	  apoptosis	   in	  human	  epithelial	   cells.	   Lipid	   raft	   localisation	   and	   oligomerisation	   of	   TRAIL-­‐R1,	   and	  formation	  of	  the	  DISC,	  events	  crucial	  for	  the	  downstream	  apoptotic	  signal,	  are	  all	  impaired	  in	  Ack1	  knockdown	  cells.	  siRNA	  mediated	  silencing	  of	  Cdc42	  also	  results	   in	   decreased	   cell	   death	   in	   response	   to	   TRAIL,	   suggesting	   that	   Cdc42	  regulates	  TRAIL	  induced	  apoptosis	  dependently	  or	  independently	  of	  Ack1.	  We	  suggest	  that	  Ack1	  regulates	  TRAIL	  induced	  apoptosis	  by	  promoting	  the	  TRAIL-­‐dependent	  translocation	  of	  TRAIL	  receptors	  to	  lipid	  rafts,	  which	  has	  previously	  been	  shown	  to	  be	  very	  important	  for	  the	  transduction	  of	  TRAIL	  induced	  death	  signals.	   	  We	  also	  note	  that	  TRAIL-­‐R1	  localises	  to	  cell-­‐cell	  contacts	  and	  that	  the	  junction	   integrity	   is	   affected	   by	   the	   absence	   of	   Ack1.	   The	   role	   of	   Ack1	   in	  regulating	   cell-­‐cell	   junctions	   appears	   independent	   of	   its	   role	   in	   regulating	  TRAIL	  induced	  apoptosis.	  	  
4.5 Final	  discussion	  and	  implications	  TRAIL	  induced	  apoptosis	  has	  been	  intensively	  studied	  in	  recent	  years.	  TRAIL	  is	  considered	   to	   be	   a	   promising	   agent	   for	   cancer	   treatment,	   due	   to	   its	   selective	  toxicity	  against	  tumour	  cells.	  However,	  many	  cancer	  cells	  develop	  resistance	  to	  TRAIL.	   Several	   mechanisms	   for	   TRAIL	   resistance	   have	   been	   proposed.	   The	  significance	  of	   the	  different	  mechanisms	  varies	   to	  a	   large	  extent	  between	  cell	  types.	  Understanding	   the	  mechanisms	  by	  which	  resistance	   is	  acquired	  will	  be	  critical	  for	  the	  therapeutic	  use	  of	  TRAIL	  in	  cancer	  therapy.	  	  In	   this	   thesis,	   a	   novel	   regulatory	   role	   of	   Ack1	   in	   apoptosis,	   death	   receptor	  signalling	   and	   lipid	   raft	   trafficking	   is	   presented,	   contributing	   further	   to	   the	  understanding	  of	  the	  molecular	  regulation	  of	  TRAIL	  receptor	  signalling.	  	  	  	  We	   suggest	   that	   Ack1	   regulates	   TRAIL	   induced	   apoptosis	   by	   promoting	   the	  translocation	  of	  the	  TRAIL	  receptors	  to	  lipid	  rafts	  after	  TRAIL	  treatment.	  Lipid	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raft	   localisation	   has	   been	   shown	   to	   promote	   apoptosis	   and	   sensitise	   cells	   to	  TRAIL	  [160].	  Many	  studies	  of	  the	  role	  of	  lipid	  rafts	  in	  death	  receptor	  signalling	  have	   been	   published,	   however	   the	   mechanistic	   insights	   explaining	   how	   the	  rafts	  are	  regulated	  and	  the	  dynamics	  of	  the	  death	  receptors	  in	  raft	  versus	  non-­‐raft	   compartments	   is	   poorly	   understood.	   Ack1	   is	   here	   identified	   as	   a	   key	  protein	   in	   TRAIL	   receptor	   dynamics.	   The	   precise	   molecular	   mechanism,	   by	  which	   Ack1	   regulates	   lipid	   raft	   and	   receptor	   dynamics	   have	   not	   been	   fully	  elucidated	   in	   this	  work.	  Although,	   it	   is	  evident	   that	  Ack1	  knockdown	   leads	   to	  disruption	   of	   a	   series	   of	   events	   early	   in	   the	   signalling	   cascade	   after	   TRAIL	  ligand	   binding,	   such	   as	   oligomerisation	   of	   TRAIL-­‐R1	   and	   the	   caspase-­‐8	  recruitment	  to	  the	  DISC	  (Figure	  23).	  	  	  Since	  Ack1	   is	   a	   tyrosine	   kinase,	   it	  would	   be	   of	   great	   interest	   to	   investigate	   if	  kinase	   activity	   of	   Ack1	   is	   required	   for	   the	   regulation	   of	   the	   TRAIL	   receptors.	  Tyrosine	   phosphorylation	   of	   Fas,	   has	   been	   shown	   to	   be	   crucial	   for	   the	  oligomerisation	  of	   the	  receptors,	  amplifying	   the	  cell	  death	  response	   [161].	  To	  our	  knowledge,	  no	  kinase	  has	  previously	  been	  shown	  to	  directly	  phosphorylate	  the	   TRAIL	   receptors.	   It	   would	   be	   very	   interesting	   to	   investigate	   if	   Ack1	  phosphorylates	   the	   TRAIL-­‐receptors	   or	   any	   other	   proteins	   involved	   in	   DISC	  formation	   and	   thereby	   possibly	   affect	   the	   sensitivity	   to	   TRAIL.	   This	   could	   be	  investigated	  by	  ectopic	  expression	  of	  a	  kinase	  dead	  Ack1	  mutant.	  A	  kinase	  dead	  mutant,	   together	   with	   other	  mutants	   disrupting	   different	   interaction	   sites	   in	  Ack1,	  such	  as	  clathrin	  and	  Cdc42	  binding	  have	  been	  generated.	  Unfortunately,	  due	  to	  technical	  difficulties,	  it	  has	  not	  been	  possible	  to	  express	  the	  mutants	  in	  an	  Ack1	  knockdown	  background.	  Transfecting	  the	  cells	  twice,	  with	  siRNA	  and	  plasmid	  DNA,	  either	  proved	  to	  be	   toxic	   for	   the	  cells	  or	   the	  ectopic	  expression	  was	   not	   successful.	   By	   using	   a	   cell	   line	   that	   is	   easier	   and	   more	   tolerant	   to	  transfection,	  the	  experiment	  might	  be	  successful.	  	  	  	  	  	  	  	  	  	  	  	  	  Interestingly,	   knockdown	   of	   the	   Rho	   GTPase,	   Cdc42,	   also	   resulted	   in	   lower	  levels	   of	   cleaved	   caspase-­‐8	   following	   TRAIL	   treatment	   (Figure	   17).	   	   These	  results	   suggest	   that	   Cdc42	   also	   plays	   an	   important	   role	   in	   TRAIL	   signalling.	  Cdc42	   is	   a	   known	   effector	   of	  Ack1,	  we	   therefore	   hypothesise	   that	   the	   role	   of	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Ack1	  in	  TRAIL	  induced	  apoptosis	  is	  Cdc42	  dependent.	  One	  way	  of	  proving	  this	  model	  would	   be	   to	   ectopically	   overexpress	   an	  Ack1	  mutant	  with	   a	   disrupted	  Cdc42	  binding	  domain	  in	  an	  Ack1	  knockdown	  background.	  If	  the	  Ack1	  mutant	  failed	   to	   restore	   the	   cell	   death	   response	   it	   would	   suggest	   that	   Ack1	   require	  Cdc42	  binding	  and	  activation	  in	  order	  to	  regulate	  the	  TRAIL	  receptors.	  	  	  While	   investigating	   the	   subcellular	   location	   of	   the	   TRAIL	   receptors	   by	  immunocytochemistry,	   it	   was	   discovered	   that	   Ack1	   knockdown	   cells	   have	  destabilised	   cell-­‐cell	   junctions	   (Figure	   21).	   Efforts	   were	   made	   in	   order	   to	  elucidate	   whether	   intact	   cell-­‐cell	   junctions	   are	   important	   for	   the	   TRAIL	  response.	   Different	   assays	   disrupting	   the	   junctions	   were	   performed	   and	   the	  results	   suggest	   that	   cell-­‐cell	   junctions	   are	   not	   required	   for	   TRAIL	   induced	  apoptosis	  (Figure	  22).	  It	  would	  be	  interesting	  to	  further	  investigate	  this	  novel	  role	   of	   Ack1	   in	   cell-­‐cell	   junction	   assembly	   and	   stability	   and	   elucidate	   the	  potential	  biological	  significance	  of	  this	  phenotype.	  Cdc42	  regulates	  the	  stability	  and	   endocytosis	   of	   junctional	   proteins.	   Madin	   Darby	   canine	   kidney	   (MDCK)	  cells	   expressing	   dominant-­‐active	   Cdc42V12	   show	   abnormal	   tight	   junction	  morphology,	   staining	   of	   occludin	   and	   ZO-­‐1	   show	   that	   the	   junctions	   were	  irregular	   in	  shape	  and	  the	  thickness	  varied	  [162].	   It	  would	  therefore	  be	   likely	  that	   Ack1	   regulates	   the	   junctions	   together	   with	   Cdc42.	   It	   would	   also	   be	  interesting	  to	  address	  whether	  other	  Cdc42	  regulated	  polarity	  protein	  such	  as	  Par6	   and	   Arp	   also	   are	   involved	   in	   TRAIL	   induced	   apoptosis	   and	   if	   the	  membrane	  compartmentalisation	  of	   the	  TRAIL	   receptors	   requires	  established	  cell	  polarity	  in	  epithelial	  cells.	  	  	  	  	  	  Ack1	   has	   previously	   been	  mainly	   associated	  with	   pro-­‐survival	   signalling	   and	  the	  protein	  is	  overexpressed	  in	  variety	  of	  human	  primary	  tumours	  in	  which	  it	  has	  been	  correlated	  with	  a	  poor	  prognosis	  [115].	  In	  contrast,	  we	  present	  a	  pro-­‐apoptotic	  role	  of	  Ack1	  specifically	  via	  the	  death	  receptor	  signalling	  pathway	  but	  not	  via	  the	  mitochondrial	  pathway	  (Figure	  13).	  It	  is	  already	  known	  that	  kinases	  can	  have	  both	  pro-­‐apoptotic	  and	  pro-­‐survival	  roles,	  for	  example	  c-­‐Abl	  that	  can	  both	  promote	  apoptosis	  [163]	  and	  mediate	  growth-­‐factor	  mitogenic	  signalling	  (reviewed	   in	   [164]).	   It	   is	   therefore	   not	   entirely	   surprising	   that	   Ack1	   has	   a	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multi-­‐faced	   role	   as	   well.	   Efforts	   are	   underway	   to	   develop	   inhibitors	   against	  Ack1	   for	  use	   in	   cancer	   treatment.	  A	   small	  molecule	   inhibitor	  of	  Ack1	  activity,	  called	  AIM-­‐100	   (4-­‐amino-­‐5,6-­‐biaryl-­‐furo[2,3-­‐d]pyrimidin),	   has	   been	   shown	   to	  inhibit	   prostate	   cancer	   cell	   proliferation.	   Inhibition	   of	   Ack1	   also	   leads	   to	   a	  suppression	   of	   the	   phosphorylation	   of	   the	   androgen	   receptor	   (pTyr267-­‐AR)	  which	  is	  known	  to	  be	  critical	  for	  the	  growth	  of	  androgen-­‐independent	  prostate	  cancer	   (AIPC).	   [165,	   166].	  Our	  data	   suggest	   that	   inhibition	  of	  Ack1	  may	  have	  unwanted	   effects	   on	   the	   apoptotic	   response	   of	   cancer	   cells	   to	   exogenous	   cell	  death	   signalling,	   which	   is	   of	   relevance	   in	   the	   selection	   of	   appropriate	  therapeutic	  targeting	  strategies.	  	  With	   the	  discovery	  of	   a	  novel	  protein,	  Ack1,	  which	   crucial	   for	  TRAIL	   induced	  apoptosis	  and	  potentially	  other	  death	  receptor	  pathways,	  we	  hope	   to	  present	  knowledge	  contributing	  to	  the	  development	  of	  effective	  cancer	  therapeutics	  in	  the	  future.	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Appendix	  
Cell	  culture	  media	  composition	  	  
HELA	  	  DMEM	  (Invitrogen)	  	  10%	  fetal	  bovine	  serum	  (FBS)	  (v/v)	  (PAA	  clone,	  PAA	  Laboratories	  Ltd.)	  	  
MCF10A	  	  DMEM/F12	  (Invitrogen)	  	  5%	  horse	  serum	  (v/v)	  (Invitrogen)	  20	  ng/ml	  EGF	  (Miltenyi	  Biotech)	  0.5	  mg/ml	  Hydrocortisone	  (Sigma)	  100	  ng/ml	  Cholera	  toxin	  (Sigma)	  10	  µg/ml	  Insulin	  (Sigma)	  	  
NCI-­H460	  	  RPMI-­‐1460	  	  10%	  FBS	  (v/v)	  	  
SW480	  Leibovitz’s	  L15	  media	  (Invitrogen)	  	  10%	  FBS	  (v/v)	  	  Cultured	  in	  100%	  air	  	  
Mammalian	  cell	  freezing	  media	  70%	  FBS	  (v/v)	  20%	  DMEM	  (v/v)	  10%	  DMSO	  (v/v)	  (Sigma)	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Homemade	  solution	  and	  Buffer	  recipes	  
	  
SDS-­PAGE	  separation	  gel	  	  Allow	  to	  polymerise	  for	  a	  minimum	  of	  30min.	  
Percentage	   7.5%	   10%	   12.5%	  
H20	   5.8	  ml	   4.9	  ml	   3.9	  ml	  
0.5	  M	  Tris-­HCl	  (pH	  8.8)	   3.0	  ml	   3.0	  ml	   3.0	  ml	  
30	  %	  acrylamide/bis-­acrylamide	   2.95	  ml	   3.7	  ml	   4.75	  ml	  
10	  %	  SDS	   120	  µl	   120	  µl	   120	  µl	  
TEMED	   16	  µl	   16	  µl	   16	  µl	  
25	  %	  APS	   16	  µl	   16	  µl	   16	  µl	  	  
SDS-­PAGE	  stacking	  gel	  Use	  4%	  stack	  for	  ≤	  10%	  separation	  gels	  and	  6%	  stack	  for	  >10%	  separation	  gels.	  Allow	  to	  polymerise	  for	  a	  minimum	  of	  30min.	  
Percentage	  	   4%	   6%	  
H20	   3.6	  ml	   3.6	  ml	  
0.5M	  Tris-­HCl	  (pH	  6.8)	   630	  µl	   630	  µl	  
30	  %	  Acrylamide/bis-­acrylamide	   660	  µl	   1	  ml	  
20	  %	  SDS	   25	  µl	   25	  µl	  
TEMED	   10	  µl	   10	  µl	  
25%	  APS	   5	  µl	   5	  µl	  	  
3X	  SDS-­sample	  buffer	  (Laemmli)	  	   	   To	  make	  10ml	  240	  mM	  Tris-­‐HCl	  pH	  6.8	   	   	   	   2.4ml	  Tris-­‐HCl	  (1M)	  6%	  SDS	   	   	   	   	   	   3ml	  SDS	  (20%)	  30%	  v/v	  Glycerol	   	   	   	   	   3ml	  Glycerol	  (100%)	  0.06	  %	  w/v	  Bromophenol	  blue	   	   	   0.006g	  Bromophenol	  blue	  150mM	  DTT	   add	  just	  before	  use:	  	  1.5	  ml	  (1M)	  DTT	  The	  buffer	  was	  used	  at	  1.5x	  concentration	  (1:1	  in	  dH20)	  unless	  other	  stated.	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10	  x	  SDS-­PAGE	  Running	  buffer	  	   	   	   To	  make	  1l	  150mM	  Tris	  base	   	   	   	   	   30.3	  g	  Trizma	  base	  196	  mM	  Glycine	   	   	   	   	   144	  g	  Glycine	  10%	  w/v	  SDS	  	   	   	   	   	   10g	  SDS	  Make	  up	  to	  1l	  with	  dH20	  	  
10x	  Transfer	  buffer	  	   	   	   	   To	  make	  1l	  	  250	  mM	  Tris-­‐base	   	   	   	   	   30.26	  g	  Trizma	  base	  	  196	  mM	  Glycine	  	   	   	   	   	   147	  g	  Glycine	  10%	  Methanol	  	   	   	   	   	   Make	  up	  to	  1l	  with	  h20	  	  Prepare	  1X	  solution	  with	  10%	  Methanol	  prior	  to	  use.	  	  
Stripping	  buffer	   	   	   	   	   	  To	  make	  250ml	  62.5	  mM	  Tris-­‐HCl	  (pH	  6.8)	  	   	   	   	   15.6	  ml	  Tris-­‐HCl	  (1M)	  2%	  v/v	  SDS	  	   	   	   	   	   	   25	  ml	  SDS	  (20%)	  100	  mM	  2-­‐beta	  mercaptoethanol	   1.75	  	  ml	  2-­‐beta	  mercaptoethanol	  	  	  
10x	  TBS	   	   	   	   	   	   To	  make	  1l	  100	  mM	  Tris	  base	  pH	  7.6	   	   	   	   12.1g	  trizma	  base	  1.5M	  NaCl	   	   	   	   	   	   87.7g	  NaCl	  	   	   	   	   	   	   	   pH	  to	  7.6	  with	  HCl	  (~40ml)	  	   	   	   	   	   	   	   Top	  up	  to	  1l	  with	  dH20	  
	  




Colloidal	  Coomassie	   	   	   	   To	  make	  1l	  1g/l	  Coomassie	  brilliant	  blue	  G250	  	   	   1	  g	  Coomassie	  brilliant	  blue	  	  	  	  	  	  50%	  H20	  (v/v)	  	   	   	   	   	   500	  ml	  H2O	  27.75%	  H2SO4	  (v/v)	  	  	   	   	   	   27.75	  ml	  H2SO4	  Stir	  with	  a	  magnetic	  bar	  for	  3h	   	   	   110	  ml	  10	  N	  NaOH	  Filter	  through	  a	  fluted	  filter	  add,	   	   	   155	  ml	  Tri-­‐chloric	  acid	  (v/v)	  11%	  10N	  NaOH	  (v/v)	  	   	   	   	   Make	  up	  to	  1l	  with	  h20	  15.5%	  Tri-­‐chloric	  acid	  (v/v)	  	   	   	   	  To	  destain	  use	  dH20.	  	  
Classical	  Coomassie	   	   	   	   To	  make	  1l	  1g/l	  Coomasssie	  brilliant	  blue	  R250	   	   1	  g	  Coomasssie	  brilliant	  blue	  	  25%	  (v/v)	  2-­‐propanol	   	   	   	   25	  ml	  2-­‐propanol	  10%	  (v/v)	  Acetic	  acid	   	   	   	   10	  ml	  Acetic	  acid	  filtrate	  through	  a	  fluted	  filter	   	   	   Make	  up	  to	  1l	  with	  H20	  	  
Coomassie	  destainer	  10	  %	  (v/v)	  Acetic	  acid	  40	  %	  (v/v)	  Methanol	  
	  





Triton	  lysis	  buffer	  for	  TRAIL	  purification	  	  20mM	  Tris-­‐HCl	  150mM	  NaCl	  10%	  Glycerol	  1%	  Triton	  X-­‐100	  1mM	  PMSF	  	  	  	  
TRAIL	  elution	  buffer	  300	  mM	  NaCl	  100	  mM	  Imidazole	  	  Dissolved	  in	  PBS	  	  
Triton	  lysis	  buffer	  for	  TRAIL	  receptor	  clustering	  assay	  20	  mM	  Tris	  HCl	  (pH	  7.5)	  150	  mM	  NaCl	  	  10%	  Glycerol	  0.2%	  Triton-­‐X	  100	  1	  mM	  EDTA	  	  
Triton	  lysis	  buffer	  for	  DISC	  formation	  assay	  20	  mM	  Tris	  HCl	  (pH	  7.5)	  150	  mM	  NaCl	  	  10%	  Glycerol	  1%	  Triton-­‐X	  100	  1	  mM	  EDTA	  	  
Triton	  lysis	  buffer	  for	  isolation	  of	  lipid	  rafts	  10	  mM	  TRIS-­‐HCl	  (pH	  7.5)	  150	  mM	  NaCl	  	  5	  mM	  EDTA	  	  1	  %	  Triton	  x-­‐100	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Triton	  lysis	  buffer	  for	  Biotin-­IP	  	  20mM	  Tris-­‐HCl	  150mM	  NaCl	  10%	  Glycerol	  1%	  Triton	  X-­‐100	  	  
10x	  Annexin	  V	  binding	  buffer	  0.1	  M	  Hepes	  pH	  7.4	  1.5	  M	  NaCl	  50	  mM	  KCl	  10	  mM	  MgCl2	  	  18	  mM	  CaCl2	  Dissolve	  in	  dH20	  Prepare	  1x	  solution	  with	  H20	  prior	  to	  use	  
	  
DNA	  extraction	  buffer	  	  0,2	  M	  Na2HPO4	  	  0,004%	  Triton	  X-­‐100	  (v/v)	  pH	  7.8	  	  
DNA	  staining	  solution	  (PI)	  	  50	  µg/ml	  Propidium	  Iodide	  0.2	  mg/ml	  RNAse	  A	  (dissolved	  in	  10	  mM	  Sodium	  acetate	  (pH	  7.4)	  in	  PBS)	  	  
Collagen	  coating	  of	  coverslips	  0.1	  %	  Collagen	  type	  I	  (rat	  tail,	  BD	  Biosciences)	  (v/v)	  	  Diluted	  in	  0.02M	  acetic	  acid.	  	  
Biotinylation	  buffer	  for	  biotin-­IP	  	  50	  µl/ml	  Biotin-­‐7-­‐NHS	  50	  mM	  sodium	  borate	  150	  mM	  NaCl	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0.5	  M	  EDTA	  (pH	  8.0)	  	  84.05	  g/l	  EDTA	  Dissolve	  in	  dH20	  Add	  NaOH	  pellets	  until	  the	  EDTA	  fully	  dissolve	  and	  reaches	  pH	  8.0	  	  
50x	  TAE	  Buffer	  	   	   	   	   	   	   To	  make	  1l	  2	  M	  Tris-­‐acetate	   	   	   	   	   	   242g	  Trizma	  base	  Glacial	  acetic	  acid	   	   	   	   	   	   57.1	   ml	   glacial	   acetic	  acid	  0.05	  M	  EDTA	   pH	  8.0	  	   	   	   	   	   100ml	  EDTA	  pH	  8.0	  	   	   	   	   	   	   	   	   Top	  up	  to	  1l	  with	  dH20	  
	  
10x	  DNA	  loading	  buffer	  	   	   	   	   	   To	  make	  200ml	  50%	  Glycerol	  (v/v)	  	   	   	   	   	   	   100ml	  glycerol	  0.2%	  Orange	  G	  (Sigma	  #0165)	  	   	   	   	   0.4	  g	  Orange	  G	  	  Dissolved	  in	  1xTAE	   	   	   	   	   	   4ml	  TAE	  (50x)	  Top	  up	  to	  200ml	  with	  dH20	  	  	  
100	  mg/ml	  Ampicillin	  (1000x)	  To	  make	  20ml	  2	  g	  Ampicillin	  	  dH20	  up	  to	  20	  ml	  Sterile	  filter	  and	  store	  at	  -­‐20°C	  	  




25	  mg/ml	  Chloramphenicol	  (500x)	  To	  make	  20	  ml	  0.5	  g	  Chloramphenicol	  (company?)	  Ethanol	  up	  to	  20	  ml	  Store	  at	  -­‐20°C	  	  
100	  mg/ml	  Spectinomycin	  (100x)	  To	  make	  20	  ml	  2	  g	  Spectinomycin	  	  dH20	  up	  to	  20	  ml	  Sterile	  filter	  and	  store	  at	  -­‐20°C	  	  
LB	  media	   	   	   	   	   	   	  	   To	  make	  1l	  20g/l	  LB	  Broth	   	   	   	   	   	   20g	  LB	  Broth	  	  (10	  g/l	  tryptone,	  5	  g/l	  yeast	  extract,	  5	  g/l	  NaCl)	  	   	   dH20	  up	  to	  1l	  	  Dissolved	  in	  dH20	  Sterilise	  by	  autoclaving	  	  
LB	  Agar	  plates	  35g/l	  LB	  agar	  (Sigma)	  	  Dissolved	  in	  dH20	  	  Sterilised	  by	  autoclaving.	  	  Cool	  down	  to	  55°C,	  add	  appropriate	  selective	  antibiotics	  	  Pour	   into	  10	  cm	  Petri	  dishes,	   approximately	  20	  ml/dish	  and	   let	   to	  dry	   for	  30	  min	  thereafter	  stored	  at	  4°C.	  	  	  	  	  
